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THE TUMOR SUPPRESSOR NOTCH INHIBITS HEAD AND NECK 
SQUAMOUS CELL CARCINOMA (HNSCC) TUMOR GROWTH AND 
PROGRESSION BY MODULATING THE EXPRESSION OF PROTO-
ONCOGENES, AXL AND CTNNAL1 (α-CATULIN) 
Shhyam Moorthy, B.S. 
 
Advisory Professor: Dr. Jeffrey N. Myers, M.D., Ph.D. 
 
 
Background: Head and Neck Squamous Cell Carcinoma (HNSCC) is the sixth most 
common malignancy worldwide, with roughly 300,000 cancer related deaths occurring 
globally each year. The survival of patients with HNSCC has not changed significantly 
over the past decade, leading investigators to search for promising molecular targets. To 
identify new treatment targets and biomarkers that could better guide therapy, we 
previously characterized the genomic alterations from primary HNSCC patient samples. 
We were among the first to discover that NOTCH1 is one of the most frequently mutated 
genes in this cancer type. The spectrum of inactivating NOTCH1 mutations in HNSCC 
suggested a tumor suppressive role for this protein; however, the mechanism of its function 
is currently unknown. 
 
Procedure: We used Sanger sequencing and immunoblotting to characterize 50 well-  
established HNSCC cell lines as being wild-type or mutant for NOTCH1. We cloned the 
full length NOTCH1 receptor to restore the NOTCH signaling function in mutant cell lines 
and activated this pathway by culturing cells on immobilized NOTCH ligand, Jagged1, 
 v 
coated plates. Clonogenic assays and competitive cell proliferation assays was used to 
evaluate cell growth and proliferation. CRISPR-Cas9 system was used to knock out 
NOTCH1 and/or NOTCH2 in wild-type cells. Tumor growth was evaluated in vivo in a 
mice orthotopic model of oral cancer. An unbiased gene expression analysis was performed 
to identify potential downstream targets of the NOTCH pathway. RNA-Seq data was 
obtained from HNSCC TCGA data and was correlated with the 120 gene expression 
signature obtained from cell lines. Flag-tagged constructs were used to overexpress HES2 
and HES5, while shRNA’s was used to knock down AXL and catulin in mutant cell lines 
to evaluate tumor growth. 
 
Results: We show here that restoration of full length NOTCH1 in mutant HNSCC cell 
lines and activation of NOTCH signaling in wild-type cell lines significantly decreases cell 
growth in vitro and tumor growth in vivo. CRISPR-Cas9 knock out of NOTCH1 and 
NOTCH2 in wild-type HNSCC cells accelerated cell growth that was reversed by 
restoration of NOTCH1 in the same cell line. To evaluate the mechanism of NOTCH 
induced growth inhibition, we performed an unbiased microarray analysis and observed 
suppression of two proto-oncogenes, AXL and CTNNAL1 (α-catulin) after NOTCH1 
activation, but not in its absence. In addition, genes modulated by NOTCH activation in 
cell lines correlated with RNA-Seq data from 498 TCGA patient tumors. Restoration of 
NOTCH1 in mutant cell lines significantly decreased protein expression levels of AXL and 
α-catulin, while CRISPR-Cas9 knock out of NOTCH1 and NOTCH2 in wild-type cells 
increased expression of these proto-oncogenes. Knock down of AXL and α-catulin using 
shRNA’s abrogated tumor growth. Lastly, we show that HES2 and HES5, transcriptiona l 
 vi 
regulatory proteins induced by NOTCH signaling might be sufficient to inhibit protein 
expression levels of AXL and α-catulin and suppress growth. 
 
Conclusions: For the first time, we are attributing a tumor suppressive function of NOTCH 
in HNSCC. We conclude that reactivation of NOTCH signaling in HNSCC inhibits tumor 
growth and progression. In addition, we are also providing a possible mechanism linking 
NOTCH1 to the decreased expression of proto-oncogenes, AXL and CTNNAL1 (α-
catulin) that potentially abrogates tumor growth. This underscores the need to understand 
the clinical significance of the NOTCH pathway and its downstream targets, which could 
then be exploited for potential therapeutic strategies. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 vii 
Contents 
APPROVED: ........................................................................................................................i 
Abstract.............................................................................................................................. iii 
Dedication ........................................................................................................................ xix 
Acknowledgments ............................................................................................................ xx 
CHAPTER 1: HEAD AND NECK SQUAMOUS CELL CARCINOMA (HNSCC)  . 1 
Anatomy and incidence ................................................................................................... 2 
Pathogenesis .................................................................................................................... 6 
Treatment ........................................................................................................................ 8 
Field cancerization .......................................................................................................... 9 
Sequencing studies in HNSCC...................................................................................... 10 
CHAPTER 2: NOTCH SIGNALING ........................................................................... 18 
Structure of NOTCH receptor ....................................................................................... 19 
Structure of NOTCH ligands......................................................................................... 21 
NOTCH activation and regulation ................................................................................ 24 
NOTCH signaling in differentiation ............................................................................. 29 
NOTCH in cancer.......................................................................................................... 31 
NOTCH as an oncogene................................................................................................ 31 
NOTCH as a tumor suppressor ..................................................................................... 33 
NOTCH in HNSCC....................................................................................................... 34 
CHAPTER 3: AXL AND α-CATULIN......................................................................... 36 
AXL............................................................................................................................... 37 
AXL in cancers.............................................................................................................. 40 
AXL in Non-small cell lung carcinoma (NSCLC)........................................................ 40 
AXL in breast cancer..................................................................................................... 41 
AXL in Acute Myeloid Leukemia (AML) .................................................................... 43 
AXL in HNSCC ............................................................................................................ 43 
AXL inhibitors .............................................................................................................. 44 
CTNNAL1: α-catulin .................................................................................................... 47 
CHAPTER 4: MATERIALS AND METHODS .......................................................... 49 
Cell lines........................................................................................................................ 50 
Western Blots ................................................................................................................ 51 
 viii 
Plasmids ........................................................................................................................ 52 
Intracellular NOTCH1 (ICN1) ...................................................................................... 52 
CRISPR-Cas9 plasmids................................................................................................. 53 
NOTCH1 Full Length (NFL1) ...................................................................................... 53 
Short Hairpin RNA’s for AXL and α-catulin................................................................ 54 
HES2 and HES5 ............................................................................................................ 54 
Transfections ................................................................................................................. 55 
Retroviral infections ...................................................................................................... 56 
Lentiviral infections ...................................................................................................... 56 
Clonogenic assays ......................................................................................................... 56 
Quantitative Real Time PCR (qRT-PCR) ..................................................................... 57 
Jagged1 and Fc immobilization..................................................................................... 58 
Competitive Cell Proliferation Assay ........................................................................... 59 
Cell Cycle Analysis ....................................................................................................... 60 
Senescence .................................................................................................................... 60 
Orthotopic Mice injections ............................................................................................ 60 
Unbiased gene expression analysis ............................................................................... 61 
Antibodies ..................................................................................................................... 63 
Statistical Analysis ........................................................................................................ 63 
CHAPTER 5: ACTIVATION OF NOTCH SIGNALING INHIBITS GROWTH  .. 64 
Chapter 5.1: NOTCH1 mutational status in HNSCC cell lines  .................................... 65 
Chapter 5.2: Activation of NOTCH1 in mutant HNSCC cell lines is detrimental to cell 
growth............................................................................................................................ 68 
Chapter 5.3: NOTCH1 activation appears to induce senescence and G1 growth arrest73 
Chapter 5.4: NOTCH1 or NOTCH2 is possibly sufficient to inhibit cell growth ........ 77 
Chapter 5.5: Restoration of full- length NOTCH1 is sufficient to inhibit cell growth .. 79 
Chapter 5.5: Activation of the NOTCH signaling pathway in wild-type cell lines 
inhibits cell growth ........................................................................................................ 88 
Chapter 5.6: Restoration of NOTCH signaling in mutant HNSCC cell lines inhibits in 
vivo tumorigenecity ..................................................................................................... 101 
Chapter 5.7: Inhibition of NOTCH signaling enhances tumor growth in vivo ........... 105 
Discussion ................................................................................................................... 109 
 ix 
CHAPTER 6: DOWSNTREAM EFFECTORS OF NOTCH MEDIATED 
GROWTH INHIBITION  ............................................................................................. 112 
Chapter 6.1: AXL and CTNNAL1 (α-catulin) are downstream of NOTCH signaling113 
Chapter 6.2: NOTCH1 modulates AXL and CTNNAL1 (α-catulin) at the protein level
 ..................................................................................................................................... 125 
Chapter 6.3: HES2 and HES5 may be sufficient to modulate AXL and α-catulin ..... 131 
Chapter 6.4: The 120 in vitro gene signature corresponds with NOTCH activation 
status in patients .......................................................................................................... 136 
Discussion ................................................................................................................... 150 
CHAPTER 7: INHIBITION OF AXL AND α-CATULIN MODULATES CELL 
GROWTH...................................................................................................................... 153 
Chapter 7.1: Knocking down AXL and α-catulin inhibits cell growth and tumor 
formation ..................................................................................................................... 154 
Chapter 7.2: HES2 and HES5 might be sufficient to inhibit cell growth ................... 163 
Discussion ................................................................................................................... 166 
CHAPTER 8: DISCUSSION AND FUTURE DIRECTIONS .................................. 168 
Activation of NOTCH signaling inhibits growth ........................................................ 172 
NOTCH and senescence.............................................................................................. 172 
NOTCH and differentiation ........................................................................................ 173 
Roles of NOTCH1 and NOTCH2 ............................................................................... 175 
Identification of downstream effectors of the NOTCH signaling pathway ................ 179 
Non-canonical NOTCH signaling ............................................................................... 185 
Canonical transcriptional modulation of NOTCH targets ........................................... 186 
Gene expression in TCGA HNSCC patient tumors .................................................... 193 
Inhibition of AXL and α-catulin modulates cell growth ............................................. 195 
HES2 and HES5 inhibtis cell growth .......................................................................... 197 
CHAPTER 9: CONCLUSIONS .................................................................................. 201 
Appendix ........................................................................................................................ 204 
Bibliography .................................................................................................................. 255 
Vita ................................................................................................................................. 297 
 
 
 
 x 
 
List of figures 
Figure 1: Anatomy of Head and Neck Squamous Cell Carcinoma (HNSCC). Permission 
obtained from Algiris, A., Karamouzis, M.V., Raben, D., and Ferris, R.L. (2008). Lancet. 
371 (9625): 1695-709. (Argiris et al., 2008)....................................................................... 4 
Figure 2: Molecular pathogenesis of HNSCC. Permission obtained from Califano, J., van 
der Riet, P., Westra, W., Nawroz, H., Clayman, G., Piantadosi, S., Corio, R., Lee, D., 
Greenberg, B., Koch, W., and Sidransky, D. (1996). Cancer Research. 56(11): 2488-92. 
(Califano et al., 1996) ......................................................................................................... 6 
Figure 3: Frequent somatic mutations in HNSCC by whole exome sequencing. 
Permission obtained from Agrawal, N., Frederick, M. J., Pickering, C. R., Bettegowda, 
C., Chang, K., Li, R. J., Myers, J. N. (2011). Science, 333(6046), 1154-1157. (Agrawal et 
al., 2011). .......................................................................................................................... 13 
Figure 4: Frequent somatic mutations in HNSCC. Permission obtained from Stransky, N., 
et al., (2011) Science.. 333(6046): p. 1157-60 (Stransky et al., 2011) ............................. 14 
Figure 5: Structure of NOTCH family receptors in drosophila and mammalian systems. 
Permission obtained from Kopan, R. and M.X. Ilagan. (2009). Cell. 137(2): p. 216-33. 
(Kopan & Ilagan, 2009) .................................................................................................... 20 
Figure 6: Structure of NOTCH ligands in drosophila and mammalian systems. Permission 
obtained from Kopan, R. and M.X. Ilagan. (2009). Cell. 137(2): p. 216-33. (Kopan & 
Ilagan, 2009) ..................................................................................................................... 23 
Figure 7:  NOTCH signaling pathway. Permission obtained from Kopan, R. and M.X. 
Ilagan. (2009). Cell. 137(2): p. 216-33. (Kopan & Ilagan, 2009)..................................... 27 
Figure 8: NOTCH1 protein expression levels in HNSCC cell lines ................................. 67 
 xi 
Figure 9:  Retroviral constructs of ICN1, ICN2 and NFL1 .............................................. 70 
Figure 10: Intracellular NOTCH1 is disadvantageous to the growth of mutant HNSCC 
cells. .................................................................................................................................. 71 
Figure 11: ICN1 infected mutant HN31 cells are smaller and rounder and some have a 
flattened package-like morphology compared to cells infected with the empty vector 
MigR1. .............................................................................................................................. 72 
Figure 12:  Mutant HNSCC cells HN31 undergoes senescence after restoring the 
activated form of NOTCH1 (ICN1). ................................................................................. 74 
Figure 13: Induction of p21 (a marker for senescence and cell cycle arrest) in HN31 cells 
infected with ICN1 but not MigR1 at two different time points (D3= Day 3 post infection 
and D5=Day 5 post infection) ........................................................................................... 75 
Figure 14: Activated NOTCH1 or NOTCH2 is sufficient to inhibit growth of HNSCC 
cell lines ............................................................................................................................ 78 
Figure 15: The fraction of mutant cells restored with NFL1 decreases progressively 
compared to cells infected with the empty vector. UM47 mutant cells infected with NFL1 
is selected against a mixed population of NFL1 and non-NFL1 expressing cells while 
cells infected with MigR1 remains steady through the 23 day time period. ..................... 82 
Figure 16: The fraction of mutant cells restored with NFL1 decreases progressively 
compared to cells infected with the empty vector. HN4 mutant cells infected with NFL1 
is selected against a mixed population of NFL1 and non-NFL1 expressing cells while 
cells infected with MigR1 remains steady through the 23 day time period. ..................... 83 
Figure 17: The fraction of mutant cells restored with NFL1 decreases progressively 
compared to cells infected with the empty vector. HN31 mutant cells infected with NFL1 
 xii 
is selected against a mixed population of NFL1 and non-NFL1 expressing cells while 
cells infected with MigR1 remains steady through the 23 day time period...................... 84 
Figure 18:  Restoration of NOTCH1 inhibits cell growth. Inhibition in the number of 
colonies of mutant cells after restoration with NFL1 and culture on Jagged1. (a: 
quantitation of clonogenic assay, b: crystal violet staining of colonies)  .......................... 85 
Figure 19:  NOTCH1 is activated only in mutant cells infected with NFL1 but not 
MigR1. Restoration of NFL1 in mutant cell lines induces cleavage of NOTCH1 when 
cultured on Jagged1 but not on Fc or uncoated plates.  ..................................................... 86 
Figure 20:  HN31, HN4 and UMSCC22A mutant HNSCC cells undergo senescence after 
restoring NFL1 and culturing on Jagged1 ........................................................................ 87 
Figure 21: Morphology change and senescence when NOTCH1 wild-type are cultured on 
Jagged1. Culture of wild-type cell lines on Jagged1 shows small, rounded and growth 
inhibited colonies, some of which undergo senescence compared to cells cultured on Fc.
........................................................................................................................................... 92 
Figure 22: Protein expression of Total-NOTCH1 and cleaved NOTCH1: Western blot 
depicting total NOTCH1 (Tm-NOTCH1) in wild-type and mutant cell lines and cleaved 
NOTCH1 (cl-NOTCH1) expression in wild-type cell lines cultured on Jagged1 ............ 93 
Figure 23: Wild-type cell lines cultured on Jagged1 are significantly growth inhibited  .. 94 
Figure 24: Inhibition of NOTCH signaling using γ-secretase inhibitor reverses NOTCH 
mediated growth suppression............................................................................................ 95 
Figure 25:  dnMAML1 reversed Jagged1 mediated growth inhibition ............................ 96 
Figure 26: CRISPR-Cas9 knockout of NOTCH1 (NOTCH1 KO), NOTCH2 (NOTCH2 
KO) or both ....................................................................................................................... 97 
 xiii 
Figure 27: Knocking out both NOTCH and NOTCH2 relieves Jagged1 mediated growth 
suppression. KO: Knockout .............................................................................................. 98 
Figure 28: Restoration of NFL1 in the double knock out cell line activates NOTCH 
signaling: CRISPR-Cas9 double knockout cell line PJA34 shows activation of NOTCH 
signaling after restoration with NFL1 and culturing cells on Jagged. KO: Knockout  ..... 99 
Figure 29: NOTCH signaling is necessary and sufficient to modulate cell growth. 
CRISPR-Cas9 NOTCH1 and NOTCH2 double knockout cell line PJA 34 promotes 
growth on Jagged1 and Fc that is inhibited after restoration with NFL1. ...................... 100 
Figure 30:  Restoration of NOTCH signaling in mutant HNSCC cell lines inhibits tumor 
growth (a) and increases overall survival (b) in a xenograft orthotopic model of oral 
cancer .............................................................................................................................. 103 
Figure 31:  NFL1 infected UM47 tumor xenografts appear more differentiated. Mutant 
UM47 infected with NFL1 (a, c) grew slowly in mouse tongues compared to UM47 
infected with control MigR1. (b, d). Anti-total NOTCH 1 staining (brown) of NFL1-
infected (a) or MigR1 infected (b) tumors. Growth of NFL1-infected tumors was more 
organized (c) and had keratin pearls (arrows) compared to MigR1 infected tumors, 
apparent after H&E stain................................................................................................. 104 
Figure 32:  NOTCH signaling may be necessary for inhibiting tumor growth.  ............. 107 
Figure 33:  Possibility of cis-inhibition when PJA34 and 183 cells are overexpressed with 
Jagged1............................................................................................................................ 108 
Figure 34:  Heat-map of 277 differentially expressed genes having treatment effects but 
not cell lines effects. Top green bar: control samples. Top orange bar: Jagged1 treated 
samples............................................................................................................................ 123 
 xiv 
Figure 35:  Heat map of 1571 differentially expressed genes that have both treatment and 
cell line effects. Top green bar: control samples. Top orange bar: Jagged1 treated samples
......................................................................................................................................... 124 
Figure 36:  Activated NOTCH1 (ICN1) is sufficient to suppress AXL and α-catulin. .. 127 
Figure 37:  Restoration of full length NOTCH1 (NFL1) in the mutant cell lines: HN31, 
UM22A and UMSCC47 after activation with Jagged1 suppress AXL and α-catulin .... 128 
Figure 38:  Inhibition of NOTCH signaling using dnMAML1 reverses Jagged1 induced 
suppression of AXL and α-catulin. ................................................................................. 129 
Figure 39: NOTCH signaling is necessary and sufficient to inhibit AXL and catulin: 
Knocking out NOTCH signaling using the CRISPR-Cas9 system induces AXL and α-
catulin which is reversed when the same cell line is restored with NFL1.  ..................... 130 
Figure 40:  Modulation of HES and HEY members after restoration of NOTCH signaling 
in HN31 cells and culturing on Jagged1 for 20h ............................................................ 133 
Figure 41:  HES2 and HES5 might be sufficient to modular protein expression of AXL, 
p-AXL, Gad6 and α-catulin. Overexpressing HES2 and HES5 using Flag tagged 
constructs in the mutant cell line HN31 inhibits protein expression of proto-oncogenes 
AXL and α-catulin. ......................................................................................................... 134 
Figure 42: Relative expression levels of Flag-Tag, HES5, AXL, p-AXL, α-catulin and 
Gas6 from the western blot shown in Figure 41 ............................................................. 135 
Figure 43: Heat-map of the 120 in vitro gene signature in Oral Cavity TCGA tumors  . 140 
Figure 44: Heat-map of the 120 in vitro gene signature in Laryngeal/Hyopharyngeal 
TCGA tumors.................................................................................................................. 142 
 xv 
Figure 45: Unsupervised clustering of 498 TCGA Oral Cavity (OC) tumors based on 
20,000 genes.................................................................................................................... 144 
Figure 46:  Unsupervised clustering of 498 TCGA Laryngeal/Hypopharyngeal (LH) 
tumors based on 20,000 genes ........................................................................................ 145 
Figure 47: Knockdown of AXL and α-catulin in wild-type cell lines 183 and PJA34 usign 
shRNA’s.......................................................................................................................... 157 
Figure 48: Knockdown of AXL and α-catulin in mutant cell lines UM22A and HN31 
using shRNA’s ................................................................................................................ 158 
Figure 49: Quantitation of the western blots after knocking out AXL and catulin in wild-
type cell lines 183 (above) and PJA 34 (below).  ............................................................ 159 
Figure 50: Quantitation of the western blots after knocking out AXL and catulin in 
mutant cell lines UM22A (above) and HN31 (below). ................................................... 160 
Figure 51: Clonogenic assay in wild-type (PJA34 and 183) and mutant cell lines 
(UM22A and HN31). Knocking down AXL (shAXL) and α-catulin (shCAT) inhibits cell 
growth in a colony forming clonogenic assay ................................................................ 161 
Figure 52: AXL and α-catulin modulates in vivo tumor formation and overall survival. 
Knocking down AXL and α-catulin using shRNA’s in a mutant cell line significantly 
inhibits tumor growth and increases overall survival ..................................................... 162 
Figure 53: HES2 and HES5 are sufficient to inhibit cell growth ................................... 165 
Figure 54: Basal NUMB expression in wild-type and mutant HNSCC cell line............ 171 
Figure 55:  Jagged1 expression in wild-type and mutant HNSCC cell lines .................. 171 
Figure 56:  ICN1 inhibits p63 expression ....................................................................... 182 
 xvi 
Figure 57:  Activation of NOTCH signaling by Jagged1 slightly inhibits protein 
expression of ΔNP63  ...................................................................................................... 183 
Figure 58: NOTCH1 and TP63 mutations tend to be mutually exclusive  ...................... 184 
Figure 59: Activated NOTCH1 increases gene expression of HES5  ............................. 188 
Figure 60: HES2 and HES5 don’t seem to transcriptionally modulate levels of AXL or 
CTNNAL1. ..................................................................................................................... 190 
Figure 61:  Promoter sequence of AXL lacks N-box or E-box motifs suggesting that HES 
and HEY might not directly transcriptionally regulate AXL gene expression.  .............. 191 
Figure 62: Promoter sequence of CTNNAL1 lacking N-box and E-box binding sites. . 192 
Figure 63: Possible mechanistic model of NOTCH mediated growth suppression........ 200 
 
 
 
List of Appendices 
Appendix 1: Differentially expressed genes after activation of NOTCH signaling in 
PJA34 and 183 cells. Green highlighted “Significance” cells show genes modulated 
based on treatment, independent of cell lines. Orange highlighted “Significance” cells 
show genes modulated based on treatment and cell lines ............................................... 205 
Appendix 2: Correlation heat-map in the Oral Cavity group ......................................... 247 
Appendix 3:Histogram of p-values testing Cluster 1 versus Cluster 2 in the Oral Cavity 
group ............................................................................................................................... 248 
Appendix 4: Ingenuity Pathway Analysis of significantly modulated pathways after 
NOTCH activation by Jagged1 in cell lines ................................................................... 249 
 xvii 
 
List of Tables 
Table 1: Core components of the NOTCH signaling pathway in Drosophila and 
mammals. .......................................................................................................................... 28 
Table 2: HNSCC cell lines. LN: Lymph Node, OC: Oral Cancer, HP: Hypopharyngeal, 
OP: Oropharyngeal, L: Lungs ........................................................................................... 51 
Table 3: Sample description.............................................................................................. 61 
Table 4: Antibodies description ........................................................................................ 63 
Table 5: NOTCH1 status in HNSCC cell lines................................................................. 67 
Table 6: ICN1 cells are arrested in the G1 phase of the cell cycle.  .................................. 76 
Table 7: Top 120 genes modulates when NOTCH signaling is activated. (Red= 
upregulates, Green= Downregulated when treated with Jagged1) ................................. 121 
Table 8: Ingenuity Pathway Analysis of significantly modulated pathways when NOTCH 
is activated in wild-type cell lines PJA34 and 183. (Red= Genes Upregulated by NOTCH, 
Green= Genes Downregulated by NOTCH).  .................................................................. 122 
Table 9: Total number of Oral Cavity (OC) patients in each cluster corresponding to 
NOTCH1 mutational status. Shown in parenthesis are expected numbers based on Chi-
Squared test ..................................................................................................................... 141 
Table 10: Total number of genes in each cluster of Oral Cavity (OC) patients 
corresponding to modulation by Jagged1 in cell lines. Shown in parenthesis are expected 
numbers based on Chi-Squared test. ............................................................................... 141 
 xviii 
Table 11: Total number of Laryngeal/Hypopharyngeal (LH) patients in each cluster 
corresponding to NOTCH1 mutational status. Shown in parenthesis are expected 
numbers based on Chi-Squared test ................................................................................ 143 
Table 12: Total number of Laryngeal/Hypopharyngeal (LH) patients in each cluster 
corresponding to NOTCH1 mutational status. Shown in parenthesis are expected 
numbers based on Chi-Squared test ................................................................................ 143 
Table 13: Clustering of genes modulated in both tumor sites corresponding to the genes 
clustered in cell lines....................................................................................................... 149 
 
 
 
 
 
 
 
 
 
 
 
 
 xix 
 
 
 
 
Dedication 
 
 
 
 
 
This thesis is dedicated to my Mom and Dad who have always showered me with their 
unconditional love and have been a source of tremendous determination and will power, 
supporting me in all my endeavors. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 xx 
Acknowledgments 
 
Five years of graduate school wouldn’t have been possible without the support 
and blessings of mentors, advisors, family and friends 
First and foremost, I’d like to thank the University of Texas Graduate School of 
Biomedical Sciences and M.D. Anderson Cancer Center for accepting me giving me all 
the support during my journey through the Ph.D. program. 
My heartfelt and deepest gratitude goes to Dr. Jeffrey Myers who humbly opened 
the doors of his lab for my training. Dr. Myers has not only been a great mentor, but also 
a role model from whom I am often motivated to pursue cancer research for the greater 
cause of curing patients.  I was very fortunate to be mentored by one of the most well 
accomplished physician-scientists in the country. I not only learned the fundamentals of 
bench work, but Dr. Myers often steered me in a way that during every experiment I 
performed, I had in mind the bigger picture of how we as scientists impact the clinical 
realm of therapy.    
I am also indebted to Dr. Mitchell Frederick who has guided me through every 
step of my training.  His dedication and hard work towards research has often motivated 
me as a graduate student.  Dr. Frederick taught me how to raise from downfalls and how 
to modestly embrace the highs and lows of research work. His composure and patience 
has always inspired me during the different stages of my training. There have been times 
of excitement and frustrations during which I have often barged into Dr. Frederick’s 
office and was always greeted by his calm and modest nature.  
 xxi 
I was fortunate to have a great committee who always supported and guided me 
through all my committee meetings in the past five years. I sincerely thank Dr. Gary 
Gallick, Dr. Patrick Zweidler-McKay, Dr. Paul Chiao and Dr. Rick Wetsel for being 
excellent mentors and guiding me through my projects with their constructive feedback. 
Dr. Rick Wetsel and Dr. Gary Gallick kindly allowed me to rotate in their respective labs 
when I first started graduate school giving me a warm welcome into the research realm. 
During my first week of graduate school, it was Dr. Rick Westel’s lab that give me 
exposure to the basics of stem cells and induced pluripotent stem cells that drove my 
passion to research and stabilized my decision to pursue a Ph.D. Dr. Gallick was not only 
my rotation mentor and committee member, but he also taught me the fundamentals of 
cancer biology and cancer metastasis in his classes/seminars. His lab gave me the first 
exposure to research in cancer therapy by targeting the IGF receptors in prostate cancer 
that motivated me to further my education in targeted therapy. Dr. Patrick Zweidler-
McKay was not only a committee member, but also our closest collaborator and often 
called “NOTCH expert” having guided us at every step of investigating the role of 
NOTCH signaling in Head and Neck Cancers through his expertise in hematopoietic 
malignancies. Special thanks to members of Dr. Zwediler-McKay’s lab; Drs. 
Sankarnarayan Kannan and Ritta Nolo for readily providing me with cells and plasmids 
whenever needed. Dr. Paul Chiao often welcomed me to his office with open doors and 
has many times given me positive feedback during my candidacy exam and my 
committee meetings. His guidance during my candidacy exam made me cross one of the 
major milestone of the Ph.D. program.  
 xxii 
Members of the Myers lab whom I often call the lab family have been great 
support during my training. Special thanks to current and former Myers lab members that 
include: Samar Jasser, Ameeta Patel, Mei Zhao, Rami Saade, Qiuili Li, Jiping Wang, 
Noriaki Tanaka, Curtis Pickering and David Neskey. In addition, I want to thank all the 
visiting scientists and former lab members who have kept the lab environment light and 
happy during times of stress.  
I don’t have words to express my gratitude to my Dad and Mom for their 
unconditional love and support throughout my education. My Dad, Mr. Srinivasan 
Moorthy and Mom, Mrs. Padma Moorthy are my greatest role models. I have learned to 
work hard and push myself beyond limits from my Dad. My Dad always taught me not to 
succumb to failures but to raise and face them to emerge successfully. My Mom has been 
great support in pursuing whatever dream I had. I often regard my Mom as my best friend 
with whom I have poured all my stress, frustrations, happiness and joy at all stages of my 
education from primary to graduate school. I thank my Dad and Mom for all the freedom 
they give me to achieve anything I want.  
Finally, I thank God for the will power and confidence through this educational 
journey in molding me into a successful doctorate   
 
 1 
 
 
 
 
 
 
CHAPTER 1: HEAD AND NECK 
SQUAMOUS CELL CARCINOMA 
(HNSCC) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 2 
Chapter 1: Head and Neck Squamous Cell Carcinoma (HNSCC) 
Anatomy and incidence 
 
Head and Neck cancers is a broad term encompassing cancers that arise in the 
upper aerodigestive tract and are usually localized to the oral cavity, oropharynx, larynx, 
hypopharynx, nasopharynx, paranasal sinuses and nasal cavity (Argiris, Karamouzis, 
Raben, & Ferris, 2008) (Figure 1). These cancers usually arise from the squamous 
epithelial cells that reside in the moist surfaces of the mucosal areas of the head and neck 
region. Thus, most head and neck cancers are squamous in nature giving it the term Head 
and Neck Squamous Cell Carcinomas (HNSCC). Head and neck cancers can also arise 
from different cell types, 90% of head and neck cancers are squamous cell carcinomas. 
Approximately 650,000 new cases and 350,000 HNSCC related deaths occur each year 
(Torre et al., 2015). HNSCC’s in the oral cavity is very common worldwide. Regions of 
high prevalence of oral cancers include Melanesia, South-central Asia, Eastern and 
Western Europe, and Southern Africa (F. Bray, Sankila, Ferlay, & Parkin, 2002). In the 
United States alone, 45,780 new cases and 8,650 head and neck cancer-related deaths 
occurred this year (Argiris et al., 2008). The approximate age for diagnosis is in a 
patient’s early 60’s. These cancers are predominant in the male population. According to 
the Surveillance Epidemiology and End Results (SEER) database, the 5-year survival for 
all stages combined in about 60%.  
Tobacco and alcohol consumption have been attributed as the major risk factors 
of HNSCC that is exacerbated when combined (Blot et al., 1988; Hashibe et al., 2006; 
Tuyns et al., 1988). Increased risk of HNSCC has been associated with polymorphisms in 
certain enzymes that have the ability to metabolize alcohol and tobacco (Hashibe et al., 
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2006). In parts of Southeast Asia, there is high incidence of oral cancers associated with 
chewing of betel quid (Proia, Paszkiewicz, Nasca, Franke, & Pauly, 2006).  
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Figure 1: Anatomy of Head and Neck Squamous Cell Carcinoma (HNSCC). Permission 
obtained from Algiris, A., Karamouzis, M.V., Raben, D., and Ferris, R.L. (2008). Lancet. 
371 (9625): 1695-709. (Argiris et al., 2008) 
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The risk of HNSCC in individuals with certain cancer susceptibility has shown to 
be increased. These include hereditary non-polyposis colorectal cancer, Li-Fraumeni 
syndrome, Fanconi’s anaemia, and ataxia telangiectasia (Foulkes et al., 1996; Trizna & 
Schantz, 1992) . Besides tobacco and alcohol, recently, the Human Papilloma Virus 
(HPV)- HPV16 and HPV18 has been identified as causal factor for HNSCC (G. D'Souza 
et al., 2007). It has been reported that approximately 25% of HNSCC’s contain HPV 
genomic DNA (Kreimer, Clifford, Boyle, & Franceschi, 2005). In terms of anatomic 
regions HPV causes HNSCC predominantly in the tonsils and base of tongue within the 
oropharynx and much less in the oral cavity and larynx (Hobbs et al., 2006). Although 
not completely mutually exclusive, HPV related HNSCC has been observed frequently in 
individuals without exposure to tobacco or alcohol and individuals who are 
immunosuppressed. HNSCC of this type is poorly differentiated and have the tendency to 
exhibit a basal cell histology (G. D'Souza et al., 2007). E6 and E7 viral oncoproteins have 
the ability to inactivate tumor suppressor genes such as p53 and pRb thus mediating their 
carcinogenic effects (Munger & Howley, 2002). HPV positive and negative tumors show 
differences in their gene expression patterns (Slebos et al., 2006).  HPV status can be an 
important biomarker for prevention, treatment and prognosis. HPV positive tumors have 
better response to therapy than HPV negative tumors (Califano et al., 1996). Furthermore, 
they are more susceptible to immune surveillance than HPV negative tumors. Lastly, 
vaccination against HPV has shown efficacy in preventing cervical cancer. This might 
also prove useful for HPV positive HNSCC (G. D'Souza & Dempsey, 2011).  
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Pathogenesis 
 
HNSCC is a heterogeneous disease whose development is governed by diverse 
genetic events leading to inactivation of tumor-suppressor genes and/or activation of 
proto-oncogenes (Figure 2). 
 
 
 
Figure 2: Molecular pathogenesis of HNSCC. Permission obtained from Califano, J., van 
der Riet, P., Westra, W., Nawroz, H., Clayman, G., Piantadosi, S., Corio, R., Lee, D., 
Greenberg, B., Koch, W., and Sidransky, D. (1996). Cancer Research. 56(11): 2488-92. 
(Califano et al., 1996) 
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HNSCC’s arise from a premalignant progenitor after which certain clonal 
populations accumulate genetic alterations that progress to invasive malignancy (Califano 
et al., 1996; Califano et al., 2000). These genetic alterations include somatic mutations, 
insertions, deletions, promoter methylation and gene amplifications that result in loss of 
tumor suppressor genes and/or activation of oncogenes. Califano et al. (Califano et al., 
2000) used PCR based microsatellite analysis to identify genetic alterations at different 
histopathological stages of progression of the lesion. The most common genetic alteration 
seen in HNSCC is the loss of 9p21, which is found in 70-80% of the cases seen in 
squamous dysplasia and HNSCC (Califano et al., 2000; van der Riet et al., 1994). Loss of 
Heterzygozity (LOH) of 9p21 is an early event in squamous neoplasia and has also been 
in pre-neoplastic lesions (van der Riet et al., 1994). The CDKN2A gene located at 9p21 
encodes p16 and p14ARF, which are responsible for G1 cell cycle regulation and MDM2-
mediated degradation of p53. Promoter methylation and homozygous deletions often 
inactivate p16 (Reed et al., 1996). Although the highest LOH frequency in benign 
squamous neoplastic lesions is 9p21, there is also LOH at 3p21 and 17p13 to a lesser 
extent (Califano et al., 1996). The loss of 3p is considered another major event that 
allows the benign hyperplasia to progress towards dysplasia (Hogg et al., 2002). For 
example, in the region 3p14, the exomic deletion of the FHIT gene (fragile histidine triad 
gene), a tumor suppressor gene, has been shown in HNSCC and other tumor types (Boyle 
et al., 1993; Hogg et al., 2002; Mao, Fan, Lotan, & Hong, 1996). The most frequently 
mutated gene TP53, located on 17p is mutated in over 80% of HNSCC ("TCGA Releases 
Head and Neck Cancer Data," 2015) . These mutations begin to appear during the 
progression of hyperplasia to dysplasia but most of these mutations occur late in the 
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progression towards invasive carcinoma (Boyle et al., 1993). Overexpression of cyclin 
D1 is often due to amplification of 11q13 has been seen in 30-60% of HNSCC and has 
been associated with lymph node metastasis and poor overall survival (Meredith et al., 
1995; Michalides et al., 1995).  Most transcriptional alterations in head and neck cancer 
pathogenesis occur during the transition from normal mucosa to premalignant lesions 
rather than premalignant lesions to invasive carcinomas (Ha et al., 2003). Amplification 
of the epidermal growth factor receptor (EGFR) is seen 90% of cases of HNSCC 
(Grandis & Tweardy, 1993). The EGFR, a receptor tyrosine kinase, binds to its ligand 
EGF and activates a molecular cascade that involves modulation of molecules involved 
with cell proliferation, growth, angiogenesis, apoptosis and metastatic potential (Rubin 
Grandis et al., 1998). Many studies have shown poor prognosis of cases with 
overexpression of EGFR. Targeting this receptor has been exploited and been successful 
for therapeutic purposes (Karamouzis, Grandis, & Argiris, 2007).  
Treatment 
 
Surgery is used as a conventional treatment strategy for HNSCC. This, however, 
is limited by tumor volume and cosmetic and functional concerns. For small tumors 
located in the oral cavity or pharynx, surgical excision is preferred with preservation of 
the functionality of the organ and good overall prognosis. Techniques such as 
microsurgical treatment or robotic techniques have shown significant progress. These 
techniques integrated with high-resolution magnified optics will likely have significant 
benefit (Ambrosch, 2007; Lefebvre, 2006).  
In addition to surgery, radiotherapy is an integral part of primary or adjuvant 
HNSCC treatment. Radiation therapy for HNSCC is typically administered daily at a 2.0 
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Gy dose for 5 days for a total of 70 Gy over a 7-week period. Post-operatively, radiation 
doses varying from 60-65 Gy are typically prescribed (Argiris et al., 2008). Clinical 
results from radiation therapy are very promising, and this is a major standard of care for 
tumors of the oropharynx, hypopharynx, and larynx.  Nevertheless,but it’s use is 
associated with significant sequelae and occasional complications in the peri-treatment 
period and many years later due to the progressive effects on tissue vasculature and 
fibrosis.(Konski et al., 2006).  
Chemotherapy plays an important role in HNSCC treatment. Platinum 
compounds, anti-metabolites, and taxanes have shown effectiveness in treating HNSCC. 
Cisplatin, a platinum based compound is regarded as the standard chemotherapeutic agent 
in combination with surgery and/or radiation. Like cisplatin, carboplatin is also used but 
is less effective as a combination regimen (Colevas, 2006). Taxane based combinations 
have been tested successfully in induction and/or concomitant treatment of locally 
advanced HNSCC. Cetuximab, an antibody against EGFR, was the first targeted agent 
introduced in chemotherapy (Grandis & Tweardy, 1993). The combination of EGFR 
inhibitors and other target agents (such as angiogenesis inhibitors) has surfaced as novel 
treatment strategies and their effectiveness in combination with surgery and/or 
radiotherapy is under investigation.  
Field cancerization 
 
Slaughter and colleagues first described the concept of field cancerization when 
they observed multiple independent tumors surrounding the mucosa adjacent to the 
HNSCC (Slaughter, Southwick, & Smejkal, 1953). Slaughter suggested that there are 
large areas in the aerodigestive tract mucosa affected by long term exposure to 
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carcinogens that results in genetic events independent of the primary tumor site resulting 
in genetically altered fields. Techniques such as chromosome X inactivation, 
microsatellite analysis and p53 mutational status have confirmed the presence of these 
alterations neighboring the primary HNSCC site, confirming Slaughter’s concept of field 
cancerization (Califano et al., 1996). Although these independent genetic lesions result in 
satellite tumor sites, there is evidence that tumors arising in these fields are clonally 
related and arise from a common neoplastic progenitor. It is possible that these 
transformed cells might have micro-metastasized across the aerodigestive tract. The 
clinical implication of a field is that it may be a potential source of local recurrence and 
second primary tumors after surgical resection of the primary tumor. The genetic 
constitution of the field is currently not completely understood but in recent studies that 
stained for p53, genetic changes at chromosome 9p, decreased Keratin 4 expression and 
decreased cornulin expression are potential biomarkers with this regard (Karamouzis et 
al., 2007).  
Sequencing studies in HNSCC 
 
Cancer, in general, arises through accumulation of genetic and epi-genetic 
changes often caused due to carcinogen exposure. This induces alterations in signaling 
pathways that result in cancer related phenotypes such as unlimited replicative potential, 
self-sufficiency in growth signals, insensitivity to anti-growth signals, ability to evade 
apoptosis, invasion and metastasis, and angiogenesis which has been well summarized by 
Hanahan and Weinberg (Hanahan & Weinberg, 2011). The accumulation of these 
aberrant pathways is often secondary to a lifetime of environmental exposure to 
carcinogens such as tobacco and alcohol that results in enhanced proliferation, 
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dedifferentiation, immortalization and loss of cell death of epithelial cells in the mucosa. 
Therefore, a deeper understanding of the molecular biology of HNSCC is needed to 
enhance the development of therapeutic approaches.  Investigators have identified several 
critical genes important in HNSCC progression. These include TP53(Poeta et al., 2009), 
CDKN2A(Demokan et al., 2012), Cyclin D1(Papadimitrakopoulou et al., 2001), 
PIK3CA(Murugan, Hong, Fukui, Munirajan, & Tsuchida, 2008), HRAS and 
EGFR(Bonner et al., 2010). The approaches used for the identification of these genes 
involved fluorescence in situ hybridization (FISH), immunohistochemistry (IHC), 
promoter methylation studies, histone modification analysis and copy number variations 
from extracted tumors compared to the surrounding normal tissues. Despite efforts to 
identify biomarkers in HNSCC, no prognostic marker has been able to predict the 
response to treatments. On the contrary, other tumor types have drug-able targets and 
specific genetic alterations predictive of treatment outcomes (Rothenberg & Ellisen, 
2012). These imclude HER2 amplifications in breast cancers, BRAF mutations in 
melanoma, and JAK2 in hematopoietic malignances. In breast cancers, PIK3CA is 
mutated at a frequency of 30%, while FGFR2, which is mutated in 20% of endometrial 
and lung cancers, has been investigated as a target in clinical trials (Thariat et al., 2015). 
Until 2011, the mutational status in HNSCC was not completely understood. 
Identification of targetable genes by next generation sequencing (NGS) opened new 
avenues for personalized cancer therapy.  
In order to gain a better understanding of the genetic alterations in HSNCC, 
Aggarwal and colleagues (Agrawal et al., 2011) (Figure 3) and Stransky and colleagues 
(Stransky et al., 2011) (Figure 4) used high throughput next generation sequencing to 
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analyze the genomic alterations found in HNSCC. Both groups performed whole exome 
sequencing from 32 and 74 primary tumors, respectively and compared the sequence to 
the corresponding normal DNA of the same patient (Figures 3 and 4). Agarwal and 
colleagues (Agrawal et al., 2011) used the Illumina or SOLiD platform to sequence the 
DNA with coverage of 77 or 40-fold respectively and approximately 90% of the targeted 
bases were represented by at least 10 reads in these platforms. They identified 911 
somatic mutations in 725 genes among the 32 tumors. Furthermore, Sanger and/or 454 
sequencing was used to validate these findings.  
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Figure 3: Frequent somatic mutations in HNSCC by whole exome sequencing. 
Permission obtained from Agrawal, N., Frederick, M. J., Pickering, C. R., Bettegowda, 
C., Chang, K., Li, R. J., Myers, J. N. (2011). Science, 333(6046), 1154-1157. (Agrawal et 
al., 2011). 
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Figure 4: Frequent somatic mutations in HNSCC. Permission obtained from Stransky, 
N., et al., (2011) Science.. 333(6046): p. 1157-60 (Stransky et al., 2011) 
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Mutations identified from these studies confirmed previous reports of alterations 
in TP53, CDKN2A, PIK3CA, PTEN and HRAS. In both studies, novel inactivating 
mutations in NOTCH1 were found. This was the first time mutations in NOTCH1 in 
solid tumors were reported. NOTCH signaling is involved in the development of 
multicellular organisms. Maintenance of stem cells and differentiation are two processes 
by which NOTCH signaling regulates development. NOTCH signaling in cancer was first 
highlighted in T-cell Acute Lymphoblastic Leukemia (T-ALL) in which constitutive 
activation of NOTCH signaling promotes tumorigenesis. The role of NOTCH1 in T-ALL 
was found as a result of translocation of the NOTCH1 gene from chromosome 7 to 
chromosome 9 adjacent to the T-cell Receptor β enchancer/promoter (Reynolds, Smith, 
& Sklar, 1987). However such translocations was found in less than 1% of all human T-
ALL. Weng et al. (Weng et al., 2004) published that more than 50% of all T-ALL have 
activating mutations in NOTCH1, revealing an oncogenic function of this protein in T-
ALL. Pear et al. (W. Pear et al., 1999) showed that mice when reconstituted with 
hematopoietic progenitor cells expressing the human intracellular NOTCH1 (ICN1) 
develop T-cell leukemia.  
NOTCH1 acts as a tumor suppressor or oncogene (Egloff & Grandis, 2012) 
depending on cancer type. In HNSCC, both Agarwal et al. (Agrawal et al., 2011), and 
Stransky et al. (Stransky et al., 2011) have shown loss of function mutations consistent 
with a tumor suppressor role. Targeting NOTCH signaling with gamma secretase 
inhibitors in T-ALL has shown pre-clinical activity in inhibiting tumorigenesis and 
currently being evaluated clinically. In contrast, the role of NOTCH signaling as a tumor 
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suppressor has been difficult to target in certain cancers due to loss of this pathway and a 
lack of NOTCH agonists.  
Evidence of NOTCH as a tumor suppressor comes from studies in keratinocytes. 
NOTCH1 signaling in murine keratinocytes upregulates early differentiation markers 
such as keratin 1 and involucrin as well as WAF1 allowing terminal differentiation in the 
suprabasal layers of the skin (Nicolas et al., 2003). Recently Pickering et al. (Pickering et 
al., 2013) performed whole exome sequencing from primary cutaneous cell carcinoma 
that identified the tumor suppressive role of NOTCH1 as a potential driver in this cancer 
type. The mutational landscape of cutaneous squamous cell carcinoma is similar to 
HNSCC. In both cancers, alterations in NOTCH1 appear to be inactivating. The missense 
mutations cluster in the EGF-like repeats and truncating mutation are distributed 
throughout the gene except the PEST domain, which in contrast is found in T-ALL. More 
than 30% to 50% tumors with NOTCH1 mutations in cSCC have inactivating NOTCH1 
mutations, further supporting the role of this gene as a tumor suppressor. Recently, Mao 
et al. (Song et al., 2014) sequenced 52 Chinese patients with HNSCC and detected 
NOTCH1 mutations in 43% of the tumors. Although, this group confirmed previous 
reports of inactivating mutations in the EGF domain, interestingly, 29% of the mutations 
were localized to the NOTCH1 the LNR domain. This is a domain is located close to the 
heterodimerization domain that harbors activating mutations in hematologic 
malignancies, however, the functional impact of these mutations remains unclear. 
Califano et al. (Sun et al., 2014) evaluated copy number variations, gene expression, 
methylation and mutations from 44 HNSCC primary tumors. They found a bimodal 
pattern of NOTCH signaling pathway expression in which a smaller set of mutants 
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exhibited inactivating NOTCH1 mutations, whereas a larger subset exhibited 
overexpression or increased gene copy number of the NOTCH receptor, ligands or 
downstream pathway activations. Although this group found significant upregulation of 
the NOTCH ligands, JAG1 and JAG2, it is unclear whether their overexpression within 
the same tumors would contribute to cis-inhibition or activation of the pathway. 
Moreover, copy number gains in NUMB, an inhibitor of the NOTCH pathway, were also 
found with JAG1 gains. This might argue that both cis-inhibition and inhibition by 
NUMB might downregulate the NOTCH signaling pathway in tumors. Whether 
overexpression of ligands in the same tumor contributes to cis-inhibition should be 
further investigated. Over the past 4 years, several efforts have been made to identify 
frequent somatic mutations in HNSCC, however few have offered insights into the 
mechanistic role of NOTCH as an oncogene or tumor suppressor. Recent TCGA data 
showed that inactivating mutations in FAT1 and NOTCH1 are not mutually exclusive. 
FAT sequesters β-catenin and inhibits the Wnt signaling cascade. These findings touch 
upon the mechanistic insights into the essential interplay between NOTCH signaling and 
the Wnt pathway. So far, we know that in a subset of HNSCC tumors, NOTCH might act 
as a tumor-suppressor and in the others it might play the role of an oncogene. This might 
depend on tumor type, stage, extracellular factors or the microenvironment, but is not 
completely understood. The main objective of this thesis is to provide data that support a 
tumor suppressor role for NOTCH1 in a subset of HNSCC through functional and 
mechanistic studies. In addition, we offer insights into how these tumors might be 
targeted by identification of the association of NOTCH signaling with two potential 
proto-oncogenes AXL and α-catulin that are suppressed after NOTCH activation.    
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Chapter 2: NOTCH signaling 
Structure of NOTCH receptor 
 
NOTCH is family of transmembrane receptors that are involved in cell-cell 
interaction. Mammals have four NOTCH (NOTCH 1-4) paralogs that have both unique 
and redundant functions. The NOTCH receptor can be broadly structured into 4 regions: 
extracellular domain, transmembrane domain, intracellular domain and PEST domain 
(Figure 5) (Kopan & Ilagan, 2009). 
The extracellular domain of all NOTCH receptors contain 29-36 tandem 
epidermal growth factor (EGF) – like repeats which are involved in binding to the 
NOTCH receptor of the adjacent cell. Interactions between the receptor of one cell and 
the ligand of a neighboring cell are called trans activation. This occurs by the binding of 
the EGF repeats 11-12 on the NOTCH receptor. On the contrary, binding of the NOTCH 
receptor and ligand on the same cell results in inhibition of the pathway called cis- 
inhibition. This includes EGF repeats 24-29 on the NOTCH receptors that bind to the 
ligand expressed by the same cell. Calcium ions play an important role in ligand-receptor 
binding. The EGF repeats binding to calcium ions can determine structure and affinity of 
binding. The extracellular region is composed of a Negative Regulatory Region (NRR) 
which has three cysteine-rich Lin12-NOTCH repeats (LNR) in addition to a 
heterodimerization domain (Figure 3). This NRR is important as it prevents activation of 
the NOTCH pathway without ligand binding. The region below the heterodimerization 
(HD) domain contains a cleavage site called S1, which is the site for furin- like 
convertases. 
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Figure 5: Structure of NOTCH family receptors in drosophila and mammalian systems. 
Permission obtained from Kopan, R. and M.X. Ilagan. (2009). Cell. 137(2): p. 216-33. 
(Kopan & Ilagan, 2009) 
Figure legend: EGF: Extracellular Growth Factor, NRR: Negative Regulatory Region, 
LNR: Lin12 NOTCH Repeats (LNR A, B and C), HD: Heterodimerization Domain, 
TMD: TransMembrane Domain, RAM: RBP-Jκ Association Module, ANK: ANKyrin 
Repeats, NLS: Nuclear Localization Sequence, TAD: TransActivation Domain, OPA: 
glutamine rich repeat, QQ: Glutamine repeats, PEST: Proline/Glutamic 
acid/Serine/Threonine rich motif, Ofut: fucosylation motifs (green: common, light blue: 
unique), Rumi: glycosylation motifs (dark blue: common, magenta: unique), NECD: 
NOTCH ExtraCellular Domain, NTMIC: NOTCH TransMembrane and Intracellular 
Domain. 
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Cleavage at S1 converts full length NOTCH into a NECD-NTMIC (NOTCH 
extracellular domain- NOTCH transmembrane Intracellular domain) that is bound by 
covalent interactions between the N and C- terminus of the HD domain. The furin-like 
cleavage at S1 is part of the secretory pathway that occurs in the golgi before NOTCH 
receptor gets translocated to the plasma membrane. The transmembrane domain (TMD) 
contains a “stop translocation” signal that has 3-4 Arg/Lys residues that regulates 
translocation of the receptor. After the TMD, begins the intracellular domain. The 
domain near the N-terminus of the intracellular region contains a RAM domain (RBPj 
association module), with 12-20 amino acids centered around a conserved WxP motif 
(Lubman, Korolev, & Kopan, 2004). RAM is linked to several ankyrin repeats (ANK) by 
one nuclear localization sequence (NLS). Following the ANK, are more NLS and a 
transactivation domain (TAD). The end C-terminus contains proline/glutamic 
acid/serine/threonine (PEST) motifs that governs the stability of NICD.  
Structure of NOTCH ligands 
 
NOTCH ligands may be present in the same cell or adjacent cells that bind to the 
extracellular domains of the NOTCH receptor. Most NOTCH ligands are also type 1 
transmembrane proteins and are membrane bound like the receptors. Cordle and 
colleagues (Cordle et al., 2008) employed X-ray and NMR techniques to study the 
structure of the NOTCH receptor. These receptors are characterized by three related 
structural motifs: N-terminal DSL (Delta/Serrate/LAG-2), EGF repeats called the DOS 
domain (Delta and OSM-11 like proteins) and EGF like repeats (Figure 6). The DSL and 
DOS domains are both involved in binding to the NOTCH receptor. Mammals have two 
types of NOTCH ligands, Jagged1/Jagged2 and Delta like ligand 1, 3 and 4 (DLL1, 3, 4). 
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Both Jagged ligands have a cysteine rich domain, which is absent from DLL1. Additional 
proteins that lack DSL or DOS domains have been reported as non-canonical ligands for 
the NOTCH receptor. For example, F3/Contactin1, NB-3/Contactin6 DNER and MAGP1 
have been reported in the central nervous system and in cultured cells (B. D'Souza, 
Miyamoto, & Weinmaster, 2008). These non-canonical receptors have been unexplored 
and their physiological functions in the NOTCH signaling pathway hasn’t been 
elucidated. After binding of the ligand to the receptor, endocytosis of the ligand is 
triggered by the cell expressing the ligand. E3 ubiquitin ligases like Neuralized and 
Mindbomb monoubiquitinate the ligand that is followed by degradation of the ligand. 
After endocytosis, in a process that is not completely understood, cells produce more 
active surface ligands (Le Borgne, 2006).  
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Figure 6: Structure of NOTCH ligands in drosophila and mammalian systems. 
Permission obtained from Kopan, R. and M.X. Ilagan. (2009). Cell. 137(2): p. 216-33. 
(Kopan & Ilagan, 2009) 
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NOTCH activation and regulation 
 
The binding of the NOTCH ligand to its receptor results in a sequence of 
proteolytic events. The first proteolytic cleavage occurs at site S2 (located just before the 
TMD and in the NRR) by ADAM metalloproteases (Figure 7). S2 cleavage is one of two 
key proteolytic cleavages that is often mediated by ADAM17/TACE. After S2 cleavage, 
an intermediate receptor called NOTCH Extracellular Truncation (NEXT) is formed that 
is still tethered to the plasma membrane. The S2 cleavage exposes the receptor to another 
key cleavage site called site 3, S3 that is located within the transmembrane domain. The 
enzyme that cleaves the NOTCH receptor at S3 is called -secretase. This enzyme 
belongs to a class of intermembrane cleaving proteases (i-CLiPs) (Wolfe & Kopan, 
2004). Only after cleavage by -secretase, the NOTCH intracellular domain (NICD) (also 
called Intracellular NOTCH (ICN) or activated NOTCH) is released from the plasma 
membrane and translocates to the nucleus. In the nucleus, it interacts with DNA binding 
proteins CSL (CBF1/RBPj) via its RAM domain. The ANK domain associates with 
CSL, which then recruits a co-activator called Mastermind- like 1(MAML1). This 
complex then binds to the promoter regions of their targets and regulate diverse 
phenotypes. Canonically, these targets belong to the HES and HEY family of genes that 
are known transcriptional repressors.  
The NOTCH ligand, meanwhile, is endocytosed by E3 Ubiquitin ligase in the 
neighboring cell. Mindbomb and Neuralized are E3 Ubiquitin ligases that recognize 
Jagged and Delta ligands respectively. After endocytosis, the process by which NOTCH 
ligands re-surface to the plasma membrane is not completely understood. Ligand 
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clustering, post-translational modifications and/or recycling ligands to specific membrane 
microdomains are some potential explanations (Pfister et al., 2003).  
Just like the NOTCH ligand, several processes also regulate the NOTCH receptor. 
E3 ubiquitin ligases such as Deltex, Nedd4, and Cbl1either recycle the receptors or target 
them for lysosomal degradation (S. J. Bray, 2006; Le Borgne, 2006). Another key 
molecule involved in regulation of the NOTCH receptor is NUMB, which in association 
with the AP2 component α-adaptin promotes NOTCH degradation. NUMB is a 
membrane-associated phosphotyrosine binding (PTB) protein that was first discovered as 
a cell fate determinant in Drospophila melanogaster (M. Park, Yaich, & Bodmer, 1998; 
Uemura, Shepherd, Ackerman, Jan, & Jan, 1989).  The antagonistic effect on NUMB on 
NOTCH signaling has drawn attention to the role of NUMB in several cancers (Flores, 
McDermott, Meunier, & Marignol, 2014). The exact mechanism of NUMB inhibiting 
NOTCH signaling is not completely understood, but two models have been suggested for 
such inhibition. Endosomal trafficking of NOTCH is essential for its activation, 
regulation and degradation (Yamamoto, Charng, & Bellen, 2010). NUMB associates with 
AP2 adapter complex via α-adaptin in clathrin coated pits and is involved in endocytic 
trafficking (Santolini et al., 2000). This model suggests the possibility of NOTCH being 
endocytosed and thus inhibited by NUMB. On the other hand, NUMB can also directly 
bind to ICN and prevent its translocation to the nucleus. This was shown by Frise et al., 
(Frise, Knoblich, Younger-Shepherd, Jan, & Jan, 1996) by co-expressing NOTCH and 
NUMB that prevented translocation of ICN. Both these models suggest an inhibitory role 
of NUMB in regulating NOTCH signaling.  
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Besides E3 ubiquitin ligases and NUMB, post-translational modifications, 
particularly glycosylation (the process of adding glycans to proteins), at the EGF repeats 
of the NOTCH receptor is another mechanism of regulation. The NOTCH receptors have 
been thought of as large glycoproteins. Two forms of O-glycosylation; O-glucose and O-
fucose modify the EGF repeats of the receptor (Haines & Irvine, 2003; Rampal, Luther, 
& Haltiwanger, 2007; Stanley, 2007). Post-translation, NOTCH receptor is fucosylated 
by O-fucosyltransferase. O-fucosylation facilitates proper folding of the receptor in the 
endoplasmic reticulum. The addition of O-fucose and/or O-glucose determines specificity 
of ligand binding. For example, fringe mediated addition of N-glucosamine on EGF 
repeat 12 enhances binding of the receptor to Delta but reduces its binding to Serrate in 
Drospophila melanogaster (Wu & Bresnick, 2007). In mammals, multiple fringe proteins 
(Lunatic, Manic and Radical fringes) regulate fucosylation of NOTCH receptors and their 
ligands. For example, luatic fringe modifies NOTCH signaling in T-cells such that it 
enhances binding to Delta like ligand but not Jagged1 (Tsukumo, Hirose, Maekawa, 
Kishihara, & Yasutomo, 2006; Visan et al., 2006). Although the mechanistic contribution 
of these saccharides to NOTCH biology is not completely understood, the development 
of improved methods to detect glycosylation and the generation o-glycosylation deficient 
NOTCH alleles will be important contributors to NOTCH biology. Table 1 summarizes 
the core components of the NOTCH signaling pathway in Drosophila and mammalian 
systems.  
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      Figure 7:  NOTCH signaling pathway. Permission obtained from Kopan, R. and M.X. 
Ilagan. (2009). Cell. 137(2): p. 216-33. (Kopan & Ilagan, 2009) 
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Table 1: Core components of the NOTCH signaling pathway in Drosophila and 
mammals.  
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NOTCH signaling in differentiation 
 
The NOTCH signaling pathway is an evolutionarily conserved pathway from 
invertebrates to vertebrates. NOTCH signaling is critical to the maintenance and renewal 
of several organs that include skin, blood, intestine, liver and muscle. NOTCH plays an 
important role in stem cells, in that it determines whether stem cell continue to proliferate 
and maintain their stemness or promote the differentiation of stem cells to progenitors or 
terminally differentiated cells. Embryonic stem (ES) cells are derived from the early 
embryonic stages and are pluripotent (Thomson et al., 1998). These cells express 
NOTCH1, however the progenitor cells from which these ES cells are derived do not 
express NOTCH1 (Hadland et al., 2001). The activation of NOTCH signaling at different 
stages of ES cell differentiation has been shown to enhance the generation of particular 
precursor cells (P. M. Chen et al., 2008; Kobayashi et al., 2009). Schroeder et al. 
(Schroeder & Just, 2000) have shown that activation of NOTCH signaling in mesodermal 
cells blocks the generation of endothelia, cardiac muscle, and hematopoietic cells while 
inhibition of NOTCH signaling in ES cells (by deletion of RBP-Jκ) directs differentiation 
of the cardiomyocyte lineage. On the other hand, NOTCH signaling also plays an 
important role in the differentiation of a variety of progenitor cells. In the hematopoietic 
system, Delta1 ligand mediated NOTCH1 activation has shown to stimulate 
megakaryocytic development from hematopoietic stem cells (Mercher et al., 2009). In T-
cell progenitors, it has been shown that NOTCH gain of function induced by 
overexpression of NOTCH1 or stimulation with DLL1 and DLL4 ligands led to aberrant 
proliferation and differentiation (de La Coste et al., 2005; Hozumi, Abe, Chiba, Hirai, & 
Habu, 2003; Jaleco et al., 2001; Pui et al., 1999). On the contrary, loss of function studies 
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using inactivated NOTCH1, mutant RBP-Jκ or using the γ-secretase inhibitor produced a 
similar phenotype in B-cell progenitor cells (Hadland et al., 2001; H. Han et al., 2002).  
Put together, NOTCH signaling instructs differentiation along the T-cell rather than the 
B-cell lineage during lymphopoiesis.  
In addition to hematopoiesis, NOTCH signaling also plays an important role in 
skin differentiation. The epidermis has four layers: basal, spinous, granular and cornified. 
Each layer expresses different markers. Adult stem cells reside either in the basal layer or 
in the bulge of the hair follicle. Stem cells at the basal layer are unipotent and these cells 
commit to terminal differentiation (Blanpain & Fuchs, 2006; Fuchs & Raghavan, 2002) 
while the stem cells at the follicle bulge are usually quiescent and enter the proliferative 
stage in response to injury (Blanpain & Fuchs, 2009; L. Li & Clevers, 2010). NOTCH 
signaling modulates differentiation and proliferation of epidermal stem cells (Ambler & 
Maatta, 2009; Okuyama, Tagami, & Aiba, 2008; Watt, Estrach, & Ambler, 2008). 
Condition gain of function (NICD overexpression) and loss of function studies 
(NOTCH1 -/-) have shown that NOTCH signaling promotes basal to spinous 
differentiation (Blanpain, Lowry, Pasolli, & Fuchs, 2006; Rangarajan et al., 2001). Dotto 
et al. (Dotto, 2008) and others (Demehri, Turkoz, & Kopan, 2009; Nicolas et al., 2003) 
have shown that embryonic ablation of RBP-Jκ in the epidermis causes epidermal 
hyperplasia. After birth, loss of NOTCH results in hyperplasia, creating a tumor-
promoting microenvironment. NOTCH as a tumor suppressor in skin highlights the 
complex role played by NOTCH signaling in controlling epidermal differentiation and 
regulating exit from the proliferative stem cell niche. In the follicular bulge stem cell 
population, NOTCH signaling functions as a gate-keeper. In the absence of NOTCH, 
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stem cells can select either epidermal or follicular differentiation (Demehri & Kopan, 
2009). The differences observed in the specific activities of NOTCH signaling in 
different stem cell populations plays a complex, context dependent role in stem cell 
biology. 
 
NOTCH in cancer 
 
NOTCH signaling plays diverse roles during the development and maintenance of 
normal tissues. This effect is recapitulated in several forms of cancer. NOTCH may act as 
a tumor suppressor or and oncogene depending on the context and exerting its effect on 
differentiation, growth, migration, angiogenesis and self-renewal. In this chapter, the role 
of NOTCH as an oncogene and tumor suppressor will be elucidated. 
NOTCH as an oncogene 
 
The best-known example of oncogenic NOTCH signaling is in T-cell acute 
lymphoblastic leukemia (T-ALL) that is a neoplasm of immature T-cells. The first known 
role of NOTCH1 in T-ALL was known because of its translocation from chromosome 7 
to chromosome 9 (Ellisen et al., 1991). This translocation was found only in 1% of all T-
ALL’s. A much broader role of NOTCH1 was revealed after the discovery of activating 
mutations in this cancer type. Activating mutation in NOTCH1 was found at frequency of 
60% (Weng et al., 2004). There are two types of activating mutations in T-ALL.  The 
first occurs at the heterdimerization domain that results in ligand independent 
metalloprotease cleavage at the S2 site.  The second consists of frame shift mutations or 
stop codons at the PEST degradation domain. Such mutations prevent degradation of 
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NOTCH and stabilize the NICD (Malecki et al., 2006). In the murine system, NOTCH1 
plays a role in the early stages of T-cell development, including commitment to T-cell 
fate and subsequent progression to the DN3 stage of development. This suggests that the 
leukemogenic activity stems from exaggerated normal development function (Radtke, 
Wilson, Mancini, & MacDonald, 2004). Besides, T-ALL, NOTCH signaling also has 
oncogenic functions in other contexts, especially breast cancer, medulloblastoma, 
colorectal cancer, non-small cell lung carcinoma and melanoma (Ranganathan, Weaver, 
& Capobianco, 2011). The oncogenic function of NOTCH in solid tumors was first 
discovered in breast cancers, which was driven by mouse mammary tumor virus 
(MMTV). Integration of MMTV in the host genome resulted in the constitutively active 
form of NOTCH4 (Gallahan, Kozak, & Callahan, 1987). The expression of NOTCH 
receptors is elevated in breast cancers and the expression of NOTCH ligands such as 
Jagged1 correlates with more aggressive disease (Reedijk et al., 2005; Weijzen et al., 
2002). Recently, activating mutations in chronic lumphocytic leukemia (CLL) has been 
identified. NOTCH1 activating mutations in this cancer type predicts to impair FBW7 
degradation of NOTCH1 (Fabbri et al., 2011). NOTCH receptor expression and its 
downstream targets are up regulated in primary human melanomas (Balint et al., 2005). 
Forced expression of intracellular NOTCH (NICD) promotes melanoma progression. 
Increased NOTCH activity has been correlated with PI3K-Akt activity in melanoma cells 
(Z. J. Liu et al., 2006). To date, no gain of function mutations have been discovered in 
solid tumors suggesting the ligand activation of the receptor dominates the role of 
NOTCH as an oncogene (Lobry, Oh, & Aifantis, 2011). Recently, other work has implied 
the role of NOTCH as an oncogene in other solid tumors such as medulloblastoma 
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(Hallahan et al., 2004) and ovarian cancer (J. T. Park et al., 2006). It is likely that there 
might be other neoplasms in which the oncogenic function of NOTCH will be uncovered 
in the future.  
NOTCH as a tumor suppressor 
 
Although activation of NOTCH can be oncogenic, there is also sufficient 
evidence to show that NOTCH can be tumor suppressive. This has been shown in skin, 
pancreatic epithelium, hepatocyte and other hematopoietic cells. In skin keratinocytes, 
activation of NOTCH in the suprabasal layers results in differentiation and cell cycle 
arrest (Rangarajan et al., 2001). Conditional knock out of NOTCH1 in the skin resulted in 
increase of the basal epidermis. Loss of NOTCH1 in the skin causes spontaneous basal 
cell carcinoma and increased sensitization to chemically induced skin carcinogenesis 
(Nicolas et al., 2003). Viatour and colleagues (Viatour et al., 2011) showed that NOTCH 
acts a tumor suppressor in hepatocellular carcinoma (HCC). They found that inhibition of 
NOTCH signaling using the γ-secretase inhibitor accelerated HCC development. 
Furthermore, using intracellular NOTCH1 (ICN1) resulted in cell cycle arrest and 
apoptosis. In order to evaluate the clinical relevance, the authors looked at patient 
survival and its correlation with NOTCH. They found better patient survival in cohorts 
that had increased NOTCH related genes. Taken together, their results suggest a tumor 
suppressive role of NOTCH in HCC. Zweidler-McKay et al. showed that in B-cell 
malignancies, NOTCH is known to arrest cell growth and induce apoptosis suggesting a 
tumor suppressor role (Zweidler-McKay et al., 2005). This role of NOTCH has also been 
elucidated in neruoblastoma using the activated intracellular form of NOTCH (ICN) or 
activation by recombinant NOTCH ligand (Zage et al., 2012).  The recently published 
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work in HNSCC sheds light on inactivating mutation seen in NOTCH1 which renders 
this protein an oncogene in this tumor type (Agrawal et al., 2011; Stransky et al., 2011; 
"TCGA Releases Head and Neck Cancer Data," 2015). These were initial sequencing 
studies that identified NOTCH as a tumor suppressor based on the mutational landscape. 
The functional significance of these inactivating mutations is currently unknown and is 
the main focus of this thesis.  
The role of NOTCH as an oncogene in breast, T-ALL, and ovarian cancer versus 
tumor suppressor in skin, HNSCC, and HCC highlights an intriguing dual role of 
NOTCH that is context dependent. NOTCH either promotes stem cell maintenance of 
terminal differentiation. It is possible that these fundamental roles of NOTCH may 
contribute to its role as an oncogene or tumors suppressor. By affecting differentiation, 
for example, NOTCH could set the stage for accumulation of additional mutations. In 
myeloid- leukeima, defective NOTCH signaling promotes differentiation of stem cells to 
granulocytic/monocytic progenitor cells (GMP). This expands the pool of putative 
leukemia initiating cells driving the accumulation of oncogenic mutations in TET that 
then results in graulocytic/monocytic leukemia (Moran-Crusio et al., 2011). Activating 
mutations in NOTCH could potentially promote T-cell progenitors population, resulting 
in T-ALL while NOTCH could also stimulate terminal differentiation of progenitor cells 
preventing further accumulation of cancer initiating populations, which might be the case 
in HCC (Lobry et al., 2011).  
NOTCH in HNSCC 
 
Currently, very little is known about the functional role of NOTCH in HNSCC. 
Following whole exome sequencing studies that identified inactivating mutations in 
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NOTCH1, there has been growing interest in the potential role of NOTCH signaling in 
the development of head and neck cancers. Besides TP53, NOTCH mutations commonly 
occur in head and neck cancers, skin and NSCLC. NOTCH signaling is still being 
assessed as a tumor suppressor in squamous cell carcinomas. Prior to the sequencing 
studies, there have been very little studies elucidating the role of NOTCH in HNSCC 
most of which was in relation to aberrations in other molecules. The purpose of this thesis 
is to attribute a tumor suppressive role of NOTCH in HNSCC and elucidate the 
functional relevance of NOTCH signaling in inhibiting growth in vitro and in vivo. Here, 
we show for the first time, that NOTCH1 inhibits two proto-oncogenes AXL and 
CTNNAL1 and make a novel connection of these molecules with NOTCH1 in abrogating 
cell growth. Elucidating how NOTCH inactivation promotes tumorigenicity could 
identify new therapeutic targets that are upregulated because NOTCH signaling is lost in 
HNSCC. We propose that AXL and CTNNAL1 may be novel targets downstream of 
NOTCH that can be exploited for therapeutic intervention in tumors that have an inactive 
NOTCH pathway. 
 
 
 
 
 
 
 36 
 
 
 
 
 
 
 
CHAPTER 3: AXL AND α-CATULIN 
 
 
 
 
 
 
 
 
 
 
 37 
Chapter 3: AXL and α-CATULIN 
AXL 
 
AXL is a receptor tyrosine kinase (RTK) that belongs to the TAM family of 
transmembrane receptors (Axelrod & Pienta, 2014). This receptor gets its name from the 
first letter of each member of its family: Tyro3, AXL and Mer (Prasad et al., 2006). 
These are a structurally distinct family of orphan RTK’s that was discovered after 
isolation of their full length cDNA’s (Graham, Dawson, Mullaney, Snodgrass, & Earp, 
1994; Lai & Lemke, 1991; O'Bryan et al., 1991). The TAM receptors have two ligands; 
growth arrest specific 6 (Gas6) and Protein S. While Gas6 can bind to all TAM receptors, 
Protein S can only bind to Tyro3 and Mer (Hafizi & Dahlback, 2006). The AXL gene is 
harbored on chromosome 19. It has 20 exonsspread over a 44 kb region. The 5’ upstream 
region of AXL is GC rich. This region does not have TATA and CAAT boxes. Using 
cloning and 5’ deletion techniques Mudduluru and Allgayer characterized the promoter 
region of AXL (Mudduluru & Allgayer, 2008). In their publication, they show that a 
minimalistic GC-region alone is sufficient to activate the AXL promoter. In addition, 
there are also several binding sites for transcription factors upstream of the AXL start 
codon. These binding sites include five Sp binding sites (SP a- Sp e), one MZF1 and one 
AP1 binding site (Mudduluru & Allgayer, 2008; Mudduluru, Leupold, Stroebel, & 
Allgayer, 2010; Mudduluru, Vajkoczy, & Allgayer, 2010). Another feature of this 
promoter shown by Sayan et al. is how CpG islands control promoter activation of AXL. 
CpG islands are critical in gene expression and consequently the control of cell cycle, 
tumor differentiation and development (Bartolomei, Webber, Brunkow, & Tilghman, 
1993; Carlone et al., 2005). In the CpG islands, promoter methylations is a common 
 38 
epigenetic modification that is used to repress gene expression. There are 19 CpG islands 
within the promoter region as putative methylation sites (Mudduluru & Allgayer, 2008). 
The transactivation potential of Sp1 and Sp3 transcription factors is affected by 
methylation of these CpG sites within the Sp transcription factor binding motifs (Zhu et 
al., 2003). Using cell lines with varying expression levels of AXL, Mudduluru and 
Allgayer elucidated that CpG islands located in proximity to the Sp family binding motifs 
were methylated in low AXL expressing cell lines. On the contrary, cell lines which had 
high AXL expression that showed no methylation (Mudduluru & Allgayer, 2008).  
Mouse loss of function mutants demonstrated the biological role of the TAM 
receptors after identification of the structure of TAM receptor and ligands (Camenisch, 
Koller, Earp, & Matsushima, 1999). Tyor 3 -/-, AXL -/-, and Mer -/- mice are all viable 
and fertile. Liu and colleagues (E. Liu, Hjelle, & Bishop, 1988) first discovered AXL 
from patients with Chronic Myelogenous Leukemia (CML). When this discovery was 
made, AXL was shown to be necessary but not sufficient for transformation. AXL is 
located in the “p” arm of chromosome 19 with a molecular weight of about 140 kDa.  
The extracellular domain of the TAM receptors have two structural modules that 
are repeated in other RTK ectodomains, defining two plus two configuration. In the 
ectodomains, the amino terminal regions have immunoglobulin domains that facilitate 
binding of the ligsnd (Sasaki et al., 2006) that is followed by type 3 fibronectin 
sequences. The transmembrane domain of most TAM receptors have a protein tyrosine 
kinase catalytic domain. Activation of this domain results in downstream activation of the 
phosphoinositide 3 kinase (PI3K)/ Akt pathway. The PI3K signaling is associated 
through a TAM-autophosphorylated Grb2-binding site, which is located approximately 
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18 residues at the carboxy terminal of the kinase domain. This region is conserved across 
all the TAM’s (Fridell et al., 1996; Ling, Templeton, & Kung, 1996). Activation of 
phospholipase C, ERK1/2, Ras and MAP kinase activation has also been shown before 
(Keating et al., 2010). The TAM ligands are large (80kDa) proteins that share the same 
multidomain arrangement. The carboxy terminal has an SHBG domain composed of two 
laminin G domains. The SHBG domain is responsible for binding to the Ig domains of 
the receptors. This binding induces their dimerization and kinase activation. The second 
domain is called Gla domain. This domain is located at the amino terminus of both 
ligands (Stitt et al., 1995). The Gla domain is known to be rich in glutamic acid residues. 
The hydroxyl groups of these residues are carboxylated post-translationally (Huang et al., 
2003).  
Like other RTK’s, AXL can also function independent of the ligand depending 
upon the context.  For example, in vascular smooth muscle cells (VSMC) and lens 
epithelial cells, ligand independent AXL activation occurs in response to hydrogen 
peroxide. The binding of the receptor to the ligand activates the AXL signaling cascade, 
which results in diverse phenotypic functions such as cell proliferation, migration, 
invasion, differentiation and EMT (Figure 6). Which signaling pathways are activated are 
regulated spatially and temporally determined by extracellular environment, cell and 
tissue type. When AXL was discovered in CML, PI3K signaling was the first discovered 
downstream cascade through which it regulates cell migration, growth, and apoptosis 
(Nielsen-Preiss et al., 2007; Ruan & Kazlauskas, 2013). Over the years, AXL has been 
shown to have diverse signaling capabilities through the PI3K, Akt, mTOR, NFκB and 
MAPK pathways.  
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Like other RTK’s binding of Gas6 to AXL down regulates its expression through 
degradation via c-Cbl ubiquitin ligase (Valverde, 2005). AXL is also regulated post-
transcriptionally by micro RNA’s miR-34a and miR-199a/b. This was shown in a 
bioinformatics screen in NSCLC, breast and colorectal cancer cell lines (Mudduluru et 
al., 2011). HIF1-, MZF1, AP1, sp1 and sp3 transcriptional factors can also regulate 
AXL expression transcriptionally.  
 
AXL in cancers 
 
AXL is overexpressed in several cancer types. Correlation studies have shown the 
association of AXL with motility and invasion and that the treatment with R428, an AXL 
inhibitor reverses this phenotype. Increased AXL expression has been evaluated as a poor 
prognostic factor for overall survival in colon cancer, osteosarcoma, and pancreatic 
cancer (Dunne et al., 2014; J. Han et al., 2013; Song et al., 2011). AXL expression is also 
a prognostic for increased lymph node metastasis and clinical stage in lung 
adenocarcinoma, breast and ovarian cancer (D'Alfonso et al., 2014; Rankin et al., 2010; 
Shieh et al., 2005) 
AXL in Non-small cell lung carcinoma (NSCLC) 
 
  AXL overexpression has been observed in 60% of NSCLC cell lines and also in a 
significant fraction of primary tumors (Shieh et al., 2005; Wimmel, Glitz, Kraus, Roeder, 
& Schuermann, 2001). In H1299 lung cancer cell lines, it has been shown that AXL is 
upregulated upon loss of p53 and in part gain of function activities of mutant p53 was 
mediated through AXL overexpression (Vaughan et al., 2012). Zhang et al. had shown 
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high AXL activation in NSCLC and demonstrated evidence for epithelial-to-
mesenchymal transition (EMT) in lung cancer models that were resistant to erlotinib in 
vitro and in vivo (Z. Zhang et al., 2012). After AXL inhibition, the sensitivity to 
erolotinib was restored showing that inhibition of AXL can overcome chemo resistance. 
They also showed low AXL expression levels in cells that have vimentin blocked. This 
suggests that AXL expression is higher during the process of EMT and that AXL 
confersresistance occurs in the process of EMT. Evaluation of AXL expression in 
patients before and after EGFR inhibitor treatment demonstrated that increased 
expression of AXL is essential for resistance to EGFR inhibitors. Around the same time, 
Byers et al. confirmed a 75-gene EMT signature by employing gene expression profiles 
(Byers et al., 2013). This was done in NSCLC cell lines and tumors from lung cancer 
patients, usingthree different arrays. This defined signature could predict resistance to 
EGFR and PI3K/Akt inhibitors. They suggested that AXL is a mediator of resistance to 
EGFR inhibitors further implicating that such resistance could be associated with a 
mesenchymal phenotype. Their signature strongly correlates with the mesenchymal group 
in which they observed upregulation of AXL but this was not seen in the epithelial group. 
Furthermore, they observed that inhibition of AXL in mesenchymal cells reversed 
resistance to the drug treatments. Taken together, AXL has two possible roles in cancer; 
association with an EMT phenotype and resistance to targeted agents.  
 
AXL in breast cancer 
 
AXL is overexpressed in highly invasive breast cancer cell lines. On the contrary, 
weakly invasive breast cancer cell lines express AXL at very low levels. It has also been 
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shown that AXL expression correlates with motility and invasiveness of breast cancer 
cell lines (Y. X. Zhang et al., 2008). Estrogen receptor has also been shown to induce 
AXL expression and this could important in proliferation, differentiation and apoptosis of 
human breast epithelium (Berclaz et al., 2001). The progesterone receptor B (PRB) 
upregulates the AXL ligand, Gas6 (Richer et al., 2002) and Her2 is also reported to 
trigger AXL activation suggesting crosstalk in clinically important pathways (Bose et al., 
2006). Berclaz et al. immunostained AXL and estrogen receptor (ER) in a panel of 23 
normal and 111 malignant breast cancer samples (Berclaz et al., 2001). They found was a 
high correlation between AXL and ER expression in malignant breast tissue. In addition, 
there was also a correlation between AXL expression and the stage of the tumor. 
Gjerdrum et al. had investigated AXL expression levels in 190 breast cancer patients and 
showed that high AXL expression negatively correlates with breast cancer survival 
(Gjerdrum et al., 2010). Holland et al. used RNAi to inhibit AXL and showed decreased 
growth of MDA-MB-231 cells in a xenograft model (Holland et al., 2005). In addition, 
AXL knockdown in MDA-MB-231 demonstrated that AXL was necessary for 
invasiveness in metastatic breast cancer cells (Gjerdrum et al., 2010). In the same cell 
lines, decreased AXL mRNA and protein levels correlates with cell invasion potential 
and decreases phosphorylation of AKT (Mackiewicz et al., 2011). Similar to NSCLC in 
which AXL expression was reduced when vimentin was blocked (Z. Zhang et al., 2012), 
Vuoriluoto et al. found that vimentin promotes EMT activation and is also necessary for 
AXL upregulation (Vuoriluoto et al., 2011).  
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AXL in Acute Myeloid Leukemia (AML) 
 
AXL was found as a prognostic marker and therapeutic target in acute myeloid 
leukemia (AML). AML cells can induce expression of Gas6 from bone marrow derived 
stromal cells. Gas6 mediates proliferation, survival and chemo resistance of AXL 
expressing AML cells. This creates a chemo protective tumor cell niche. The small 
molecule AXL inhibitor BGB324 (R428), is able to overcome this mechanism and 
synergize with chemotherapy (Ben-Batalla et al., 2013). AXL overexpression also 
promotes migration and invasion of prostate cancer cells in vitro (Paccez et al., 2013; 
Shiozawa et al., 2010). It is also associated with higher frequency of distant metastasis in 
patients with pancreatic adenocarcinoma (Linger et al., 2013; Song et al., 2011). Recently 
performed work has shown that AXL can mediate resistance to anti-EGFR inhibitors 
(Byers et al., 2013; Giles et al., 2013; Ye et al., 2010; Z. Zhang et al., 2012). Patients with 
AML had high AXL mRNA levels and worse progression free survival (Rochlitz et al., 
1999). AXL expression in drug resistance was shown by Hong et al. wherein they 
observed high expression of AXL in AML patients refractory to doxorubicin treatment 
(Hong et al., 2008). In the same study, expression of endogenous AXL was shown to be 
induced by chemotherapeutic drugs in a dose-dependent manner in AML cell lines.  
AXL in HNSCC 
 
Brand and colleagues evaluated if AXL is a functional molecular target in 
HNSCC and whether targeting AXL could enhance the efficacy of standard treatments 
used to treat these patients (Brand et al., 2015). They show that AXL inhibition (using 
siRNA’s and a pharmacological inhibitor- R428) effectively reduced HNSCC cell 
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growth, migration and invasion. The pharmacological inhibitor of AXL, R428, has shown 
specificity for AXL (Holland et al., 2010) and is now being evaluated clinically in Phase 
1 trials (Fleuren et al., 2014). Brand et al. (Brand et al., 2015) showed that using 
increasing doses of R428, all AXL expressing HNSCC cell lines were significantly 
growth inhibited. Furthermore, they also used patient derived xenografts (PDX) that were 
resistant to radiation therapy and showed higher AXL expression in these PDX models. 
Their study concluded that AXL is highly expressed in HNSCC and is associated with 
worse clinical outcomes.  
AXL inhibitors 
 
As described earlier, overexpression of AXL has been implicated in a variety of 
cancer types. Genetic and possibly epigenetic mechanisms potentially regulate the 
activation of AXL in cancers. Like other RTK’s that have inhibitors such as imatinib 
mesylate (Gleevec), Herceptin, Tarceva and Iressa (Gschwind, Fischer, & Ullrich, 2004), 
AXL has also been the subject of study for therapeutic intervention. The development of 
AXL inhibitors could potentially improve the treatment of different cancer types in which 
AXL is deregulated. Recently, RNA interference (RNAi) and therapeutic agents have 
been used to validate the efficacy of AXL inhibition. In 2010, Ye and colleagues 
developed a monoclonal antibody (YW327.6S2) against AXL which has high affinity for 
this receptor (Ye et al., 2010).  This antibody has been shown to decrease xenograft 
tumor growth and potentiates the effect of anti-VEGF treatment. It also enhances the 
effect of erlotinib in decreasing NSCLC tumor growth as well as breast cancer metastasis. 
The identification of 3-quinolinecarbonitrile (Keri et al., 2005) compounds demonstrated 
potent inhibitory activity against AXL as well as inhibition of motility and invasiveness 
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especially in breast cancer cell lines (Y. X. Zhang et al., 2008). NA80x1 is a compound 
that directly inhibits AXL phosphorylation. This compound was previously reported to 
display inhibitory activity against Src kinase (Boschelli, Barrios Sosa, Golas, & 
Boschelli, 2007; Boschelli et al., 2001). SKI-606 is a Src/Abl inhibitor that also is a 
potent AXL inhibitor. SKI-606 can inhibit AXL 20 times lower than NA80x1. In their 
publication, it was suggested that both SKI-606 and NA80x1 might be potential 
therapeutic targets against breast cancer growth and metastasis. However, both these 
compounds have many off target effects and show effects in the micro-molar range, 
which is clinically not a viable option.  
In 2010, a small molecule AXL inhibitor called R428  ((1-(6,7-dihydro-5H-
benzo[6,7]cyclohepta[1,2-c] pyridazin-3-yl)-N3-((7-pyrrolidin-1-yl)-6,7,8, 9-tetrahydro-
5Hbenzo[7]annulene-2-yl)-1H-1,2,4-triazole-3,5- diamine) was identified by Holland and 
colleagues (Holland et al., 2010) that had effects in the nanomolar range. This small 
molecule inhibits AXL activity and blocks downstream events of AXL such as Akt 
phosphorylation, cell invasion and cytokine production. Dose dependent reduction in 
Snail, an EMT transcriptional regulator, inhibition of angiogenesis and tumor formation 
was also seen. Holland et al. also translated this in vivo and observed an increase in 
survival. Breast cancer and lung cancer models in animals after receiving R428 had a 
median survival of over 80 days compared to non-treated animals that had a survival of 
52 days. Furthermore, R428 had a synergistic effect with cisplatin treated mice resulting 
in suppression of liver metastasis.  
Using an in silico approach, Mollard et al. developed a series of compounds that 
potentially inhibits AXL and identified 2,4,5-trisubstituted pyrimidines as potent AXL 
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inhibtior in the nanomolar range (Mollard et al., 2011). Cerchia et al. employed the 
concept of RNA Aptamers to develop GL21.T, a potential AXL inhibitor (Cerchia et al., 
2012). DNA or RNA aptamers are molecules that bind to targets with high specificity and 
affinity. GL21.T binds to the extracellular regions of AXL and Tyro3. The authors used a 
xenograft fluorescent model and demonstrated that this aptamer specifically accumulates 
in the tumor region and mice treated with this aptamer had close to 70% smaller tumors 
compared to non-treated controls.  
Thus, the identification of molecules with different structures (antibodies, small 
molecules, and aptamers) reveals the versatility that can be exploited in the development 
of inhibitors against AXL. In this context, identification and development of therapies 
involving the inhibition of AXL as well as targeting its downstream effectors may 
represent novel targeted therapeutics.  
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CTNNAL1: α-catulin 
 
CTNNAL1 is a gene encoding the protein α-catulin, an 82kDa vinculin/α-catenin 
family protein. This gene was oringinally identified as a down-regulated transcript in 
sodium butyrate treated pancreatic cancer cells which were undergoing differentiation 
and apoptosis (J. S. Zhang et al., 1998). The N-terminal region of α-catulin has structural 
similarities to human vinculin and α-catenin thus giving it the name α-catulin (α-
CATenin and vinCULIN). It contains binding sites for β-catenin, α-actinin and talin 
suggesting that α-catulin may be a cytoskeletal linker protein (Janssens, Staes, & van 
Roy, 1999). Vinculins and α-catenins are functionally and structurally related proteins. 
Both have analogous functions despite their low sequence similarity. Both these 
molecules are important for the formation of adhesion complexes since they can both 
bind to actin. During cell-cell contacts, α-catenin binds to either β-catenin or plakoglobin 
(γ-catenin) linking the transmembrane to the actin cytoskeleton (Aberle, Schwartz, & 
Kemler, 1996). During cell-substrate contacts, vinculin in linked to integrins via talins 
(transmembrane receptors for binding to the extracellular matrix) (Burridge, 
Chrzanowska-Wodnicka, & Zhong, 1997). The formation of adhesion complexes and its 
association to the actin cytoskeleton is necessary for proper differentiation and 
homeostasis and also for cell growth, motility, gene expression and apoptosis (Rudiger, 
1998). Notwithstanding the sequence similarities of α-catulin with α-catenin and vinculin, 
α-catulin does not inhibit the Wnt/β-catenin signaling pathway (Merdek, Nguyen, & 
Toksoz, 2004). The CTNNAL1 gene is located on chromosome 9q31-32. This is a region 
that is frequently lost and is a tumor suppressor marker that has been reported in many 
cancers (Schultz et al., 1995). This suggests that α-catulin might have a tumor 
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suppressive function. There are, however, conflicting reports that show evidence of α-
catulin binding directly to IKK-β and Lbc (a Rho GEF) which promotes cell migration 
and is resistant to apoptosis (B. Park et al., 2002; Wiesner et al., 2008). This evidence 
suggests an oncogenic potential of α-catulin. In their publication, Wiesner et al. 
performed a genetic screen using the regulatory C-terminal HLH domain of IKK-β as bait 
and identified α-catulin as an IKK-interacting protein. α-catulin augments activation of 
NF-κB after stimulation with TNF-α or IL1. Thus, α-catulin serves as a scaffold protein 
linking the IKK-β and Rho signaling pathways. Consequently, the biological functions 
are promotion of cell migration and protection of cells from undergoing apoptosis. These 
are the hallmarks of a gene with tumorigenic potential suggesting an oncogenic role of α-
catulin. Recently, Kreisede and colleagues have shown that α-catulin is highly expressed 
in melanoma cells compared to melanocytes and that α-catulin is a key driver of tumor 
formation, growth, invasion and metastasis by upregulating E-cadherin and 
downsregulating Snail/Snug and MMP2/MMP9 . Cao et al. reported that α-catulin was 
highly expressed in squamous cell carcinoma and its knockdown increased migratory and 
invasive behavior in vitro and in vivo (Cao, Chen, Masood, Sinha, & Kobielak, 2012). 
Furthermore, the increase of NF-κB expression by α-catulin elevates fibronectin and 
αvβ3 expression and promotes cell migration, invasion and metastasis in lung cancer cells 
(Liang et al., 2013). More recently, Kreisede et al. have shown that downregulation of α-
catulin using shRNA’s diminished NF-κB, MAPK and AP-1 activation in melanoma 
cells and sensitized these cells to cisplatin treatment (Kreiseder et al., 2015) . Although 
recent studies have underscored the importance of α-catulin in tumor growth, 
progression, invasion and metastasis, currently there are no inhibitors targeting this 
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protein. Investigating the modulation of α-catulin might shed light into exploiting other 
molecules regulating α-catulin which may be further extended to targeted therapy.   
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Chapter 4: Materials and Methods 
Cell lines 
 
HNSCC cell lines were obtained from sources outlined in (Zhao et al., 2011) and 
were Short Tandem Repeat (STR) profiled for authenticity. Zhao and colleagues have 
described the assembly, characterization and STR profile of all these cell lines which is 
outlined in Table 2 .All cells were cultured in DMEM complete media containing 10% 
FBS, Penicillin/Streptomycin, glutamate, non-essential amino acids, vitamins, pyruvate 
and Myco-Zap ®. Cells were incubated in a 370C, 5% Carbon Dioxide incubator. 
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Cell line Primary site Age Sex TNM Stage Primary Source 
HN31 LN       
Dr. John Ensley, Wayne State 
University 
PJA34 OC 50 M     
UMSCC 47 
(UM47) OC 53 M T3N1M0 
Dr. Thomas E. Carey, University of 
Michigan 
UMSCC 22A 
(UM22A) HP 58 F T2N1M0 
Dr. Thomas E. Carey, University of 
Michigan 
183 OP 54 M T3N0M0 
Dr. Peter G. Sacks, New York 
University  
HN4 REC(L) 57 M T2N0M0 
Dr. D.M. Easty, Ludwig Institute of 
Cancer Research, London 
CAL27   54 F T2N1M0   
PCI15B LN 69 M T2N0M0 Dr. Theresa Whiteside, UPMC 
UMSCC1 REC (OC) 73 M T2N0M0 
Dr. Thomas E. Carey, University of 
Michigan 
JHU022 LN   M T3N2B 
Dr. David Sidransky, Johns Hopkins 
University 
 
Table 2: HNSCC cell lines. LN: Lymph Node, OC: Oral Cancer, HP: Hypopharyngeal, 
OP: Oropharyngeal, L: Lungs 
 
Western Blots 
 
HNSCC cells were lysed with Radio Immune Precipitation Assay (RIPA) lysis 
buffer (Tris: 50mmol/L, NaCl: 150mmol/L, EDTA: 1mmol/L, NP-40: 1%, SDS: 1%, 
deoxycholate: 0.5%, glycerol: 10%, mercaptoethanol: 10%, NaF: 10mmol/L, 
orthovanadate: 1mmol/L, pyrophosphate: 2.5 mmol/L and protein inhibitors). After 
lysing, cells were subjected to sonification and then allowed to solubilize in the buffer for 
30 min. The lysates were then centrifuged at 14,000 rpm at 40C for 30 min after which 
the supernatant was collected. Protein quantitation was performed using the Pierce ™ 
BCA protein assay kit (ThermoFisher Scientific). The protein lysate after the protein 
assay was mixed with 5% β-mercptoethanol and SDS and loaded onto either 7.5% or 4-
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20% gradient gels (Mini-PROTEAN ® TGX Pre-Cast protein gels) based on the size of 
the protein blotted. Gels were run using 10X premixed electrophoresis buffer containing 
25mM Tris, 192 mM glycine and 0.1%SDS at pH 8.3 mixed with double distilled water 
at 80-110 V for 2-2.5h. Gels were then transferred on nitrocellulose membranes using 
10X premixed transfer buffer containing 25mM Tris, 192 mM glycine and 20% methanol 
at pH 8.3 either for 2h or overnight at 40C at 100 V. After transfer, the membrane was 
blocked using 5% milk-TBST for 2 hours with constant movement. The membrane was 
then incubated with the primary antibody at concentrations ranging from 1:100- 1:1000 
depending on the antibody overnight at 40C with constant movement. After incubation, 
the membrane was washed for 5 min. with TSB buffer containing 0.1% Tween-20 about 
5 times. Secondary antibody containing species-specific Horseradish peroxidase- 
conjugated antibody for 1h at room temperature with constant movement. Protein signals 
were developed using SuperSignal West chemiluminescent system (Pierce ® 
Biotechnology) on an X-ray film. 
Plasmids 
 
Intracellular NOTCH1 (ICN1) 
 
 Plasmids encoding the activated forms of NOTCH1 and NOTCH2 were obtained 
from Dr. Patrick Zweidler-McKay’s lab. ICN1-MigR1 was constructed by sub cloning 
the ICN1 region (codons 1770-2555) of the human total NOTCH1 (W. S. Pear et al., 
1996) into the BgIII site of MigR1 (W. S. Pear et al., 1998). This is a bicistronic vector 
that co-expresses GFP after the Internal Ribosome Entry Site (IRES) providing a 
surrogate marker for gene expression.  
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CRISPR-Cas9 plasmids 
 
CRISPR-Cas9 NOTCH1 and NOTCH2 plasmids were obtained from Santa Cruz 
Biotechnology (sc400167). Each plasmid contained a pool of three plasmids, encoding 
the Cas9 nuclease and a target specific 20 nucleotide guide RNA (gRNA) for maximum 
knockout efficiency. CRISPR-Cas9 plasmids for NOTCH1 and NOTCH2 were 
transfected into PJA34 cells and sorted to obtain a pure population of GFP positive cells. 
Knockout was confirmed by western blotting for total NOTCH1, Cleaved-NOTCH1 and 
total NOTCH2.    
NOTCH1 Full Length (NFL1) 
 
The full length NOTCH1 cDNA was obtained from Origene that was initially 
untagged and cloned into a pCMV6-XL6 vector. We obtained the MigR1 empty vector 
(6.5 kb) from Dr. Patrick Zweidler-McKay’s lab. We cloned NFL1 (7.3 kb) into the 
MigR1 vector. The MigR1 vector was first digested with BglII and EcoR1 restriction 
sites to insert a Multiple Cloning Site (MCS) containing the restriction sites for Mfe1 and 
Xho1. This is because NFL1 lacked a BglII restriction site but had an Mfe1 site. Since 
Mfe1 and EcoR1 contain compatible cohesive ends, we swapped the MCS on MigR1 
with another one that contains Mfe1 and Xho1 restriction sites. We then cleaved the 
MigR1 construct with Mfe1 and Xho1 and cleaved the NFL1 with EcoR1 and Xho1 and 
ligated the two constructs to engineer a MigR1-NFL1 (13.8 kb) construct.  
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Short Hairpin RNA’s for AXL and α-catulin 
 
Several of the shRNA’s were obtained from Dharmacon (GE Life Sciences) through 
the shRNA and ORFeome core facility at M.D. Anderson Cancer Center. We obtained 
four shRNA’s for each gene: AXL and CTNNAL1. The mature antisense sequences for 
AXL are:  
1) AACTTAGATGCTTAGGATC 
2) TGATAGCTAAGAAGGAGAG 
3) TGAGGATGGAGTCGTCCTG 
4) TCTTTGAAACCTAGAACCT 
The mature antisense sequences for CTNNAL1 are  
1) ATCTTTATGATTAATAAGC 
2) TCAATGACCTTATCCAATG 
3) TATTTCCAGAGGTTCTGTC 
4) TCCAATGCCACTTTCATAC 
Each shRNA was cloned into pGIPZ lentiviral vector driven by a human CMV promoter 
that also harbors a GFP construct before the IRES sequence. In addition, these lentiviral 
vectors carry a gene encoding N-acetyl transferase mediating puromycin resistance.  
HES2 and HES5 
 
HES2 and HES5 gene constructs were obtained from Dr. Patrick Zweidler-
Mckay’s lab and subcloned into a MigR1 vector.  
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Transfections 
 
Retroviral transfections were performed in HEK-293GP2 cells. Cells were plated 
at a density of 6 million cells on the day before transfection. On the day of transfection, 
10.8 μg plasmid was used with 1.2 μg of packaging plasmid, VSV-G (Dr. Zwediler-
McKay’s lab) suspended in Serum free DMEM media. In a separate tube, Genjet was 
suspended in serum free DMEM media and later mixed with the tube containing the 
plasmid and VSVG. The Genjet-plasmid complex was incubated at room temperature for 
20 min. before addition to HEK 293-GP2 cells. After adding the complex to the cells, 
they were incubated at 370C, 5% CO2 incubator for 45 min. after which complete media 
was added. About 8h after incubation, the media was replaced with complete media and 
incubated in a 330C 5% CO2 incubator for 48-72h. Viral supernatants were collected at 
48h and 72h time points. 
Lentiviral transfections were performed using HEK 293 F17 cells. Cells were 
plates at a density of 6 million cells the day before transfection. On the day of 
transfection, 10 μg of DNA, 5ug of envelope plasmid, pMD2.G (addgene) and 5 μg of 
packaging plasmid pCMV-dr8.2 dvpr (addgene) were mixed in Opti-Mem Reduced 
Serum Media (gibco, Life technologies). In a separate tube, Lipofectamine 2000 
(ThermoFischer Scientific) was mixed with Opti-Mem Reduced Serum Media and 
incubated at room temperature for 10 min. Plasmid-lipofectamine complex was then 
allowed to form for 45 min. at room temperature after which this complex was added to 
cells. About 8h after transfection, media was replaced with complete media with serum 
and incubated in a 370C 5% CO2 incubator for 48-72h. Viral supernatants were collected 
at 48h and 72h time points 
 56 
Retroviral infections 
 
Retroviral infections were performed on adherent cells plated a day before 
infection. Briefly, 300,000 cells were plated in each well of a six well plate before 
infections. On the day of the infection, 2 ml of the viral supernatant was added to the 
cells after removing the media. This was considered a 100% viral titer. Similar titers were 
made at 50%, 25%, and 12.5% by adjusting the amount of viral titer and media such that 
the total volume is 2ml in each well. To each well, 2 μl of polybrene (1 mg/ml. Santa 
Cruz Biotechnology) was then added. The six well plates were then centrifuged at 
12,000g for 1.5 hr at room temperature and incubated at 370C for 48-72h. 
Lentiviral infections 
 
Lentiviral infections were performed on non-adherent cells on the day of infection 
on 10 cm tissue culture plates. Briefly, 1.5 million cells were suspended in 1ml of 
complete media after which 5 ml of viral supernatant was added and plated on 10 cm 
dishes. This was considered a 100% viral titer. Similar titers were made at 50%, 25%, 
and 12.5% by adjusting the amount of viral titer and media such that the total volume is 6 
ml in each 10 cm plate. Each well also had 2.4 μl of polybrene. After transduction, plates 
were incubated at 370C for 12-14h before media was changed to complete media and 
incubated for an additional 48-72h.  
Clonogenic assays 
 
Clonogenic assays were conducted on 6-well plates. The plating efficiency was 
determined for each HNSCC cell line by seeding the cells at different densities in the 
wells and allowing them to form colonies over a 10-14 day period. Roughly, 1000-2000 
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cells per well were found to be good plating numbers for cell lines used in this assay. 
After transduction, cells were sorted for GFP positive cells by flow cytometery and 
allowed to recover for 48h. Post recovery, cells were plated at a density of 1000 cells per 
well and incubated in a 370C, 5% CO2 incubator. About 10-14 days after plating, cells 
were washed with PBS twice after removing the growth media and stained with crystal 
violet (0.5% w/v) for 5 min. Cells were washed again with water and colonies were 
observed under a microscope. A colony was marked if it contained at least 50 cells. By 
visual observation, we recorded one colony per well containing 50 cells and set that 
colony as the threshold for colony number and size. Later, using the Image J software 
(NIH), we measured the size of the marked colony and excluded any colonies that were 
smaller than the threshold. Such an analysis allowed us to measure both colony number 
and colony size at the same time.    
Quantitative Real Time PCR (qRT-PCR) 
 
Total RNA was extracted using RNAqueous ® - 4PCR DNA-free RNA isolation 
kit (Ambion, Life technologies). Briefly, cells were scrapped using a scraper after adding 
the guanidinium lysis buffer solution. The sample lysate was then mixed with ethanol and 
applied to a silica-based filter. This filter selectively and quantitatively binds mRNA and 
larger rRNA. Small RNA’s such as tRNA and 5S rRNA are not bound. The filter is 
washed to remove residual DNA, protein and other contaminants and the RNA is eluted 
in nuclease-free water containing EDTA. Post elution from the filter, the RNA was 
treated with ultra-pure DNase 1 to remove any trace amounts of DNA. Finally, using the 
DNase Inactivation agent, Dnase and divalent cations are removed. RNA concentration 
was measured using NANODROP 2000 spectrophotometer (Thermo Scientific). cDNA 
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was prepared by reverse transcription using SuperScript ® First-Strand synthesis 
(Invitrogen, Life Technologies) in a Veriti Dx 96-well thermal cycler (Applied 
Biosystems, Life technologies) according to the manufacturer’s instructions that included 
temperature cycles ranging from 40C to 700C. FAM-MGB TaqMan PCR primers and 
probes specific for HES1, HES2, HES3, HES4, HES5, HEY1, HEY2 and GAPDH were 
purchased commercially (ThermoFisher Scientific). A total of 100ng of cDNA was used 
per reaction and each reaction was measured in quadruplets using a c1000 Bio-Rad 
Thermal Cycler (Bio-Rad). The expression of each target gene was normalized against 
GAPDH that was calculated by the ΔCT method (ΔΔCT = [ΔCT of target gene]-[ΔCT of 
internal control gene (GAPDH)]) and the fold change of expression was calculated using 
the comparative CT method, 2(-ΔΔCT) 
Jagged1 and Fc immobilization 
 
Recombinant human Jagged1-Fc chimera was bought from R&D Biosystems. 
Recombinant Jagged1 was dissolved in PBS and sterile filtered using 0.22 μm syringe 
driven filters (Millex ®- GV). Before coating six well plates with Jagged1 or human IgG-
Fc (control), 1 mg/ml of protein G, (PROSPEC) was added to 1.5 ml of PBS in each well 
and incubated at room temperature overnight. Next day, plates were washed with 2ml of 
PBS and blocked with 1% Bovine Serum Albumin (Rockland Immunochemicals) 
dissolved in PBS for 2h. Plates were then washed with PBS and coated with 10 μg/ml of 
recombinant Jagged1 or Fc and incubated either at room temperature for 3.5h or 
overnight at 40C to allow immobilization of Jagged1 or Fc onto the surface after which 
cells were cultured on Jagged1 or Fc coated plates.  Cells were plated at a density of 
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300,000 cells/well for western blot and harvested 72h later or 1000-2000 cells/well for a 
clonogenic assay.  
 
Competitive Cell Proliferation Assay 
 
ICN1 and MigR1: Cells were plated at a density of 300,000 cells/ well in six well 
plates a day before transduction with ICN1 or MigR1. Retroviral infections were 
performed at a low Multiplicity Of Infection (MOI) such that only 30-50% of the cells 
are infected with either ICN1 or MigR1. After transduction, cells were allowed to grow 
for 72h after which cells were trypsinized. Post trypsinizations, a fraction of the cells 
were analyzed for GFP by flow cytometry (100,000 cells with the use of FL1; BD FACS 
Calibur) while the rest were plated at a density such that they can be sequentially 
passaged every three days for two weeks. FlowJo Software (TreeStar Inc) was used to 
calculate the percentage of GFP positive cells in the mixed population. 
NFL1: Cells were plated at a density of 300,000 cells per well in six well plates 
before transduction with NFL1. Similar to ICN1 and MigR1, cells were infected at a low 
multiplicity of infection such that only 30-50% of the cells are infected with NFL1. Three 
days post infection, cells were plated on immobilized Jagged1, Fc or uncoated plates. 
Seventy two hours after culturing on immobilized ligand coated plates, cells were 
trypsinized and a fraction of cells was analyzed by flow cytometry (100,000 cells) while 
the rest were replated on Jagged1, Fc or uncoated plates for another three days. FlowJo 
Software (TreeStar Inc) was used to calculate the percentage of GFP positive cells in the 
mixed population.  
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Cell Cycle Analysis 
 
Cell cycle assessment was performed on XL flow cytometer or FACS Calibur or 
FACS Fortessa analyzer. The cell cycle data was analyzed on FlowJo software. 
Senescence 
 
After transduction and flow sorting, cells were plates at a density of 2000 cells per 
well in a 6-well plate and allowed to attach overnight. At day 4 or 6, cells were exposed 
to a fixative for 10 minutes, washed again with PBS and incubated with 1ml senescence 
staining solution overnight at 370C. 
Orthotopic Mice injections 
 
The Institutional Animal Care and use Committee (IACUC) of the University of 
Texas MD Anderson Cancer Center approved all animal experimentation. Our orthotopic 
nude mouse tongue model has been previously described in the literature. Nude mice 
were obtained from Jackson Laboratories and acclimatized for 2 weeks prior to 
injections. HNSCC cell lines HN31, UM47 and PJA34 were transduced with ICN1, 
NFL1, MigR1 or dnMAML1 and sorted for GFP positive cells by flow cytometry. Prior 
to sorting, cells were optimized using variable titers for the intensity of GFP and 
percentage of viable cells such that all viral titers were matched equally. Cells were 
allowed to recover for 48h prior to mice injections. 50,000 cells were then injected in the 
dorsal tongue of mice in a volume of 30 ul of Serum free DMEM media. Mice were 
examined twice a week for 4 weeks where tumor size and weight loss were assessed and 
recorded.  Tongue tumors were measured with microcalipers, and tumor volume 
calculated as (A)(B2)π/6, where A is the longest dimension of the tumor and B is the 
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dimension of the tumor perpendicular to A. At the end of study, mice were euthanized by 
CO2 asphyxiation when they lost more than 20% of their preinjection body weight or 30 
days following the initiation of treatment. For immunohistochemical analysis, mice were 
sacrificed and tongue tumors were collected. Tissues were then fixed in 4% 
paraformaldehyde, paraffin-embedded, sectioned and stained with hematoxylin and eosin 
(H&E). Tumor growth and overall survival was measured until mice were sacrificed and 
plotted using Graphpad Prism.  
Unbiased gene expression analysis 
 
Three biological replicates of two HN cell lines, PJ34 and 183, were treated with 
Jagged ligand or control, Fc for 5 days. Table 3 contains detailed sample information. 
Gene expression was measured by Affymetrix HuGene 2.0 ST array. 
Sample Cell line Comment 
PJA 34 on Jagged1 (A) PJA34 Treated 
PJA 34 on Jagged1 (B) PJA34 Treated 
PJA 34 on Jagged1 (C) PJA34 Treated 
PJA34 on Fc (A) PJA34 Control 
PJA34 on Fc (B) PJA34 Control 
PJA34 on Fc (C) PJA34 Control 
      
183 on Jagged1 (A) 183 Treated 
183 on Jagged1 (B) 183 Treated 
183 on Jagged1 (C) 183 Treated 
183 on Fc (A) 183 Control 
183 on Fc (B) 183 Control 
183 on Fc (C) 183 Control 
 
Table 3: Sample description 
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All the data pre-processing steps have been done by the Department of 
Bioinformatics at M.D. Anderson Cancer Center by Dr. Jing Wang’s team. A linear 
model was fit to each probeset with both treatment and cell line as fixed effects. 
Therefore, we started with their preliminary result. Based on these raw p-values, we 
modeled them using a beta-uniform mixture (BUM) mode to generate different p-value 
cut offs based on selected false discovery rates (FDR). Based on the identified significant 
deferentially expressed probesets using the FDR of 0.05, we assessed concordance 
correlation of multiple probesets that map to the same gene, and selected only one 
probeset for each gene if their expression is inconsistent, and averaged the expression of 
those probesets if their expression is consistent. Therefore, we generated one record for 
each gene. The RNA-seq data include 279 TCGA Head and Neck cancer patient samples. 
The 131 genes of interest were originated from the significant gene list from the 
comparison of JAG treated and control HN cells based on Affyymetrix HuGene 2.0 ST 
array data. The TCGA RNA-seq data were downloaded from Broad firehose and have 
already been processed with RSEM and normalized. We read in the TCGA RNA-seq data 
and the genes of interest. We added 1 to the data and did log2 transformation. Then, we 
accumulated the data into the one with the expression of the interested genes. There were 
131 genes of interest, but we can only find 118 genes that matched in the TCGA data. We 
then produced heat maps with Pearson distance and ward linkage based on the data with 
279 samples and 118 genes.  
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Antibodies 
 
The antibodies used in this project is outlined in Table 4: 
Antibody Source Catalog number Concentration Diluent 
Total-NOTCH1 Santa Cruz sc 6014 1 to 750 2.5% Milk-TBST 
Total-NOTCH2 Santa Cruz sc 5545 1 to 750 2.5% Milk-TBST 
Cleaved-NOTCH1 Cell Signaling D3E8 1 to 750 2.5% Milk-TBST 
P21 CalBioChem OP64 1 to 1000 5% BSA-TBST 
ΔNP63 Santa Cruz Sc 8431 1 to 1000 2.5% Milk-TBST 
AXL Cell Signaling C89E7 1 to 1000 2.5% Milk-TBST 
Phospho-AXL Cell Signaling D12B2 1 to 1000 2.5% Milk-TBST 
Gas6 Santa Cruz sc 1936 1 to 1000 5% BSA-TBST 
Α-catulin Santa Cruz sc 390584 1 to 1000 2.5% Milk-TBST 
Flag Cell Signaling 2368S 1 to 1000 2.5% Milk-TBST 
HES5  AbCam Ab25374 1 to 100 5% BSA-TBST 
Actin  Sigma A1978 1 to 2000 5% BSA-TBST 
 
Table 4: Antibodies description 
 
 
Statistical Analysis 
 
The Student t and a one-way ANOVA tests were carried out to analyze in vitro data. For 
mouse studies, a 2-way ANOVA test was used to compare tumor volumes between 
control and treatment groups. All data were expressed as mean ± standard error, and P < 
0.05 was considered significant 
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 65 
Chapter 5: Activation of NOTCH signaling inhibits growth 
Parts of this chapter are adapted from my previous co-author publication in 
Cancer Discovery in 2013 (Pickering et al., 2013). According to the journal: “Authors of 
articles published in AACR journals are permitted to use their article or parts of their 
article in the following ways without requesting permission from the AACR. All such 
uses must include appropriate attribution to the original AACR publication. 
Authors may do the following as applicable: Submit a copy of the article to a doctoral 
candidate's university in support of a doctoral thesis or dissertation” 
Chapter 5.1: NOTCH1 mutational status in HNSCC cell lines 
 
Rationale: NOTCH1 is mutated at a frequency of 15-19% (Agrawal et al., 2011; 
Stransky et al., 2011; "TCGA Releases Head and Neck Cancer Data," 2015). To explore 
the mutation rate of NOTCH1 in cells, our lab had previously sequenced a panel of 44 
HNSCC cell lines that had previously been characterized for TP53 mutations and 
tumorigenicity (Sano et al., 2011; Zhao et al., 2011). The spectrum of homozygous 
mutations found in NOTCH1 closely mirrored previously sequenced tumors (Agrawal et 
al., 2011). Table 5 lists sequencing results for some HNSCC cell lines that included 
nonsense mutations (UMSCC47, UMSCC22A, PCI15B), a frame shift (HN4), and a 
C478F missense mutation (HN31), which corresponds to an amino acid critical for ligand 
binding. However, expression of NOTCH1 at the translational level was not established. 
In order to validate the sequencing studies, we evaluated total-NOTCH1 protein 
expression levels 
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Results: We performed a western blot to evaluate the NOTCH1 protein 
expression levels in wild-type and mutant cell lines based on Sanger sequencing (Figure 
8). Cell lines that were wild-type for NOTCH1 (PJA34, 183, CAL27, UMSCC1 and 
JHU022) expressed the total-NOTCH1 protein, while cell lines mutant for NOTCH1 
(HN4, UMSCC22A, UM47 and PCI15B) did not express the protein. HN31 has a C478F 
missense mutation and expresses total NOTCH1 but the mutation prevents NOTCH1 
from being activated.  The results from the western blot corroborate with sequencing 
studies and provided us an in vitro model system to manipulate the phenotypic effect of 
NOTCH1.  
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Cell Line NOTCH1 
UM47 G192X 
HN4 A343Fs 
HN31 C478F ms 
UM22A E1679X 
PCI15B Q1957X 
PJ34 Wt 
CAL27 Wt 
183 Wt 
UMSCC1 Wt 
JHU022 Wt 
NOM9 Wt 
Table 5: NOTCH1 status in HNSCC cell lines  
 
Figure 8: NOTCH1 protein expression levels in HNSCC cell lines 
 
Total-NOTCH1 
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Chapter 5.2: Activation of NOTCH1 in mutant HNSCC cell lines is detrimental to cell 
growth 
 
Rationale: NOTCH1 is mutated in about 15-19% of HNSCC (Agrawal et al., 
2011; Stransky et al., 2011; "TCGA Releases Head and Neck Cancer Data," 2015). 
HNSCC cell lines were previously classified as being mutant or wild-type from Sanger 
sequencing and protein expression levels. Based on the spectrum of mutations from 
sequencing studies, we know that a subset of HNSCC have an inactive NOTCH pathway. 
The functional relevance of these mutations has not been explored. Since mutant HNSCC 
cell lines have inactive NOTCH1, we sought to determine the phenotypic effects of 
restoring a functional NOTCH signaling pathway in these cells. 
Results: Retroviral constructs of the intracellular forms of NOTCH1 (ICN1) that 
was cloned into a Murine Stem Cell Driven Vector (MSCV) IRES driven GFP vector 
called MigR1 (kindly provided to us by Dr. Zweidler-McKay) was engineered to 
overexpress the protein. Additionally, the full- length, wild type NOTCH1 receptor 
(NFL1) was cloned into the same parental retroviral vector (MigR1) (Figure 9). Mutant 
NOTCH1 bearing HNSCC cell lines HN31, HN4, PCI15B and UMSCC47 were infected 
with ICN1 or MigR1 at low multiplicity of infection such that only a small fraction of the 
infected population (20-50%) expressed the vector. Using this method, a mixed 
population of green and non-green cells was obtained and a competitive cell proliferation 
assay (also known as “horserace” assay) was performed. The fraction of green cells in the 
mixed population was monitored by flow cytometry and recorded every 3 days. The cells 
were sequentially passaged such that some cells were evaluated for GFP by flow analysis 
and the rest were cultured for another three days. By doing so, the modulation in GFP 
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positive population could be monitored over a 15-day period. The population of cells 
expressing GFP was normalized to day three after infection. The fraction of cells having 
ICN1 (green cells) progressively declined after infection (Figure 10). At day 15, the 
relative fraction of ICN1 cells had been reduced to 40% of its initial value. This 
suggested that the population of cells having ICN1 was selected against those cells that 
do not express the protein, implying that the activation of NOTCH1 in mutant HNSCC 
cells could be disadvantageous to their growth and proliferation. Moreover, the 
morphology of cells infected with ICN1 was vastly different from cells infected with 
MigR1. Some of these cells were smaller, circular and had a flattened morphology 
reminiscent of senescent cells, while others were rounded and spheroid in shape that 
eventually detached from the substrate (Figure 11).  
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Figure 9:  Retroviral constructs of ICN1, ICN2 and NFL1 
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Figure 10: Intracellular NOTCH1 is disadvantageous to the growth of mutant HNSCC 
cells. 
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Figure 11: ICN1 infected mutant HN31 cells are smaller and rounder and some have a 
flattened package-like morphology compared to cells infected with the empty vector 
MigR1. 
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Chapter 5.3: NOTCH1 activation appears to induce senescence and G1 growth arrest 
 
Rationale: Inhibition of cell growth can be attributed to various factors such as 
cell death (apoptosis/necrosis), senescence, cell cycle arrest or mitotic catastrophe. Since 
growth inhibition was found in mutant cells after restoration and activation of NOTCH1, 
the phenomenon governing the growth arrest was evaluated in these cells. In esophageal 
squamous cell carcinoma (ESCC), Kagawa et al. demonstrated that the activated form of 
NOTCH1 (ICN1) induced cellular senescence corroborated by G0/G1 cell cycle arrest, 
flat and enlarged morphology and senescence associated β-galactosidase activity 
(Kagawa et al., 2015). Based on morphology, some cells appeared to have an enlarged, 
flat, and pancake-like structure, while some cells exhibited a spheroid apoptotic-like 
morphology after restoring ICN1 in mutant HNSCC cell lines.  
Results: To evaluate senescence, mutant cells expressing ICN1 and/or MigR1 were 
evaluated for β-galactosidase using immunohistochemistry. Nearly 30% of the HN31 
ICN1 cells stained positively, indicating that some of these cells do undergo senescence 
(Figure 12). Furthermore, western blotting performed three days and five days after 
infection with ICN1 or MigR1 revealed increased expression of p21 (marker for 
senescence) only in the NOTCH1 mutant cells infected with ICN1 (Figure 13). Cell cycle 
analysis demonstrated that the ICN1 infected cells were arrested in the G1 phase of the 
cell cycle relative to the MigR1 infected cells (Table 6). In addition, a small percentage 
(15%) of the cells were also present at the sub-G0 phase indicating that some of these 
cells undergo apoptosis. Taken together, senescence, cell cycle arrest and apoptosis 
appear to contribute to the delayed growth in NOTCH1 infected cells. 
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Figure 12:  Mutant HNSCC cells HN31 undergoes senescence after restoring the 
activated form of NOTCH1 (ICN1).   
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Figure 13: Induction of p21 (a marker for senescence and cell cycle arrest) in HN31 cells 
infected with ICN1 but not MigR1 at two different time points (D3= Day 3 post infection 
and D5=Day 5 post infection) 
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Table 6: ICN1 cells are arrested in the G1 phase of the cell cycle. 
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Chapter 5.4: NOTCH1 or NOTCH2 is possibly sufficient to inhibit cell growth 
 
Rationale: NOTCH has four family members; NOTCH 1-4. Among the NOTCH 
family members, NOTCH1 is the most frequently mutated in HNSCC (15-19%), 
followed by NOTCH2 (2-5%) (Agrawal et al., 2011). NOTCH1 and NOTCH2 mutations 
are not mutually exclusive in HNSCC cells. Li et al. demonstrated deletions in the 
NOTCH2 genes in HNSCC cell lines and tumors (H. Li et al., 2014). Whether NOTCH1 
and NOTCH2 contribute to similar phenotypes is currently unknown. To investigate if 
NOTCH2 had any effect on cell growth, the NOTCH1 mutant (HN31) and NOTCH wild-
type cell lines (PJA34) were infected either with the empty vector-MigR1, activated form 
of NOTCH1 (ICN1) or activated form of NOTCH2 (ICN2).  
Results: Cells were transduced and sorted for GFP positive cells such that the 
percentage and intensity of GFP was similar in all conditions. Forty-eight hours after 
sorting, cells were seeded at 1000 cells per well in 6-well plates for a colony forming 
clonogenic assay. After seeding, cells were evaluated for change in morphology every 
two days and stained with crystal violet after colony sizes reached about 50 cells in the 
control MigR1 plates (12 days after seeding). ICN1 and ICN2 alone were sufficient to 
inhibit cell growth compared to the empty vector (MigR1) and parental controls (Figure 
13). Parental and MigR1 transduced cells had similar colony number 10 days after 
plating, but the colony number and size in cells transduced with ICN1 or ICN2 
significantly declined by more than 90%. This suggests that ICN2 may also be sufficient 
to inhibit cell growth. 
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Figure 14: Activated NOTCH1 or NOTCH2 is sufficient to inhibit growth of HNSCC cell 
lines 
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Chapter 5.5: Restoration of full-length NOTCH1 is sufficient to inhibit cell growth 
 
Rationale: Transducing cells with activated NOTCH1 is often not ideal since cells 
are subjected to non-physiological amounts of the protein. In other cancer types such as 
hepatocellular carcinoma (Qi et al., 2003), neuroblastoma (Zage et al., 2012) and B-ALL 
(Kannan et al., 2011), the activated form of NOTCH has been used to elucidate growth 
inhibitory phenotypes. Although such studies have demonstrated how NOTCH inhibits 
growth, to date, the impact of expression of the full-length NOTCH receptor on mutant 
NOTCH1 bearing cells has not been evaluated. To test this, the full- length NOTCH1 
receptor was cloned in the retroviral system, and the impact of NOTCH1 signaling was 
evaluated by growing the cells on plates coated with the NOTCH ligand, recombinant 
Jagged1.  
Results: NOTCH1 mutant cells HN31 and UMSCC 47 were infected at a low 
multiplicity of infection (MOI of 20% to 50%) with retrovirus bearing either full length 
NOTCH1 (NFL1-GFP) or the empty vector (MigR1-GFP) such that there was a mixed 
population of green and non-green cells. These cells were then cultured on the 
recombinant NOTCH ligand, Jagged1 that is fused to an Fc chimera and coated onto 
plastic cell culture plates. Jagged1 and Fc were coated on plates the day before seeding 
cells. As a control, cells were cultured on the Fc chimera coated plates that is not fused to 
Jagged1. Additionally, cells were also plated on plates without Jagged1 or Fc (Uncoated 
plates). A competitive cell proliferation assay was then performed by sequentially 
passaging these cells every three days on Jagged1, Fc or uncoated (UC) plates and 
analyzing GFP positive cell fraction by flow cytometry. The population of NFL1-GFP 
positive cells cultured on Jagged1 was suppressed by at least 50% relative to NFL1-GFP 
 80 
cells cultured on Fc and uncoated plates (Figure 15Figure 16Figure 17). In sharp contrast, 
the fraction of cells infected with MigR1 remained relatively steady through the time 
course. Compared to MigR1 infected cells, all cells infected with NFL1 were selected 
against the mixed population of cells. This, in part, implies that signaling between NOTH 
receptors and endogenous NOTCH ligands contributes to growth inhibition in NFL1 
infected cells plated on Fc or uncoated plates.  Taken together, these results suggest that 
restoration on NFL1 and possible activation of the NOTCH pathway by culturing these 
cells on Jagged1 is disadvantageous to the growth of these mutant cells. In order to 
investigate long-term growth of these cells, a colony forming clonogenic assay was 
performed in which HNSCC cells UM47, HN31 and HN4 were infected with NFL1 or 
MigR1 and sorted by flow cytometry to obtain a pure population of green cells. After 
sorting, these cells were cultured at a low density (1000 cells/well in 6-well plates) on 
Jagged1 or Fc coated plates for a 10-day period. The cells were then stained with crystal 
violet after 10 days and the number of colonies (a colony was defined as one having at 
least 50 cells) were counted. Mutant cells infected with NFL1 and cultured on Jagged1 
were significantly growth inhibited compared to those cultured on Fc and the MigR1 
infected controls ( 
 
 
 
Figure 18). Based on these findings, it was hypothesized that this inhibition in cell 
growth is mediated by the activation of NOTCH signaling. To test this, a western blot 
was performed on these mutant cell lines after infection with NFL1 or MigR1 and 
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culturing on Jagged1 or Fc. Mutant cell lines infected with NFL1 cultured on Jagged1 
expressed high levels of cleaved (activated) NOTCH1, while cells infected with the 
empty vector did not induce cleavage of NOTCH1 (Figure 19). The presence of cleaved 
NOTCH1 only in mutant cell lines infected with NFL1 suggests that activation of the 
NOTCH signaling pathway contributes to the growth inhibitory phenotype. Maximal 
induction of cleaved NOTCH1 was observed in NFL1 infected mutant cells cultured on 
Jagged1, however, we also observed cleaved NOTCH1 induction in NFL1 infected cells 
cultured on Fc and uncoated plates as well. This confirms the phenotype previously seen 
in the competitive cell proliferation assays (Figure 15Figure 16Figure 17) that activation 
of the NOTCH pathway through endogenous ligand contributes to inhibition of growth. 
Previously, while using ICN1, we observed that mutant cells underwent senescence 
(Figure 12). We examined if a similar phenomenon also occurs after restoring the full-
length NOTCH1 protein. Similar to our previous results, we observed that mutant cells 
with NFL1 cultured on Jagged1 stained positive for β-galactosidase indicating that 
restoration of NFL1 and activation of the pathway by Jagged1in mutant cells possibly 
contributes to senescence mediated growth arrest. On the contrary, Jagged1 mediated 
senescence was not observed in MigR1 infected cells. Mutant cells infected with NFL1 
cultured on Fc also did not exhibit a senescent morphology. Although these cells express 
modest cleaved NOTCH1 levels and are growth inhibited compared to MigR1 infected 
cells, it is possible that the expression levels of NOTCH1 was not strong enough to 
induce senescence.   
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Figure 15: The fraction of mutant cells restored with NFL1 decreases progressively 
compared to cells infected with the empty vector. UM47 mutant cells infected with NFL1 
is selected against a mixed population of NFL1 and non-NFL1 expressing cells while 
cells infected with MigR1 remains steady through the 23 day time period.  
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Figure 16: The fraction of mutant cells restored with NFL1 decreases progressively 
compared to cells infected with the empty vector. HN4 mutant cells infected with NFL1 is 
selected against a mixed population of NFL1 and non-NFL1 expressing cells while cells 
infected with MigR1 remains steady through the 23 day time period.  
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Figure 17: The fraction of mutant cells restored with NFL1 decreases progressively 
compared to cells infected with the empty vector. HN31 mutant cells infected with NFL1 
is selected against a mixed population of NFL1 and non-NFL1 expressing cells while 
cells infected with MigR1 remains steady through the 23 day time period.  
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Figure 18:  Restoration of NOTCH1 inhibits cell growth. Inhibition in the number of 
colonies of mutant cells after restoration with NFL1 and culture on Jagged1. (a: 
quantitation of clonogenic assay, b: crystal violet staining of colonies) 
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Figure 19:  NOTCH1 is activated only in mutant cells infected with NFL1 but not MigR1. 
Restoration of NFL1 in mutant cell lines induces cleavage of NOTCH1 when cultured on 
Jagged1 but not on Fc or uncoated plates. 
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Figure 20:  HN31, HN4 and UMSCC22A mutant HNSCC cells undergo senescence after 
restoring NFL1 and culturing on Jagged1 
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Chapter 5.5: Activation of the NOTCH signaling pathway in wild-type cell lines 
inhibits cell growth 
 
Rationale: We previously demonstrated that restoration of NOTCH signaling in 
mutant HNSCC cells inhibits cell growth. NOTCH1 is mutated in about 15-19% of 
HNSCC (Agrawal et al., 2011; Stransky et al., 2011; "TCGA Releases Head and Neck 
Cancer Data," 2015), however, majority of the tumors have wild-type NOTCH1. 
Although these tumors express the wild-type receptor, the NOTCH pathway may not be 
activated due to alterations is Jagged1, overexpression of NUMB, improper 
glycosylation, or proteosomal degradation. Thus, we wanted to investigate the functional 
relevance of activating the NOTCH pathway in a wild-type setting. To activate the 
NOTCH pathway, wild-type cells were cultured on Jagged1 and hypothesized that 
Jagged1 would induce growth inhibition in wild-type cells similar to the mutant cells. 
Results: PJA34 and CAL27 NOTCH1 wild-type cells were cultured on 
recombinant Jagged1 or Fc coated plates. Jagged1 and Fc were coated on cell culture 
plates the day before seeding. Both wild-type cell lines were plated at a low density to 
observe morphology change and colony formation. Cells cultured on Jagged1 appeared to 
be slower in growth, small, and spherical (Figure 21). Similar to the mutant cells, a small 
fraction of wild-type cells when cultured on Jagged1 appeared flattened and exhibited a 
pancake-like morphology. These cells stained positive for β-galactosidase indicating that 
NOTCH activation may result in some cells undergoing senescence (Figure 21). 
Moreover, when protein expression levels for cleaved NOTCH was evaluated by western 
blotting, activation of NOTCH signaling was observed only in cells cultured on Jagged1 
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but not on Fc (Figure 22). These results imply that activation of the NOTCH signaling 
pathway in wild-type cells might be responsible for aberrations in cell morphology. To 
measure the long term effects of activating NOTCH signaling in these cells, a colony 
forming clonogenic assay was performed in which wild-type cell lines (PJA34, 183, 
CAL27 and UMSCC1) were cultured on Jagged1 or Fc for a 10-day period. All wild-type 
cell lines were significantly growth inhibited when cultured on Jagged1 (Figure 23). 
Furthermore, cleaved NOTCH1 expression was observed only in cells cultured on 
Jagged1 but not Fc. Taken together, the change in morphology, growth inhibition and 
expression of cleaved NOTCH1 was evident only in wild-type cells cultured on Jagged1 
suggesting that NOTCH activity induces these changes. To confirm that NOTCH 
signaling does indeed play a role in modulating cell growth, NOTCH activation was 
inhibited using the γ-secretase inhibitor DAPT (N-[N-(3,5-Difluorophenacetyl)-L-
alanyl]-S-phenylglycine t-butyl ester) at two different concentrations (2μM and 10μM) in 
CAL27 and PJA34 wild-type cell lines after culturing them on Jagged1 or Fc. After 
addition of DAPT, a reversal in growth inhibition was observed when cell were cultured 
on Jagged1 (Figure 24). This result suggests that NOTCH activation might be necessary 
for growth inhibition. Since inhibition of γ-secretase may exert a dose dependent effect, 
the wild-type cell lines PJA34 was infected with the dominant negative form of 
Mastermind- like 1 (MAML1) that has a mutation that prevents MAML1 from binding to 
ICN, thus physiologically blocking the NOTCH pathway. After sorting infected cells to 
obtain a pure population of dnMAML1-GFP cells, PJA 34 dnMAML1 cells were 
cultured on Jagged1 or Fc using parental PJA34 cells as controls. PJA34 parental cells as 
observed before had suppressed levels of cell growth when cultured on Jagged1 
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compared to Fc. However, dnMAML1 was able to reverse the Jagged1 mediated growth 
inhibition (Figure 25). Both approaches to inhibit NOTCH signaling (GSI and 
dnMAML1) showed a reversal of Jagged1 mediated cell growth inhibition. In addition to 
these approaches, we also employed the CRISPR-Cas9 system to knock out NOTCH1 
and NOTCH2 in PJA34 cell lines. This system was used not only to knockout both 
NOTCH isoforms, but also to determine which specific NOTCH member (NOTCH 1 or 
NOTCH 2) mediates growth inhibition. Using this technique, stable knockouts of either 
or both NOTCH receptors was achieved (Figure 26). To determine cell growth potential, 
PJA 34 parental cells, NOTCH1 knockout cells (NOTCH1 KO), NOTCH2 knockout 
(NOTCH2 KO) cells and NOTCH1/NOTCH2 double knockout cells (dKO) were 
cultuted on Jagged1 or Fc in a colony forming assay. Knocking out either NOTCH1 
(NOTCH1 KO) or NOTCH2 (NOTCH2 KO) in PJA34 cells did not relieve the growth 
inhibition relative to parental cells on Jagged1. However, knocking out both NOTCH1 
and NOTCH2 (double knockout- dKO) significantly reversed Jagged1 mediated growth 
inhibition (Figure 27). The CRISPR-Cas9 knockout studies suggested that both NOTCH1 
and NOTCH2 are required for inhibiting cell growth. To show that NOTCH signaling is 
sufficient to inhibit cell growth, full length NOTCH1 (NFL1) was infected in the double 
knockout (dKO) PJA34 cell line to evaluate cell growth in a colony forming clonogenic 
assay. Abrogation in protein expression levels of total NOTCH1 and cleaved NOTCH1 
was observed in PJA34 dKO cells cultured on Jagged1 or Fc (Figure 28). However, after 
restoration of NFL1 in PJA34 dKO cells, the abrogation in protein expression levels of 
total-NOTCH1 and cleaved NOTCH1 was rescued (Figure 28) suggesting restoration of 
the pathway. Next, PJA34 parental cells, dKO cells and dKO cells after restoration of 
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NFL1 (dKO+NFL1) were subjected to a clonogenic assay on Jagged1 or Fc. As expected, 
PJA34 parental cells on Jagged1 was growth suppressed that was abrogated by PJA34 
dKO cells cultured on Jagged1 and Fc. However, restoration of NFL1 in the double 
knockout (dKO+NFL1) cell lines suppressed growth similar to the parental cells when 
cultured on Jagged1 and rescued the PJA34 dKO phenotype (Figure 29). Taken together, 
we have shown that NOTCH activation in wild-type cells inhibits cell growth and that 
NOTCH1 is necessary and sufficient to inhibit cell growth in vitro.  
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Figure 21: Morphology change and senescence when NOTCH1 wild-type are cultured on 
Jagged1. Culture of wild-type cell lines on Jagged1 shows small, rounded and growth 
inhibited colonies, some of which undergo senescence compared to cells cultured on Fc. 
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Figure 22: Protein expression of Total-NOTCH1 and cleaved NOTCH1: Western blot 
depicting total NOTCH1 (Tm-NOTCH1) in wild-type and mutant cell lines and cleaved 
NOTCH1 (cl-NOTCH1) expression in wild-type cell lines cultured on Jagged1 
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Figure 23: Wild-type cell lines cultured on Jagged1 are significantly growth inhibited 
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Figure 24: Inhibition of NOTCH signaling using γ-secretase inhibitor reverses NOTCH 
mediated growth suppression. 
 
 
 
 96 
 
 
 
 
Figure 25:  dnMAML1 reversed Jagged1 mediated growth inhibition 
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Figure 26: CRISPR-Cas9 knockout of NOTCH1 (NOTCH1 KO), NOTCH2 (NOTCH2 
KO) or both 
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Figure 27: Knocking out both NOTCH and NOTCH2 relieves Jagged1 mediated growth 
suppression. KO: Knockout 
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Figure 28: Restoration of NFL1 in the double knock out cell line activates NOTCH 
signaling: CRISPR-Cas9 double knockout cell line PJA34 shows activation of NOTCH 
signaling after restoration with NFL1 and culturing cells on Jagged. KO: Knockout 
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Figure 29: NOTCH signaling is necessary and sufficient to modulate cell growth. 
CRISPR-Cas9 NOTCH1 and NOTCH2 double knockout cell line PJA 34 promotes 
growth on Jagged1 and Fc that is inhibited after restoration with NFL1.  
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Chapter 5.6: Restoration of NOTCH signaling in mutant HNSCC cell lines inhibits in 
vivo tumorigenecity 
 
Rationale: We have demonstrated that activation of the NOTCH signaling 
pathway in mutant and wild-type HNSCC cell lines inhibits in vitro cell growth abilities. 
To evaluate in vivo tumor growth of mutant cell lines after restoration with NOTCH1, we 
infected mutant cell lines HN31 and UM47 with ICN1 or NFL1 and hypothesized that 
restoration of NOTCH signaling would inhibit in vivo tumor forming ability. Tumor 
forming ability was evaluated in an orthotopic tongue model of oral cancer. 
Results:  NOTCH signaling was restored in mutant cell lines HN31 and 
UMSCC47 using full- length NOTCH1 (NFL1) or the intracellular form of NOTCH1 
(ICN1). The empty vector MigR1 and parental cells were used as controls. After 
retroviral infections with ICN1, NFL1 and MigR1, cells were sorted for GFP by flow 
cytometry. Forty-eight hours after sorting later, 50,000 cells were injected per mouse 
cells into the dorsal right region of the tongue in nude mice. Ten mice were injected in 
each condition. We then monitored tumor formation for a 25 day period measuring tumor 
size every 3 days. Mutant cells infected with NFL1 or ICN1 when injected in mice had 
significantly lower tumor volumes and an increase in overall survival was observed 
(Figure 30a and b). At the end of the 25 day period, the tumor volume in NFL1 and ICN1 
injected mice was less than 50% compared to the parental and empty vector (MigR1) 
controls. The effect was even pronounced in cells having ICN1 (blue dashed line in the 
graph of Figure 30a) compared to NFL1 cells (although there was no significant 
difference between ICN1 and NFL1) and these mice began to form tumors only 20 days 
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post injection. The slow-growing in vivo tongue tumors derived from mutant UM47 
infected with NFL1 expressed NOTCH1 (Figure 31a), grew in a more organized fashion 
than control MigR1 infected cells lacking NOTCH1 protein (Figure 30b), and had 
frequent keratin pearls (Figure 30c) suggesting increased differentiation compared to 
MigR1 infected tumors which had higher tumor cellularity (Figure 30d). These results 
suggested that in addition to inhibiting in vivo tumor forming ability, NOTCH activation 
in vivo can also induce differentiation, in part, explaining the reduction in cell growth.  
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Figure 30:  Restoration of NOTCH signaling in mutant HNSCC cell lines inhibits tumor 
growth (a) and increases overall survival (b) in a xenograft orthotopic model of oral 
cancer 
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Figure 31:  NFL1 infected UM47 tumor xenografts appear more differentiated. Mutant 
UM47 infected with NFL1 (a, c) grew slowly in mouse tongues compared to UM47 
infected with control MigR1. (b, d). Anti-total NOTCH 1 staining (brown) of NFL1-
infected (a) or MigR1 infected (b) tumors. Growth of NFL1-infected tumors was more 
organized (c) and had keratin pearls (arrows) compared to MigR1 infected tumors, 
apparent after H&E stain 
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Chapter 5.7: Inhibition of NOTCH signaling enhances tumor growth in vivo 
 
Rationale: I previously showed that NOTCH1 is sufficient to inhibit tumor 
growth. Proweller et al. demonstrated that in mouse keratinocytes, expression of the pan-
NOTCH inhibitor dominant negative Mastermind like-1 (dnMAML1) resulted in a 
hyperplastic epidermis and spontaneous development of cutaneous squamous cell 
carcinoma (cSCC) (Proweller et al., 2006). Their results imply that in tumor types 
wherein NOTCH acts as a tumor suppressor (such as skin cancer in this case), 
transcriptional inhibition of this pathway accelerates tumor growth. On the contrary, in 
pancreatic cancer, NOTCH acts as an oncogene. In this cancer type, it was shown that 
dnMAML1 delays the formation of pancreatic intraepithelial neoplasia (Thomas et al., 
2014). Taken together, dnMAML1 appears accelerate or inhibit tumorigenesis in cancers 
in which NOTCH acts as a tumor suppressor and oncogene respectively. In HNSCC, 
since NOTCH1 has inactivating mutations similar to cSCC (Pickering et al., 2014), I 
hypothesized that abrogation of all NOTCH signaling would exacerbate tumor formation. 
To determine the comprehensive function of NOTCH mediated growth suppression and 
overcome potential redundancies between receptors, I proposed to abrogate some of 
canonical (LAG1-CSL- dependent) NOTCH signaling using dnMAML1 in a NOTCH 
wild-type cell line that is non-tumorigenic in mice.  
Results:  I infected PJA34 cells with dnMAML1 (MigR1-GFP-tagged) or with the 
empty vector MigR1 and sorted these cells to obtain a pure population GFP positive cell 
by flow cytometery. The transductions were performed such the percentage and intensity 
of GFP cells were equal in all conditions. In addition, I also transduced Jagged1, the 
ligand for the NOTCH receptor in the same cell line before mice injections. Twelve days 
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post injection in the dorsal tongue of mice, tumors in the dnMAML1 and Jag1 group 
began to develop. By end of 20 days, tumor volumes in the Jag1 and dnMAML1 mice 
were significantly larger than the control groups (Figure 26). Although only 5/10 
dnMAML1 formed tumors, the growth of these tumors was significantly larger than the 
parental and MigR1 group. Jagged1 and NOTCH receptor in the same cell can potentially 
result in cis-inhibition (Cordle et al., 2008). It might be possible that cis-inhibition rather 
than trans activation in PJA34 cells overexpressing Jagged1 contributes to accelerated 
tumor growth. To address the issue of cis-inhibition, we co-cultured wild-type parental 
cells with wild-type Jagged1 overexpressing cells. We performed a western blot to 
evaluate expression levels of cleaved NOTCH1. Parental cells expressed very little 
cleaved NOTCH1, while parental cells mixed with Jagged1 overexpressing cells had 
higher amounts of cleaved NOTCH1 (Figure 27). Interestingly, levels of cleaved 
NOTCH1 was lower in Jagged1 overexpressing cells. This suggests that although there 
might have been some cis-inhibition in parental-Jagged1 mixed cells, there was more 
transactivation resulting in cleaved NOTCH1. In Jagged1 overexpressing cells, cis 
inhibition might have possibly resulted in lower levels of cleaved NOTCH1. In mice, 
when Jagged1 cells were injected, there might have been greater cis-inhibition than trans-
activation resulting in increased tumor volumes. Since MAML1 exerts its effects in the 
nucleus, it might be possible that there was no little or nuclear localization of dnMAML1 
after transduction in these cells. I did not determine the nuclear presence of dnMAML1 in 
these cells, thus, in 50% mice that did not form tumors in the dnMAML1 group, 
dnMAML1 may have not have translocated to the nucleus.  
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Figure 32:  NOTCH signaling may be necessary for inhibiting tumor growth. 
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Figure 33:  Possibility of cis-inhibition when PJA34 and 183 cells are overexpressed 
with Jagged1 
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Discussion 
 
In this chapter, for the first time the growth inhibitory effects after restoration of 
NOTCH signaling in mutant and wild-type NOTCH1 expressing HNSCC cell lines has 
been demonstrated. In addition, we found that NOTCH1 is sufficient to inhibit 
tumorigenicity and might also be necessary for mediating inhibitory growth signals.  
Using the activated form of NOTCH (ICN1) and the full- length NOTCH1 (NFL1), it has 
been shown that NOTCH1 is sufficient to inhibit in vitro growth by competitive cell 
proliferation assays and clonogenic assays. In Acute Myeloid Leukemia (AML), Kannan 
et al. have shown that ICN1 induces growth arrest through a competitive cell proliferation 
assay (Kannan et al., 2013). Moreover they have shown arrest of cells in the G1 phase of 
the cell cycle, which is also consistent with our data. Since NOTCH1 acts as a tumor 
suppressor in AML, our results corroborate with previously reported findings.  The 
reason for growth inhibition is not completely understood. As we have shown, 
senescence in part contributes to growth arrest, while a small fraction of cells also under 
cell death. Devgan et al. have shown that in keratinocytes, p21 is downstream of 
NOTCH1 signaling and regulates keratinocyte growth (Devgan, Mammucari, Millar, 
Brisken, & Dotto, 2005). Although we have also shown an induction in p21 when 
NOTCH1 is activated, it doesn’t completely account for growth inhibition since only 
30% of the cells undergo senescence. More than 60% of the cells were arrested in the G1 
phase of the cell cycle and about 15% in the sub-G0 phase after transduction with 
activated NOTCH1 (ICN1). Kannan et al. have shown that in B-ALL, NOTCH signaling 
induces PARP mediates apoptosis (Kannan et al., 2011). Since only 15% of cells were 
arrested in the sub-G0 phase, the apoptotic mechanism was not further investigated. 
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When using a more physiological full- length NOTCH1 (NFL1), the growth inhibitory 
effects mirrored ICN1. Even in this case the percentage of senescent cells was lower 
suggesting that there might be other mechanisms besides senescence and cell death 
contributing to growth arrest. Indeed, the role of NOTCH in differentiation cannot be 
discounted because in mice that were injected with mutant cells having NFL1 or ICN1, 
the formation of keratin pearls representative of a differentiated phenotype were 
observed. Thus, it is possible that such induction in differentiation may contribute to 
growth arrest. Rangarajan and colleagues (Rangarajan et al., 2001) used a tamoxifen 
inducible system to delete the NOTCH1 gene in the keratinocytes of mice. They show 
that NOTCH1 promotes differentiation, transcriptionally up regulates p21 and inhibits 
keratinocyte growth (Rangarajan et al., 2001). Their results confirm our findings of 
NOTCH1 inducing p21, inhibiting tumor growth and possibly activating a differentiation 
program. Furthermore, we have shown that either the intracellular form of NOTCH1 or 
NOTCH2 (ICN1 or ICN2) may be sufficient to inhibit cell growth. NOTCH2 is mutated 
at a lower frequency compared to NOTCH1 and these mutations are not mutually 
exclusive. Thus, there is a possibility that in tumors that have an intact NOTCH1, 
mutations in NOTCH2 may contribute to tumor progression. Our findings indicate that 
both ICN1 and ICN2 can contribute to growth inhibition. To represent a more 
physiological condition, the full-length NOTCH2 needs to be cloned and experiments 
similar to NFL1 must be performed which is part of our future directions. NOTCH1 and 
NOTCH2 may be required for growth inhibition. To prove that both these isoforms may 
be necessary, the NOTCH signaling pathway was inhibited by expression of the pan-
NOTCH inhibitor, dnMAML1. In a weakly tumorigenic NOTCH1 wild-type cell line, 
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inhibiting the NOTCH signaling pathway increased tumor growth but this effect was seen 
only in 50% of the mice injected. dnMAML1 has been shown to induce basal hyperplasia 
impairing squamous differentiation in mouse esophageal epithelium (Ohashi et al., 2010). 
In our system, we might have to evaluate the nuclear localization of dnMAML1. Since 
dnMAML1 suppresses the transcriptional activity of NOTCH in the nucleus, it is possible 
that the lack of nuclear localization after transduction in cells prevents NOTCH pathway 
inhibition. In light of this caveat; to better inhibit the pathway we have stably knocking 
out NOTCH1, NOTCH2 or both using the CRISPR-Cas9 approach. For the first time, we 
demonstrate the use of CRISPR technology to knock out the NOTCH gene in HNSCC 
cell lines and show that knocking out both NOTCH1 and NOTCH2 relieves growth 
suppression in vitro. Furthermore, we have also demonstrated that restoring NOTCH1 in 
double knock out cells rescues abrogation of growth inhibition, implying that NOTCH1 
is necessary and sufficient to modulate cell growth.   In future studies, we will examine 
the in vivo tumorgienecity after injected these cells in mice and hypothesize that 
knocking out both NOTCH1 and NOTCH2 would exacerbate tumor growth.  
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Chapter 6: Downstream effectors of NOTCH mediated growth inhibition 
Chapter 6.1: AXL and CTNNAL1 (α-catulin) are downstream of NOTCH signaling 
 
Rationale: In Chapter 5, the effects of activating the NOTCH signaling pathway 
in wild-type and mutant cell lines was elucidated and its growth suppressive effect was 
demonstrated. There are several mediators of cell growth and diverse signaling cascades 
involved in regulating cell growth and proliferation. Previous publications have 
extensively detailed the oncogenic role NOTCH in breast, pancreatic cancer and T-ALL. 
Others have characterized NOTCH as a tumor suppressor in skin, esophageal cancer, B-
ALL and hepatocellular carcinoma. For example, in B-ALL, Kannan et al. examined the 
role of NOTCH inducing HES1 and PARP mediated apoptosis (Kannan et al., 2011). 
Rangarajan and colleagues have described the role of p21 in contributing to NOTCH 
induced differentiation and growth arrest (Rangarajan et al., 2001). In esophageal cancer, 
Kagawa et al. attributed a p16 –Rb pathway or a p14-p53 pathway to senescence 
(Kagawa et al., 2015). To date, the mechanism of NOTCH acting as a tumor suppressor 
in HNSCC has not been explored. Identifying modulators downstream of the NOTCH 
pathway would help in targeting certain molecules that are upregulated in the absence of 
NOTCH signaling, and could potentially lead to better-targeted therapeutics. We had 
previously shown the induction of p21 as a possible potential downstream target of 
NOTCH1 based on the senescent morphology observed after activation with ICN1 in one 
mutant cell line (HN31). To identify the downstream modulators of the NOTCH 
signaling pathway in an unbiased fashion, we performed a microarray after activating the 
NOTCH pathway in two wild-type cell lines PJA34 and 183 by culturing them on 
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Jagged1 for 5 days. Subsequently, the Affymetrix 2.0 gene array was used to evaluate 
gene expression. 
Results: Each condition was performed in biological triplicates and normalized 
before analyzing differences for expression between genes when these wild-type cells 
were cultured on Jagged1 compared to Fc.  We used the BRB-ArrayTools in a univariate 
test. All the data pre-processing steps were performed by the Department of 
Bioinformatics (M.D. Anderson Cancer Center). Linear model was fit to each probeset 
using both treatment (culture on Jagged1 or Fc) and cell lines (PJA34 and 183) as fixed 
effects. Based on the raw p-values, they generated a model using beta-uniform mixture 
(BUM) to generate different p-value cut-offs based on a False Discovery Rate (FDR) of 
0.05. Using this FDR, based on the identified significantly modulated probesets, 
concordance correlation of multiple probesets that map to the same gene was evaluated. 
Only one probeset for each gene was selected if their expression was inconsistent. If their 
expression was consistent, an average of the expression of those probesets was reported.  
We found 1808 genes to be differentially regulated when comparing both 
treatment and cell line conditions (Appendix 1). There are 277 differentially expressed 
genes that have treatment effects (Jagged1 versus Fc) without cell line difference (PJA34 
versus 183). Appendix 1 contains the average expression of 1808 differentially expressed 
genes including the p-value and the relative fold change of the treated group to the 
control group (relative to Fc). Out of these 1808 genes, we filtered genes that had more 
than a 1.4 fold difference in gene expression when these cells were cultured on Jagged1 
versus Fc. Based on this filter, we narrowed the number of genes to 120 of which 50 
genes were upregulated and 70 genes were downregulated by Jagged1 induced NOTCH 
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activation (Table 7). Some of the genes that were upregulated when NOTCH was 
activated are tumor suppressor genes like EPHA4, TP53INP1, PDCD 4, KRT4, KRT13 
while genes that were downregulated when NOTCH was activated include AXL, MMP9, 
INTGA3, LAMC2 and CTNNAL1 among others. The set of 120 altered genes was then 
subjected to an unbiased core analysis using the Ingenuity Pathway software (IPA) to 
identify the most significantly altered cellular functions and pathways (Table 8). Based 
on the Ingenuity Pathway analysis, the three most significantly altered pathways when 
NOTCH is activated is cell movement (P= 2.7 e-12) followed by cell growth and 
proliferation (P=3.95 e-11) that was followed by cell adhesion/interaction (P=8.05e-10). 
Our finding that cell growth and proliferation was one of the significantly altered 
phenotypes validated our previous report (Chapter 5) of NOTCH significantly affecting 
cell growth and tumor progression. The current microarray analysis extends our earlier 
report to identify potential candidate genes that might be involved in modulating cell 
growth. Based on the significance of change (P-values), intensity of change (1.4 fold 
threshold) and novelty of these candidate targets with NOTCH1 (based on literature 
published), we identified two proto-oncogenes that were down modulated when NOTCH 
was activated. AXL was the most significantly altered gene in both cell lines (6.41e-9) 
and had approximately 3-fold downregulation when NOTCH was activated by Jagged1. 
CTNNAL1 (α-catulin) had the highest downregulation among all genes in the 183 wild-
type cell line (24 fold). We were interested in genes suppressed by NOTCH signaling 
since these genes may be potentially targeted therapeutically and thus investigated the 
modulation of AXL and α-catulin after NOTCH activation.  
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Official Gene 
Symbol 
Gene Symbol 
used in TCGA 
TCGA 
Regulation 
by 
NOTCH 
activation 
P-value Fold 
change 
in 
PJ34 
Fold 
change 
 in 183 
CAV1 CAV1 Down 
regulated 
3.59E-09 -1.88 -2.21 
AXL AXL Down 
regulated 
6.41E-09 -2.74 -3.55 
FHL2 FHL2 Down 
regulated 
1.15E-07 -1.79 -2.05 
CMTM8 CMTM8 Down 
regulated 
1.64E-07 -1.47 -1.62 
SERPINE1 SERPINE1 Down 
regulated 
2.07E-07 -2.74 -2.22 
PTRF PTRF Down 
regulated 
3.53E-07 -2.02 -2.16 
NAV3 NAV3 Down 
regulated 
4.33E-07 -2.02 -1.84 
LAMC2 LAMC2 Down 
regulated 
5.09E-07 -2.60 -4.66 
DRAM1 DRAM1 Down 
regulated 
5.62E-07 -1.88 -2.08 
AFAP1L2 AFAP1L2 Down 
regulated 
6.00E-07 -1.49 -1.60 
NETO2 NETO2 Down 
regulated 
1.31E-06 -1.79 -1.59 
TMCC3 TMCC3 Down 
regulated 
2.29E-06 -1.72 -1.88 
SEMA7A SEMA7A Down 
regulated 
2.29E-06 -1.57 -1.59 
ITGA5 ITGA5 Down 
regulated 
2.34E-06 -1.55 -1.67 
HOMER3 HOMER3 Down 
regulated 
2.38E-06 -1.61 -1.46 
ZBED2 ZBED2 Down 
regulated 
2.55E-06 -1.89 -1.70 
SYT16 SYT16 Down 
regulated 
2.68E-06 -1.76 -1.62 
SLC16A2 SLC16A2 Down 
regulated 
3.34E-06 -1.80 -2.57 
FGFBP1 FGFBP1 Down 
regulated 
3.66E-06 -1.84 -2.19 
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FHOD1 FHOD1 Down 
regulated 
3.75E-06 -1.44 -1.47 
ITGA3 ITGA3 Down 
regulated 
5.03E-06 -1.56 -1.88 
PXN PXN Down 
regulated 
5.48E-06 -1.51 -1.83 
PKP2 PKP2 Down 
regulated 
5.73E-06 -1.51 -1.54 
THSD4 THSD4 Down 
regulated 
6.42E-06 -1.50 -1.54 
KLK6 KLK6 Down 
regulated 
1.11E-05 -1.83 -1.76 
SOX15 SOX15 Down 
regulated 
1.34E-05 -1.76 -1.40 
PLEK2 PLEK2 Down 
regulated 
1.86E-05 -1.79 -1.61 
MOBKL2B MOBKL2B Down 
regulated 
1.94E-05 -1.58 -1.52 
LOXL2 LOXL2 Down 
regulated 
2.16E-05 -2.49 -1.63 
PLAUR PLAUR Down 
regulated 
2.35E-05 -1.91 -1.74 
MMP9 MMP9 Down 
regulated 
2.35E-05 -1.60 -2.53 
UPP1 UPP1 Down 
regulated 
2.80E-05 -1.43 -1.55 
LOXL4 LOXL4 Down 
regulated 
2.94E-05 -3.12 -1.80 
SLC7A2 SLC7A2 Down 
regulated 
3.00E-05 -1.50 -2.24 
TMEM27 TMEM27 Down 
regulated 
3.16E-05 -1.63 -1.48 
ANKRD2 ANKRD2 Down 
regulated 
3.72E-05 -1.67 -1.56 
AP2B1 AP2B1 Down 
regulated 
4.28E-05 -1.43 -2.22 
LEPREL1 LEPREL1 Down 
regulated 
6.37E-05 -1.63 -1.51 
SLC39A14 SLC39A14 Down 
regulated 
6.56E-05 -1.46 -2.26 
CD55 CD55 Down 
regulated 
8.36E-05 -1.42 -1.73 
HEG1 HEG1 Down 
regulated 
8.76E-05 -1.49 -1.87 
PI4K2A PI4K2A Down 
regulated 
9.68E-05 -1.49 -1.40 
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FST FST Down 
regulated 
0.00010061 -1.99 -5.32 
NXPE3 
FAM55C Down 
regulated 
0.000109425 -1.52 -1.69 
VEGFC VEGFC Down 
regulated 
0.000109475 -2.01 -1.50 
SIRPA SIRPA Down 
regulated 
0.000121239 -1.80 -1.42 
KIRREL KIRREL Down 
regulated 
0.000126131 -1.77 -1.46 
OLR1 OLR1 Down 
regulated 
0.00013061 -6.59 -2.08 
KIAA0040 KIAA0040 Down 
regulated 
0.000150652 -1.55 -1.46 
CYR61 CYR61 Down 
regulated 
0.000154488 -1.92 -1.70 
VLDLR VLDLR Down 
regulated 
0.00018433 -1.58 -2.03 
RAB32 RAB32 Down 
regulated 
0.000209603 -1.48 -1.80 
TIMP4 TIMP4 Down 
regulated 
0.000261133 -1.40 -1.46 
ABCG2 ABCG2 Down 
regulated 
0.000307053 -1.84 -6.60 
FAM101B FAM101B Down 
regulated 
0.000374899 -2.28 -1.45 
MFAP5 MFAP5 Down 
regulated 
0.000455964 -1.48 -3.14 
NT5E NT5E Down 
regulated 
0.000464717 -1.48 -2.34 
COL17A1 COL17A1 Down 
regulated 
0.000479488 -1.43 -3.37 
CPA4 CPA4 Down 
regulated 
0.000582963 -1.45 -1.56 
EMP3 EMP3 Down 
regulated 
0.000688038 -2.13 -1.53 
CTNNAL1 CTNNAL1 Down 
regulated 
0.0009852 -2.12 -24.86 
TIMP3 TIMP3 Down 
regulated 
0.001204042 -1.54 -1.41 
CDH13 CDH13 Down 
regulated 
0.001276195 -1.61 -1.45 
FAM46B FAM46B Down 
regulated 
0.001472671 -1.41 -1.65 
IL6R IL6R Down 
regulated 
0.002073781 -1.61 -1.63 
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HBEGF HBEGF Down 
regulated 
0.002619748 -1.44 -1.72 
EREG EREG Down 
regulated 
0.003182918 -1.93 -1.46 
EPHA2 EPHA2 Down 
regulated 
0.003589923 -1.49 -1.62 
FOSL1 FOSL1 Down 
regulated 
0.004399443 -2.54 -1.82 
B4GALT6 B4GALT6 Down 
regulated 
0.004750404 -1.46 -1.50 
BCL6 BCL6 Up 
regulated 
0.002698801 1.61 1.49 
TNKS TNKS Up 
regulated 
0.002485846 1.77 1.41 
HLA-DRA HLA-DRA Up 
regulated 
0.001875278 3.39 1.50 
SCARNA9 SCARNA9 Up 
regulated 
0.001560804 2.16 1.53 
LONP2 LONP2 Up 
regulated 
0.001107504 1.45 1.41 
SCARNA17 SCARNA17 Up 
regulated 
0.00090611 1.47 1.67 
GUSBP3 GUSBP3 Up 
regulated 
0.000559537 1.50 1.46 
AKR1C3 AKR1C3 Up 
regulated 
0.00054151 1.52 1.76 
ZNF117 ZNF117 Up 
regulated 
0.000509494 1.63 2.63 
MUC16 MUC16 Up 
regulated 
0.000431455 2.03 1.47 
PGLYRP4 PGLYRP4 Up 
regulated 
0.000373443 1.44 2.23 
IKZF2 IKZF2 Up 
regulated 
0.00033363 1.41 1.45 
DLX5 DLX5 Up 
regulated 
0.000332635 1.77 1.64 
KRT4 KRT4 Up 
regulated 
0.000263173 2.00 7.95 
PRODH PRODH Up 
regulated 
0.00016933 1.83 1.59 
MYH14 MYH14 Up 
regulated 
0.000141238 1.57 1.73 
TXNIP TXNIP Up 
regulated 
0.000124053 2.63 1.67 
KLHL24 KLHL24 Up 
regulated 
0.00010392 1.74 1.55 
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KRT13 KRT13 Up 
regulated 
9.57E-05 1.77 3.60 
GOLGA8A GOLGA8A Up 
regulated 
7.85E-05 1.70 1.40 
GLUL GLUL Up 
regulated 
6.63E-05 1.67 1.43 
TMEM45B TMEM45B Up 
regulated 
6.02E-05 1.43 2.06 
GOLGA8B GOLGA8B Up 
regulated 
4.87E-05 1.76 1.43 
MANSC1 MANSC1 Up 
regulated 
4.58E-05 1.56 1.73 
FAM102B FAM102B Up 
regulated 
2.85E-05 1.66 1.41 
DSP DSP Up 
regulated 
2.46E-05 1.47 1.65 
PRKX PRKX Up 
regulated 
2.37E-05 1.56 1.66 
PCMTD2 PCMTD2 Up 
regulated 
2.07E-05 1.41 1.48 
CNKSR3 CNKSR3 Up 
regulated 
1.67E-05 1.41 1.92 
GCLC GCLC Up 
regulated 
1.57E-05 1.77 1.41 
RNF138P1 RNF138P1 Up 
regulated 
1.42E-05 2.98 2.43 
FAM214A 
KIAA1370 Up 
regulated 
1.28E-05 1.41 1.46 
HES5 HES5 Up 
regulated 
1.15E-05 1.46 1.64 
ST6GALNAC2 ST6GALNAC2 Up 
regulated 
1.15E-05 1.46 1.57 
ACPP ACPP Up 
regulated 
9.76E-06 1.62 1.44 
SLC12A2 SLC12A2 Up 
regulated 
8.22E-06 1.57 2.29 
PBX1 PBX1 Up 
regulated 
7.54E-06 1.64 1.82 
CYP1A1 CYP1A1 Up 
regulated 
6.40E-06 1.65 2.25 
PPAP2A PPAP2A Up 
regulated 
4.43E-06 1.83 3.05 
TNFSF10 TNFSF10 Up 
regulated 
3.47E-06 1.41 1.63 
KIAA1147 KIAA1147 Up 
regulated 
3.24E-06 1.47 1.71 
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PDCD4 PDCD4 Up 
regulated 
2.01E-06 1.72 2.08 
PLD1 PLD1 Up 
regulated 
8.95E-07 1.66 2.02 
LURAP1L 
C9orf150 Up 
regulated 
7.13E-07 1.74 2.03 
SLPI SLPI Up 
regulated 
1.58E-07 1.44 1.56 
TP53INP1 TP53INP1 Up 
regulated 
1.21E-07 2.99 2.27 
EPHA4 EPHA4 Up 
regulated 
8.73E-08 1.65 1.94 
VTCN1 VTCN1 Up 
regulated 
2.24E-08 3.08 2.96 
KRT15 KRT15 Up 
regulated 
2.22E-08 1.90 1.69 
RAB40B RAB40B Up 
regulated 
1.78E-08 1.70 1.98 
 
Table 7: Top 120 genes modulates when NOTCH signaling is activated. (Red= 
upregulates, Green= Downregulated when treated with Jagged1) 
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Table 8: Ingenuity Pathway Analysis of significantly modulated pathways when NOTCH 
is activated in wild-type cell lines PJA34 and 183. (Red= Genes Upregulated by NOTCH, 
Green= Genes Downregulated by NOTCH). 
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Figure 34:  Heat-map of 277 differentially expressed genes having treatment effects but 
not cell lines effects. Top green bar: control samples. Top orange bar: Jagged1 treated 
samples.  
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Figure 35:  Heat map of 1571 differentially expressed genes that have both treatment and 
cell line effects. Top green bar: control samples. Top orange bar: Jagged1 treated 
samples 
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Chapter 6.2: NOTCH1 modulates AXL and CTNNAL1 (α-catulin) at the protein level 
 
Rationale: We had previously observed induction of AXL and CTNNAL1 (α-
catulin) at the gene expression level after activating NOTCH signaling in wild-type cell 
lines. AXL and α-catulin are overexpressed in many cancers (Dunne et al., 2014; Schultz 
et al., 1995). Elevated protein expression of AXL has been evaluated as a poor prognostic 
factor for overall survival in colon cancer, osteosarcoma, and pancreatic cancer (Dunne et 
al., 2014; J. Han et al., 2013; Song et al., 2011). Furthermore, AXL expression is also a 
prognostic for increased lymph node metastasis and clinical stage in lung 
adenocarcinoma, breast and ovarian cancer (D'Alfonso et al., 2014; Rankin et al., 2010; 
Shieh et al., 2005). Recently, Kreisede and colleagues have shown that α-catulin is highly 
expressed in melanoma cells and that α-catulin is a key driver of melanoma tumor 
formation, growth, invasion and metastasis (Kreiseder et al., 2013). In order to validate 
that the transcriptional modulation of AXL and α-catulin by NOTCH1, we performed a 
western blot to evaluate the expression of these two proto-oncogenes at the protein level. 
Results: We first overexpressed the activated form of NOTCH1 (ICN1) in a 
NOTCH1 wild-type and mutant cell line (PJA34 and HN31 respectively) and evaluated 
protein expression of AXL and α-catulin 3 days and 5 days after infection. At both time 
points, there was significant suppression of both AXL and α-catulin in ICN1 infected 
cells compared to MigR1 (empty vector) infected cells suggesting that the activated form 
of NOTCH1 might be sufficient to modulate these two proto-oncogenes (Figure 36). 
Next, the full length NOTCH1 receptor (NFL1) was expressed in the mutant cell lines 
HN31, UM22A and UM47 and these cells were then cultured on Jagged1 for 3 days to 
evaluate AXL and α-catulin levels in a more physiological setting. Expression levels of 
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both the proto-oncogenes was diminished by at least 50% when NOTCH signaling was 
activated by Jagged1 compared to cells cultured on Fc and empty vector infected cells 
(Figure 37). To prove that the down modulation of AXL and α-catulin was indeed due to 
NOTCH signaling, the wild-type cells PJA34 were infected with dnMAML1 (to inhibit 
NOTCH signaling) before culturing these infected cells on Jagged1 or Fc for 3 days. 
Inhibiting the NOTCH signaling pathway using dnMAML1 reversed the Jagged1 
mediated suppression of both these proto-oncogenes (Figure 38). In addition to using 
dnMAML1, we also knocked out NOTCH1 and NOTCH2 using the CRISPR-Cas9 
system in the wild-type cell lines PJA34 and found that knocking out both NOTCH 
isoforms induces expression of AXL and α-catulin (Figure 39). The wild type cell line 
when cultured on Jagged1 suppresses AXL and α-catulin, however double knockout of 
NOTCH1 and NOTCH2 (dKO) reverses this suppression suggesting that NOTCH1 and 
NOTCH2 might be necessary to suppress these proto-oncogenes. Interestingly, 
restoration of NFL1 in the dKO PJA 34 cell line relieves the induction of these molecules 
when cultured on Jagged1. Furthermore, even restoration of NFL1 in the NOTCH1 KO 
PJA 34 inhibited AXL and α-catulin when cultured on Jagged1. This suggests that 
NOTCH signaling may be necessary and sufficient to inhibit AXL and α-catulin.  
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Figure 36:  Activated NOTCH1 (ICN1) is sufficient to suppress AXL and α-catulin. 
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Figure 37:  Restoration of full length NOTCH1 (NFL1) in the mutant cell lines: HN31, 
UM22A and UMSCC47 after activation with Jagged1 suppress AXL and α-catulin 
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Figure 38:  Inhibition of NOTCH signaling using dnMAML1 reverses Jagged1 induced 
suppression of AXL and α-catulin. 
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Figure 39: NOTCH signaling is necessary and sufficient to inhibit AXL and catulin: 
Knocking out NOTCH signaling using the CRISPR-Cas9 system induces AXL and α-
catulin which is reversed when the same cell line is restored with NFL1. 
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Chapter 6.3: HES2 and HES5 may be sufficient to modulate AXL and α-catulin 
 
Rationale: Canonically, the activation of the NOTCH pathway induces expression 
of the HES and HEY family of genes which are known transcriptional modulators 
(mostly repressors) of target genes involved with cell proliferation, differentiation, 
migration, and angiogenesis. We initially identified AXL and α-catulin suppression from 
gene expression arrays and since HES and HEY are direct downstream targets of the 
NOTCH signaling pathway, we hypothesized that HES or HEY members might be 
involved in regulating the expression of these proto-oncogenes. 
Results:  First, the mRNA expression levels of the HES and HEY family members 
after activating NOTCH signaling was evaluated in a NOTCH1-mutant cell line (HN31) 
expressing NFL1 and culturing cells on Jagged1 or Fc for 20h since hEs and HEY are 
early expression genes. Shown in Figure 40 is qRT-PCR analysis showing significantly 
altered members of HES and HEY after NOTCH activation. There was a 3-5 fold 
increase in HES2, HES5 and HEY2, but no significant change in HES1, HES3, HES4 
and HEY1 (Figure 40). Among the selected candidate targets, HES2 and HES5 had the 
highest increase (3.5 and 5 fold respectively) compared to HEY2 (2.5 fold). 
Following the identification of these downstream targets, we evaluated if these 
molecules are sufficient to inhibit AXL and α-catulin expression. For this, MigR1-flag 
tagged- GFP constructs of HES2 and HES5 were expressed in the NOTCH1 mutant cell 
line HN31. Forty-eight hours after infection, these cells were purified for GFP by flow 
cytometry, and were harvested for western blotting. Both HES2 and HES5 were 
sufficient to suppress protein levels of AXL by at least 55% and α-catulin by at least 33% 
compared to the parental and empty vector controls (Figure 42: Relative expression levels 
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of Flag-Tag, HES5, AXL, p-AXL, α-catulin and Gas6 from the western blot shown in 
Figure 41). Furthermore, there was also a decrease in phopho-AXL and Gas6 (a ligand 
for AXL) suggesting that AXL activity is also abrogated when HES2 and HES5 are 
overexpressed. Taken together, NOTCH1 can inhibit HES2 and HES5, which might be 
sufficient to modulate AXL and α-catulin protein expression. 
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Figure 40:  Modulation of HES and HEY members after restoration of NOTCH signaling 
in HN31 cells and culturing on Jagged1 for 20h 
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Figure 41:  HES2 and HES5 might be sufficient to modular protein expression of AXL, p-
AXL, Gad6 and α-catulin. Overexpressing HES2 and HES5 using Flag tagged constructs 
in the mutant cell line HN31 inhibits protein expression of proto-oncogenes AXL and α-
catulin. 
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Figure 42: Relative expression levels of Flag-Tag, HES5, AXL, p-AXL, α-catulin and 
Gas6 from the western blot shown in Figure 41 
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Chapter 6.4: The 120 in vitro gene signature corresponds with NOTCH activation status 
in patients 
 
Rationale: Previously, we identified 120 differentially regulated genes when the 
NOTCH signaling pathway was activated in wild-type cell lines PJA34 and 183. Some of 
these genes, such as AXL (Brand et al., 2015), CTNNAL1 (Cao et al., 2012), INTGA3 
(Nakada et al., 2013), INTGA5 (Janes & Watt, 2006), VEGFC (Wang, Chen, Fang, & 
Yang, 2013), and keratins (Rangarajan et al., 2001) have shown to be overexpressed in 
different cancers. The correlation between NOTCH mutational status in HNSCC patients 
and expression of the identified genes is not known. Since the gene expression array was 
performed in vitro after activating NOTCH signaling, we evaluated the correlation 
between the 120 identified genes in vitro to NOTCH mutational status in HNSCC 
patients. We hypothesized that genes modulated by NOTCH signaling in vitro would 
correlate with HNSCC patients having an active NOTCH gene signature.  
Results: We evaluated RNA-seq data from 498 TCGA HNSCC patient samples 
based on the in vitro gene signature. The 120 genes of interest originated from the 
significant gene list based on Affymetrix HuGene 2.0 ST array data. There are more than 
20,000 genes for the expression data and the whole data set was divided into two parts 
according to tumor sites: Oral Cavity (OC) and Laryngeal/Hypopharyngeal (LH). The 
TCGA RNA-Seq data was downloaded from Broad GDAC Firehose and was processed 
and normalized by the Department of Bioinformatics (M.D. Anderson Cancer Center). 
We read the TCGA RNA-Seq data and subsetted the data into one with the expression of 
the interested genes. The NOTCH1 and NOTCH2 mutation status were overlaid and 
patients were assigned two or three groups based on clustering.  We then produced heat 
 137 
maps with pearson distance and ward linkage based on 498 patient samples, 120 genes 
and two anatomical sites. We found two distinct clusters; genes upregulated after 
NOTCH activation were grouped into cluster A (left red bar of Figure 43Figure 44) while 
all genes that were downregulated by NOTCH activation formed cluster B (left green bar 
of Figure 43 Figure 44). In cluster A of the Oral cavity subset, we found 49 genes 
upregulated by Jagged1 and 17 genes downregulated, while in cluster B, only 1 gene was 
upregulated by Jagged1 and 53 genes were downregulated (Table 9). Similarly, we 
observed 44 Jagged1 upregulated genes and 24 downregulated genes in cluster A of the 
Laryngeal/Hypopharyngeal subset, and 6 upregulated and 46 downregulated genes in 
cluster B of the same subset (Table 12). Since we performed an unsupervised clustering 
analysis, we observed similar clustering of the 120 genes to the cell lines in vitro and thus 
confirmed our previous in vitro microarray analysis. In the two anatomical sites, we 
observed at least two clusters; patients having an inactive NOTCH gene signature (cluster 
1) or an active NOTCH gene signature (cluster 2). Since patients in cluster 1 had gene 
expression levels opposite of those in cell lines (i.e. genes upregulated in cell lines when 
NOTCH was active was downregulated in cluster 1 in patients and vice versa), those 
patients possibly have an inactive NOTCH pathway. Genes modulated in cluster 2 
resemble cell lines with an activated NOTCH pathway. Thus, it is possible that these 
patients might have an active NOTCH pathway.  Moreover, patients in cluster 2 lack any 
NOTCH1 or NOTCH2 mutations. In the Oral Cavity patient subset, 34 patients were 
mutant for NOTCH1 and 113 patients harbored a wild-type receptor in Cluster 1, while in 
cluster 2, only one patient had NOTCH1 mutations and 39 patients harbored the wild-
type NOTCH1 (Table 10). In the Laryngeal/Hypopharyngeal cluster, cluster 1 had 15 
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NOTCH1 mutant patients and 28 wild-type, while cluster 2 had 1 NOTCH1 mutant 
patient and 29 wild-type NOTCH1 patients (Table 11). In cluster 3 of both sites, are 
patients that might have the NOTCH pathway inactivated in ways besides somatic 
mutation. Thus, these patients might be clustered under an active NOTCH gene signature 
but might have an inactive NOTCH downstream pathways. Correlation heat maps, and a 
histogram depicting the number of differentially expressed genes with various FDR cut-
offs and p-values for the Oral Cavity group are shown in appendix 2 and 3 respectively. 
Shown in Table 13 are the associations of the 120 differentially expressed genes with the 
different clusters (in cell lines A versus B) in the TCGA patient samples in both 
anatomical sites. We observe that in patients, clustering is similar to cell lines and 
correlate with each other. In addition to subjecting the 120-gene signature to an unbiased 
clustering analysis in patients, we were also interested in the most significantly 
modulated genes among all the genes in patient tumors. We performed an unsupervised 
clustering and generated a heat map of the significantly differentially expressed genes 
from the t-test between group 1 and group 2 based on an FDR of 0.000001 at all 
anatomical sites (Figure 45and Figure 46). When the differential expression of these 
genes were analyzed, we were surprised to find that in addition to high mRNA levels of 
keratins, integrins, AXL and modest increase in α-catulin, two of the top effectors were 
aldehyde dehydrogenase ALDH1A1 and ALDH1A3. Both these are stem cell markers 
whose mRNA levels was high in patients with an active NOTCH pathway. We observed 
a 32-fold increase in ALDH1A1 in Oral Cancer patients with active NOTCH pathway 
and 10 fold increase in ALDH1A3. Similarly, we found a 13 fold increase in ALD1A1 in 
Laryngeal/hypopharyngeal cancers and 19 fold increase in ALDH1A3. ALDH1A1 and 
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ALDH1A3 were two of the top stem cell makers that we didn’t observe from the 
microarray in vitro. This finding is intriguing because it implies that activation of 
NOTCH signaling can potentially turn on a stem cell program and increase maintenance 
of stem cells. We had shown earlier that in mutant cells after restoring NOTCH1, and 
injecting these cells in mice, we observed the formation of keratin pearls indicating 
differentiation. While, we do observe differentiation markers from the TCGA data, we 
now also have evidence of a possible increase in stem cell markers. We speculate that 
NOTCH activation increases differentiation and thus inhibits cell growth, but the 
upregulation of ALDH1A3 and ALDH1A5 opens up new avenues on how NOTCH may 
regulate a stem cell phenotype that needs to be investigated in the future.  
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Figure 43: Heat-map of the 120 in vitro gene signature in Oral Cavity 
TCGA tumors 
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Table 9: Total number of Oral Cavity (OC) patients in each cluster corresponding to 
NOTCH1 mutational status. Shown in parenthesis are expected numbers based on Chi-
Squared test 
 
Table 10: Total number of genes in each cluster of Oral Cavity (OC) patients 
corresponding to modulation by Jagged1 in cell lines. Shown in parenthesis are expected 
numbers based on Chi-Squared test. 
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Figure 44: Heat-map of the 120 in vitro gene signature in 
Laryngeal/Hyopharyngeal TCGA tumors 
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Table 11: Total number of Laryngeal/Hypopharyngeal (LH) patients in each cluster 
corresponding to NOTCH1 mutational status. Shown in parenthesis are expected 
numbers based on Chi-Squared test 
 
Table 12: Total number of Laryngeal/Hypopharyngeal (LH) patients in each cluster 
corresponding to NOTCH1 mutational status. Shown in parenthesis are expected 
numbers based on Chi-Squared test 
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Figure 45: Unsupervised clustering of 498 TCGA Oral Cavity (OC) tumors based on 
20,000 genes. 
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Figure 46:  Unsupervised clustering of 498 TCGA Laryngeal/Hypopharyngeal (LH) 
tumors based on 20,000 genes 
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Official Gene 
Symbol 
Gene Symbol 
used in TCGA 
TCGA 
Regulated 
by 
NOTCH 
Oral 
Cavity 
Gene 
Cluster 
(A or B) 
Larnyx 
Hypopharynx 
Gene Cluster 
(A or B) 
CAV1 CAV1 1 B B 
AXL AXL 1 B B 
FHL2 FHL2 1 B B 
CMTM8 CMTM8 1 B B 
SERPINE1 SERPINE1 1 B B 
PTRF PTRF 1 B B 
NAV3 NAV3 1 B B 
LAMC2 LAMC2 1 B B 
DRAM1 DRAM1 1 B A 
AFAP1L2 AFAP1L2 1 B B 
NETO2 NETO2 1 B A 
TMCC3 TMCC3 1 B A 
SEMA7A SEMA7A 1 B B 
ITGA5 ITGA5 1 B B 
HOMER3 HOMER3 1 B B 
ZBED2 ZBED2 1 B B 
SYT16 SYT16 1 B A 
SLC16A2 SLC16A2 1 B B 
FGFBP1 FGFBP1 1 A B 
FHOD1 FHOD1 1 B B 
ITGA3 ITGA3 1 B B 
PXN PXN 1 B B 
PKP2 PKP2 1 B A 
THSD4 THSD4 1 A A 
KLK6 KLK6 1 A B 
SOX15 SOX15 1 A B 
PLEK2 PLEK2 1 B B 
MOB3B 
MOBKL2B 1 B B 
LOXL2 LOXL2 1 B B 
PLAUR PLAUR 1 B B 
MMP9 MMP9 1 B B 
UPP1 UPP1 1 A B 
LOXL4 LOXL4 1 A A 
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SLC7A2 SLC7A2 1 A A 
TMEM27 TMEM27 1 A A 
ANKRD2 ANKRD2 1 B A 
AP2B1 AP2B1 1 B A 
LEPREL1 LEPREL1 1 B B 
SLC39A14 SLC39A14 1 B A 
CD55 CD55 1 A B 
HEG1 HEG1 1 B A 
PI4K2A PI4K2A 1 B B 
FST FST 1 B B 
NXPE3 FAM55C 1 B A 
VEGFC VEGFC 1 B B 
SIRPA SIRPA 1 B B 
KIRREL KIRREL 1 A A 
OLR1 OLR1 1 B B 
KIAA0040 KIAA0040 1 B A 
CYR61 CYR61 1 B B 
VLDLR VLDLR 1 A A 
RAB32 RAB32 1 B B 
TIMP4 TIMP4 1 B A 
ABCG2 ABCG2 1 B A 
FAM101B FAM101B 1 B B 
MFAP5 MFAP5 1 B A 
NT5E NT5E 1 B B 
COL17A1 COL17A1 1 B B 
CPA4 CPA4 1 B B 
EMP3 EMP3 1 B B 
CTNNAL1 CTNNAL1 1 B A 
TIMP3 TIMP3 1 B B 
CDH13 CDH13 1 B B 
FAM46B FAM46B 1 A A 
IL6R IL6R 1 A A 
HBEGF HBEGF 1 A B 
EREG EREG 1 B B 
EPHA2 EPHA2 1 A B 
FOSL1 FOSL1 1 B B 
B4GALT6 B4GALT6 1 A B 
BCL6 BCL6 0 A A 
TNKS TNKS 0 A A 
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HLA-DRA HLA-DRA 0 A A 
SCARNA9 SCARNA9 0 A A 
LONP2 LONP2 0 A A 
SCARNA17 SCARNA17 0 A A 
GUSBP3 GUSBP3 0 A A 
AKR1C3 AKR1C3 0 A A 
ZNF117 ZNF117 0 A A 
MUC16 MUC16 0 A A 
PGLYRP4 PGLYRP4 0 A B 
IKZF2 IKZF2 0 A A 
DLX5 DLX5 0 A A 
KRT4 KRT4 0 A A 
PRODH PRODH 0 A A 
MYH14 MYH14 0 A A 
TXNIP TXNIP 0 A A 
KLHL24 KLHL24 0 A A 
KRT13 KRT13 0 A A 
GOLGA8A GOLGA8A 0 A A 
GLUL GLUL 0 A A 
TMEM45B TMEM45B 0 A B 
GOLGA8B GOLGA8B 0 A A 
MANSC1 MANSC1 0 A A 
FAM102B FAM102B 0 A A 
DSP DSP 0 A B 
PRKX PRKX 0 A A 
PCMTD2 PCMTD2 0 A A 
CNKSR3 CNKSR3 0 A A 
GCLC GCLC 0 A A 
RNF138P1 RNF138P1 0 A A 
FAM214A KIAA1370 0 A A 
HES5 HES5 0 A B 
ST6GALNAC2 ST6GALNAC2 0 A A 
ACPP ACPP 0 A A 
SLC12A2 SLC12A2 0 A A 
PBX1 PBX1 0 A A 
CYP1A1 CYP1A1 0 A A 
PPAP2A PPAP2A 0 A A 
TNFSF10 TNFSF10 0 A A 
KIAA1147 KIAA1147 0 A A 
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PDCD4 PDCD4 0 A B 
PLD1 PLD1 0 A A 
LURAP1L C9orf150 0 A A 
SLPI SLPI 0 A B 
TP53INP1 TP53INP1 0 A A 
EPHA4 EPHA4 0 A A 
VTCN1 VTCN1 0 A A 
KRT15 KRT15 0 A A 
RAB40B RAB40B 0 A A 
 
Table 13: Clustering of genes modulated in both tumor sites corresponding to the genes 
clustered in cell lines 
 
 
 
 
 
 
 
 
 
 
 
 
 150 
Discussion 
 
In chapter 6, the identification of several downstream molecules of the NOTCH 
signaling pathway that may contribute to growth inhibition is elucidated. We have shown 
that activating NOTCH signaling in the wild-type cell lines PJA34 and 183 by culturing 
them on Jagged1 upregulates the expression of potential tumor suppressor genes and 
inhibits proto-oncogene expression. From this unbiased gene expression analysis, we 
were able to make associations of the NOTCH signaling pathway with effectors that were 
not known before. Among key genes down regulated by growth on JAG1 are CTNNAL1 
(α-catulin), AXL kinase, integrins α3 and α5, LAMC2 (i.e., a component of Laminin-5), 
and several genes known to mediate invasion such as MMP9 and urokinase-type 
plasminogen activator receptor (PLAUR). Among genes upregulated by JAG1 exposure 
were keratins 4 and 13 (i.e., principal keratins produced by squamous epithelial cells 
during differentiation). Tumor suppressor genes upregulated by JAG1 included TRAIL 
(i.e., TNFSF10) as well as PDCD4, which is a negative regulator of the TRAIL inhibitor 
FLIP, and is also an established target of oncogenic microRNA 21 (miR-21). In both 
PJA34 and 183 cells, AXL, α-catulin, LAMC2, and keratin 4 (KRT4) were among the 
top 15 most significantly altered genes following growth on JAG1, based upon P-value. 
KRT4 and α-catulin had the largest changes in magnitude induced by JAG1 in183 cells, 
whereas AXL and LAMC2 were among the top twelve genes with greatest fold-change in 
both cell lines.  
We also confirmed the regulation of two downstream targets AXL and α-catulin 
at the protein level. Although the gene expression array suggests that these molecules 
may be regulated at the transcriptional level, we still need to explore the transcriptional 
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binding sites of these effectors. AXL has three AP1 binding motifs and five sp binding 
sites in its promoter regions (Mudduluru & Allgayer, 2008). Chu et al. have demonstrated 
that the intracellular form of NOTCH1 (ICN1) can repress AP1 mediated transactivation 
(Chu, Jeffries, Norton, Capobianco, & Bresnick, 2002). Thus, it is possible that NOTCH1 
may transcriptionally regulate AXL, however, since AP1 transcriptional factors regulate 
several other genes, it is difficult to attribute that the transcriptional modulation of AXL 
is due to NOTCH1 alone. CTNNAL1 has five putative binding sites in the promoter 
region that can recruit LEF-1, AP-2α and CREB (Xiang et al., 2012). Our future work 
will aim at how NOTCH1 or its canonical downstream targets (HES and HEY family 
members) modulate AXL and α-catulin.  
Among the canonical downstream targets of the NOTCH pathway, we found that 
HES2 and HES5 were upregulated by more than 3-fold in comparison with HES1, 3, 4 
and HEY1. In hematopoietic malignancies, the expression of HES1 and HES5 has been 
shown in several blood cell lineages including T-cells, B-cells and hematopoetic stem 
cells (Yu et al., 2006). The expression of HES and HEY family members is modulated in 
a cyclic fashion. We evaluated the expression of these genes 12h, 16h, 20h and 24h after 
activation of the NOTCH signaling pathway since these are early response genes, and 
observed maximum induction of HES2 and HES5 at the 20h time point, while other HES 
and HEY members had no difference at each time point between culturing them on 
Jagged1 versus Fc. It would be interesting to investigate the lack of induction of HES1, 2, 
4 and HEY1 when NOTCH is activated. Epigenetic changes such as promoter 
methylations may contribute to this effect. In neuroblastoma cell lines, Zage et al. have 
shown moderate to heavy methylations in CpG islands of the promoter regions of HES2 
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and HES5 (Zage et al., 2012). In addition, frequent deletions in the regions of the 1p36 
chromosome that harbors HES2, HES3, HES4 and HES5 is observed in neuroblastoma 
(Maris & Matthay, 1999). Thus, it might be possible that in HNSCC, methylations or 
deletions in such regions may modulate the expression levels of these genes.   
TCGA analysis of NOTCH mutant head and neck cancer patient specimens 
revealed a surprising modulation of genes involved in the maintenance of stem cells. 
Alcolea and colleagues created an esophageal epithelial system in which they inhibited 
NOTCH signaling using dominant negative mastermind (dnMAML1) in just one cell of 
the basal cell population and monitored the expansion of these cells in vivo (Alcolea et 
al., 2014). They found that a year after inhibiting NOTCH signaling in basal cells, the 
population of differentiating cells drastically decreased selecting only for these 
undifferentiated basal cells. Although they don’t claim these cells to be in a stem cell 
state, it is possible that this population was enriched and might contribute to tumor 
initiation. In our system, since we observe markers of stem cells from the TCGA patient 
tumors that have an active NOTCH1 gene signature, there might be a population of cells 
exhibiting stem cell characteristics after NOTCH activation. However, we did not 
observe significant modulation of these genes in cell lines. Differences between cell lines 
and tumors include intensity of NOTCH signaling, infiltrating muscle cells and tumor 
purity, microenvironment regulation, and other genetic alterations in tumors (NUMB, 
p63, etc.) may contribute to the discrepancies between genes regulated in cell lines versus 
tumors.   
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Chapter 7: Inhibition of AXL and α-catulin modulates cell growth 
Chapter 7.1: Knocking down AXL and α-catulin inhibits cell growth and tumor formation 
 
Rationale: In chapter 5, we demonstrated that NOTCH inhibits cell growth and in 
chapter 6, we elucidated that NOTCH1 is sufficient and necessary to decrease the 
expression of AXL and α-catulin. AXL and α-catulin are proto-oncogenes that are 
overexpressed in several cancers. Both proto-oncogenes have shown to be involved with 
cell growth, proliferation, migration and metastasis (Cao et al., 2012; Graham, 
DeRyckere, Davies, & Earp, 2014). Moreover, targeting AXL in HNSCC cell lines 
increased their sensitivity to cetuximab and radiation (Brand et al., 2015). Fan et al. 
showed that α-catulin promoted the growth of oral squamous cell carcinoma by inhibiting 
senescence (Fan et al., 2011). Although there is evidence that AXL and α-catulin 
suppress growth, the functional relevance of these proto-oncogenes in a NOTCH mutant 
background hasn’t been fully explored. We first demonstrated that restoration of 
NOTCH1 inhibits tumor growth, then we showed that NOTCH1 inhibits AXL and α-
catulin. To evaluate AXL and α-catulin meditated modulation of cell and tumor growth, 
we knocked down the expression of these proto-oncogenes using shRNA’s and 
hypothesized that AXL and α-catulin might be necessary for tumor growth. 
Results:  We obtained four different lentiviral sort hairpin RNA’s that were GFP 
tagged for each target gene, AXL and α-catulin, and stably transfected the mutant cell 
lines HN31, and UMSCC22A and wild-type cell lines PJA34 and 183 with sh RNA’s 
against AXL (shAXL) and α-catulin (shCAT) and purified them by flow cytometry. The 
percentage and intensity of GFP positive cells were matched for each lentiviral shRNA 
construct prior to transductions. After obtaining a pure population of cells expressing the 
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shRNA’s, we cultured cells at low densities in a colony forming clonogenic assay for 10 
days. Shown in Figure 47 and Figure 48 are western blots indicating that both AXL and 
catulin have been knocked down by more than 70%. Knocking down AXL and α-catulin 
significantly reduced cell growth in all cell lines (Figure 51). In all cell lines, we 
observed at least 50% decline in cell growth after inhibition of AXL and α-catulin. Based 
on our previous results, when NOTCH1 was activated in HN31 and PJA34, we observed 
greater than 50% decline in cell growth. Moreover, we have also shown that NOTCH1 is 
necessary and sufficient to inhibit AXL and α-catulin. Here we show that knocking down 
AXL and α-catulin recapitulates the NOTCH induced growth inhibition.   
Since we found that decreasing AXL and α-catulin expression is associated with 
decreasedcell growth in vitro , we then investigated the role of modulation of expression 
of these proto-oncogenes on tumor growth in vivo. After knocking down AXL and α-
catulin using shRNA’s in HN31 mutant cells, the cells were purified for GFP by flow 
cytometry and injected them into the tongue of mice in an orthotopic model of oral 
cancer. We injected 50,000 cells per mouse and had 11 mice in each condition. As seen 
in Figure 52, knocking down AXL and α-catulin led to significantly abrogated tumor 
growth by more than 75% compared to the shEMPTY and parental control cells injected 
mice at 17 days post injection (P<0.001). Tumors in the control groups (parental and 
shEMPTY) were initiated 5 days post injection, while tumors in the AXL and CAT group 
began to develop only at day 10. In the parental and empty vector control groups, all 11 
mice developed tumors 17 days after injection but in the shAXL and shCAT groups, only 
6 and 8 mice respectively developed tumors. The overall survival in mice that had 
shAXL and shCAT cells injected was greater than the control groups (P<0.01). The 
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median survival of mice in the parental and shEMPTY groups was 24 and 21 days 
respectively, while the shAXL and ShCAT mice groups survived for more than 35 days. 
The in vivo effect of AXL was slightly greater than α-catulin in that, tumor sizes in 
shAXL groups were smaller than in the shCAT group and the former had a slightly 
greater overall survival than the latter (although not significant). Comparing these results 
to restoration of NFL1 in vivo, we observe a similar trend in tumor growth inhibition. 
Restoration of NFL1 in HN31 cells lead to a 60-70% decline in tumor volumes at day 25 
post injection, while knocking down AXL and α-catulin resulted in a similar decline 
slightly earlier (day 18). Taken together, our results imply that knockdown of AXL and 
α-catulin recapitulates the NOTCH induced phenotype in wild-type and mutant cells 
suggesting that AXL and α-catulin might be involved with NOTCH mediated suppression 
of tumor growth.  
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Figure 47: Knockdown of AXL and α-catulin in wild-type cell lines 183 and PJA34 usign 
shRNA’s 
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Figure 48: Knockdown of AXL and α-catulin in mutant cell lines UM22A and HN31 
using shRNA’s 
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Figure 49: Quantitation of the western blots after knocking out AXL and catulin in wild-
type cell lines 183 (above) and PJA 34 (below).  
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Figure 50: Quantitation of the western blots after knocking out AXL and catulin in 
mutant cell lines UM22A (above) and HN31 (below). 
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Figure 51: Clonogenic assay in wild-type (PJA34 and 183) and mutant cell lines 
(UM22A and HN31). Knocking down AXL (shAXL) and α-catulin (shCAT) inhibits cell 
growth in a colony forming clonogenic assay  
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Figure 52: AXL and α-catulin modulates in vivo tumor formation and overall survival. 
Knocking down AXL and α-catulin using shRNA’s in a mutant cell line significantly 
inhibits tumor growth and increases overall survival  
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Chapter 7.2: HES2 and HES5 might be sufficient to inhibit cell growth 
 
Rationale: We have previously shown that HES2 and HES5 are canonical 
downstream targets of the NOTCH signaling pathway that is significantly up regulated in 
HNSCC cell lines compared to other HES and HEY family members (Figure 40). In 
addition, we have also shown that NOTCH1 is necessary and sufficient to inhibit cell 
growth and protein expression levels of AXL and α-catulin which might be downstream 
of NOTCH and are necessary for inducing the same phenotype. Furthermore, we have 
shown that HES2 and HES5 might be sufficient to inhibit protein expression of AXL and 
α-catulin. HES and HEY family are known canonical downstream transcriptional 
modulators (mostly repressors) of the NOTCH signaling pathway. Since AXL and α-
catulin were suppressed after NOTCH activation resulting in growth inhibition, we 
wanted to investigate if these canonical targets are sufficient to modulate cell growth. 
Results: Using HES2 and HES5 MigR1, GFP-tagged constructs, we 
overexpressed these genes in the NOTCH1 mutant cell line HN31. Prior to sorting these 
cells for pure population of GFP cells, viral titers were optimized such that each 
overexpression condition (HES2, HES5 and MigR1) express similar intensity and 
percentage of GFP positive cells. Since each virus may have varied efficacy after 
infection, it was imperative that the titers be matched to each other to avoid confounding 
variables that may be caused due to the infections process itself rather than the constructs.  
After sorting for a pure population of GFP positive cells and confirming the expression of 
these flag tagged constructs (Figure 41), we performed an in vitro colony forming 
clonogenic assay in which we plated 1000 cells from each sorted cell conditions into 6-
well plates. HES2 and HES5 significantly inhibited growth compared to the parental and 
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empty vector conditions (Figure 53). The number of colonies in the parental and MigR1 
were similar, but HES2 and HES5 were sufficient to induce more than 75% suppression 
in growth of HN31 cells (P<0.01). This result suggested that NOTCH activated HES2 
and HES5 appear to be sufficient in modulating cell growth. In future studies, we will 
examine the regulation of AXL and catulin by HES2 and HES5 in inhibiting cell growth.  
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Figure 53: HES2 and HES5 are sufficient to inhibit cell growth 
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Discussion 
 
In chapter 7, we demonstrate the roles of AXL and α-catulin in modulating cell 
growth in vitro and in vivo. We have shown that knocking down these proto-oncogenes 
using shRNA’s significantly inhibits cell growth in a colony-forming assay. Previously, 
in chapter 5, after restoration of the NOTCH signaling pathway in wild-type and mutant 
cells, we show greater than a 50% decrease in cell growth. Then, in chapter 6, we 
demonstarted that NOTCH activation in mutant and wild-type cell lines inhibits AXL and 
α-catulin. Here, we observe that AXL and α-catulin might be necessary in modulating 
cell growth. Using siRNA’s, Brand et al. demonstrated that cell lines expressing high 
levels of AXL are sensitive to siRNA-mediated inhibition of AXL (Brand et al., 2015). 
However, in their experiments, siRNA’s against AXL induced less than a 50% inhibition 
in cell proliferation. Our results are more robust in that we performed stable transfections 
with shRNA’s and assayed cell growth over a longer time period and observed more than 
a 60% inhibition in cell growth. A caveat to this experiment is that the role of AXL and 
α-catulin independent of NOTCH activation still remains unexplored. For this, we might 
have to overexpress these proto-oncogenes in a background in which NOTCH has been 
knocked out (for example in CRISPR-Cas9 knockout cells) before culturing these cells 
on Jagged1 to prove that AXL and α-catulin are sufficient to modulate growth. Finally, 
we show that HES2 and HES5 might be sufficient to modulate cell growth. We have 
previously shown that activation of NOTCH signaling induces HES2 and HES5 
expression. Furthermore, HES2 and HES5 can possibly down regulate AXL and α-
catulin. HES2 and HES5 may be sufficient to inhibit growth by more than 60% a mutant 
HNSCC cell line, HN31. In Acute Myelogenous Leukemia (AML), Zage et al. showed 
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that HES1 was sufficient to induce more than a five-fold decrease in growth of AML 
cells (Zage et al., 2012). At this point, we don’t have evidence demonstrating that HES2 
and HES5 are required for inhibiting cell growth. To prove that these targets are required, 
we are knocking down HES2 and HES5 in wild-type cell lines before culturing them on 
Jagged1 to show that loss of these molecules upregulates AXL and α-catulin and relieves 
NOTCH induced growth inhibition. The transcriptional targets of the HES and HEY 
family have not been well studied. Genes like Achaete-scute-like 1 (ASCL/HASH1), 
atonal homolog-1 (ATOH1) and neurogenin-1 have been reported before (Kageyama, 
Ohtsuka, Hatakeyama, & Ohsawa, 2005). In the future, we aim to understand NOTCH 
signaling at the transcriptional level and elucidate how NOTCH modulates AXL and α-
catulin in regulating cell growth.  
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CHAPTER 8: DISCUSSION AND FUTURE 
DIRECTIONS 
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Discussion and future directions 
The main goal of my thesis is to understand the tumor suppressive role of NOTCH1 in 
HNSCC. In 2011, our lab had published results from whole exome sequencing of 32 
primary patient tumors in which frequent somatic mutations in NOTCH1 was identified 
(Agrawal et al., 2011). Until then, TP53 was known to be mutated frequently, followed 
by p16, PIK3CA, Hras and overexpression/amplifications in Cyclin D1 and EGFR. The 
sequencing studies performed by Agarwal et al. (Agrawal et al., 2011) and Stransky et al. 
(Stransky et al., 2011) identified for the first time frequent somatic mutations in 
NOTCH1. More recently, the TCGA utilized a broader sequencing platform and 
observed NOTCH1 mutations at a similar frequency as the other two studies ("TCGA 
Releases Head and Neck Cancer Data," 2015). The role of NOTCH1 in cancers surfaced 
from studies in T-ALL in which this receptor has activating mutations in the 
transmembrane and PEST domains that results in constitutive activation of the pathway 
rendering it an oncogene in this tumor type (Weng et al., 2004). In HNSCC, inactivating 
mutations were primarily located at the extracellular domain of NOTCH1 and were 
mostly missense and nonsense mutations. These mutations prevented the binding of the 
NOTCH receptor with the ligand inactivating this pathway in a subset of HNSCC. Based 
on sequencing studies, only a small fraction of HNSCC (15-19%) harbor inactivating 
NOTCH1 mutations while the majority seems to express the wild-type NOTCH1 
receptor. Although wild-type NOTCH1 is expressed in many tumors, these tumors 
resemble the mutant subset. In such tumors, there might be other aberrations such as 
overexpression of NUMB; a negative regulator of NOTCH activation, overexpression of 
Jagged1; resulting in cis-inhibition or modulations in fringe glycosylation; that results in 
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improper receptor-ligand binding. Indeed, we have seen the overexpression in NUMB in 
some of our cell lines that are both wild-type and mutant for NOTCH1 ( 
Figure 54). In addition, cell lines that are both wild-type and mutant for NOTCH1 
express Jagged1 (Figure 55) that can potentially lead to cis-inhibition (Figure 33). In this 
dissertation, I hypothesized that the inactivating mutations observed in NOTCH1 in 
HNSCC render it a tumor suppressor in this tumor type and the activation of a functional 
NOTCH pathway would inhibit growth of these tumors.  
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Figure 54: Basal NUMB expression in wild-type and mutant HNSCC cell line 
 
 
Figure 55:  Jagged1 expression in wild-type and mutant HNSCC cell lines  
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Activation of NOTCH signaling inhibits growth 
 
Based on sequencing data that showed frequent inactivating mutations in 
NOTCH1 in this cancer type (Agrawal et al., 2011), for the first time, we demonstrate the 
functional relevance of these inactivating mutations. Using the intracellular and full-
length NOTCH1 constructs (ICN1 and NFL1) in mutant cell lines, we observed a 
decrease in the population of cells expressing NOTCH1. Cells expressing NOTCH1 were 
selected against cells expressing the empty vector in a competitive cell proliferation 
assay. In a similar assay, Kannan et al. have shown that ICN was sufficient to inhibit 
AML cell growth (Kannan et al., 2013). Although, we do not completely understand what 
causes growth inhibition, we did observe morphological changes after transducing cells 
with ICN1 or NFL1 that might explain this observance.  
NOTCH and senescence 
 
Cellular senescence was a phenotype that accompanied growth inhibition in 
mutant cell lines after transduction with ICN1 and NFL1 when cultured on Jagged1. 
Senescence partially explains the flat, enlarged and pancake-like morphology that we 
observe after NOTCH activation. Senescence serves as a fail-state mechanism to prevent 
oncogene-induced aberrant proliferation. It has been shown that in esophageal 
keratinocytes, ICN1 inhibited cell proliferation, induced expression of p21 and arrested 
cells in the G1 phase of the cell cycle (Kagawa et al., 2015). We observed a similar 
phenotype in that ICN1 did inhibit p21, and arrest cell in the G1 phase of the cell cycle. 
Senescence, however, was observed only in a small fraction of cells and it is unclear what 
inhibits growth in cells that do not undergo senescence. Mechanisms other than 
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senescence governing growth inhibition such as cell death, or mitotic catastrophe still 
need to be explored.  
NOTCH and differentiation 
 
The NOTCH pathway is known to regulate differentiation and it is possible that 
NOTCH induced differentiation might inhibit cell growth. Studies performed in mice 
keratinocytes with specific deletion of NOTCH1 in the epidermis abolished cell growth 
and disrupted well-defined borders between the basal and upper differentiating layers 
(Rangarajan et al., 2001). Induction of p21 is one of the earliest events underlying 
differentiation induced growth arrest (Missero, Di Cunto, Kiyokawa, Koff, & Dotto, 
1996) and we show here that ICN1 is sufficient to induce p21 in a NOTCH1 mutant cell 
line. Furthermore, mice injected with the mutant cell line UM47 expressing NFL1 
showed the formation of keratin pearls indicative of differentiation. Signaling between 
NOTCH ligands, Jagged1 and Jagged2 and NOTCH receptors 1 and 2 increases in 
differentiating keratinocytes in the suprabasal layers of the epidermis (Luo, Aster, 
Hasserjian, Kuo, & Sklar, 1997). This suggests that they are part of a positive feedback 
mechanism required for differentiation and epidermal border formation (Rangarajan et 
al., 2001). Another line of evidence that NOTCH1 might induce differentiation is 
modulation of p63, a p53 family member that is involved with cell fate determination and 
stem cell maintenance (Mills et al., 1999; Yang et al., 1999). We observed a marked 
suppression in protein levels of ΔNp63 after infecting a mutant cell line with ICN1 
(Figure 56). In the murine system, p63 is likely to play a significant function in 
preventing differentiation and maintenance of premature senescence (Keyes et al., 2005; 
King et al., 2003). Elevated levels of ΔNp63 has been shown to be associated with a 
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variety of epithelial tumors, including squamous cell carcinomas in which NOTCH 
expression is suppressed (Lefort et al., 2007; Parsa, Yang, McKeon, & Green, 1999; 
Pellegrini et al., 2001). This suggests that NOTCH and ΔNp63 might be linked. Here, we 
show that ICN1 might induce ΔNp63, thus promoting differentiation and contributing to 
growth inhibition. NOTCH and ΔNp63 can have opposing effects. While NOTCH1 
suppresses expression of ΔNp63, overexpression of ΔNp63 has been shown to inhibit 
NOTCH activity and maintenance of immature keratinocytes (Okuyama et al., 2008). We 
have not shown the expression levels of ΔNp63 in NOTCH1 wild-type cells, but it may 
be possible that the activity of ΔNp63 might inhibit NOTCH activation although these 
cells express a functional receptor. Taken together, we have independent evidences of 
NOTCH inducing p21 and NOTCH inducing differentiation. Whether there is a link 
between NOTCH, p21 and differentiation in HNSCC needs to be explored in the future. 
Interestingly, although ICN1 causes cells to round up and appears to come off the 
substrate, we did not observe the induction of apoptosis. Infection of mutant cells with 
ICN1 arrested 15% of the cells in the sub G0 phase of the cell cycle indicative of cell 
death. In B-ALL, one of the mechanisms of NOTCH induced apoptosis involves HES1 
activating PARP1 leading to self and global PAR-ylation, reduction in NAD and ATP 
levels, nuclear translocation of AIF and subsequent B-ALL apoptosis (Kannan et al., 
2011). However, when we performed a western blot for cleaved PARP and total PARP, 
we did not observe induction of apoptosis after NOTCH activation. This rules out the 
possibility of apoptotic cell death.  
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Roles of NOTCH1 and NOTCH2 
 
The majority of the data in my dissertation focuses on the role of NOTCH1 in 
HNSCC. However, mutations in NOTCH2 are also observed in this tumor type. More 
recently, a publication by Li et al. found deletions in NOTCH2 in primary tumors and 
HNSCC cell lines (H. Li et al., 2014). Since NOTCH1 and NOTCH2 mutations are not 
mutually exclusive, it is hard to predict if the mutations in one of the NOTCH members 
can be overcome by another functional receptor. We observed that ICN1 and ICN2 are 
sufficient to inhibit growth in a wild-type and mutant cell line. Furthermore, we have also 
shown that both NOTCH1 and NOTCH2 are necessary to inhibit cell growth. The 
functional difference between NOTCH1 and NOTCH2 lies in the intracellular region of 
the receptor. Kraman and McCright performed a study in which they replaced the non-
conserved region of ICN2 with the homologous region of ICN1 and created mice with 
NOTCH1-NOTCH2 fusion protein (Kraman & McCright, 2005). Mice homozygous for 
this fusion were phenotypically normal and organs that required NOTCH2 functionality 
had developed normally with the fusion protein. They suggested that ICN1 can 
functionally replace the corresponding region of ICN2. Since we used the intracellular 
form of NOTCH1 and NOTCH2, our results are consistent with findings from Kraman 
and McCright and also corroborates the study that demonstrates that ICN1 and ICN2 
could activate transcription in vitro (Kurooka, Kuroda, & Honjo, 1998). Our results are 
also consistent with another finding that elucidates that ICN1 and ICN2 could both 
induce growth arrest and senescence in small cell lung cancer cells (Sriuranpong et al., 
2001). In our evaluation of NOTCH2 induced growth inhibition, we only overexpressed 
the activated form of this protein. To gain a complete understanding of the role of 
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NOTCH2 in HNSCC, we will clone the full length NOTCH2 receptor similar to NFL1 
and perform similar functional studies.  
Although we have shown that either ICN1 or ICN2 can inhibit cell growth, it 
appears that knocking out both together is necessary to relieve growth inhibition. Using 
the CRISPR-Cas9 technique to knock out NOTCH1 (NOTCH1 KO), NOTCH2 
(NOTCH2 KO) or both (double KO) and then culturing the cells on Jagged1, we 
observed that the dKO is required to relieve Jagged1 induced growth inhibition. It 
appears that both NOTCH1 and NOTCH2 are able to signal through Jagged1. The other 
compensates the loss of one of the NOTCH receptors. To circumvent the issue of which 
particular NOTCH receptor contributes to tumorigenesis, we used a pan NOTCH 
inhibitor, dnMAML1 to evaluate tumor formation. The dnMAML1 significantly 
increased tumor growth in a weakly tumorigenic cell line but only 50% of the mice 
injected formed tumors. This can possibly be attributed to the lack of nuclear localization 
of dnMAML1 because of which its inhibitory effects on NOTCH signaling wasn’t 
exerted. Mastermind- like 1 functions as a transcriptional co-activator in the nucleus 
where it binds to ICN. To determine if NOTCH singling was indeed inhibited in 50% of 
mice from the dnMAML1 group, we have to immunostain these tumors with HES or 
HEY. Alternatively, in the other 50% dnMAML1 mice without tumors, nuclear 
localization of dnMAML1 can be determined. It is possible that the lack of nuclear 
localization of dnMAML1 after transduction in these wild-type cells might have caused 
decreased inhibition of NOTCH activity. Another shortcoming to inhibiting the NOTCH 
pathway using dnMAML1 is the difficulty in incorporating both copies of the construct 
in mammalian cells after infection. We sorted cells after infection based on optimal GFP 
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intensity and number of GFP infected cells. There is a possibility that some cells 
incorporate only one copy of the gene that may not have an immediate effect in vitro, but 
may decline in efficacy in vivo. Lastly, technical limitations while injecting these cells in 
the tongue of mice might have also contributed to such aberrations.  
Since our results from inhibiting NOTCH activity had these discrepancies, we 
exploited the CRISPR-Cas9 technology to knockout NOTCH1 and NOTCH2 in the same 
wild-type cell line; PJA34. Until now, loss-of-function studies using the CRISPR-Cas9 
technology in HNSCC have not been performed. In other cancer types such as AML, 
melanoma, colon, PDAC, NSCLC and liver cancer, this system has been used to knock 
out genes such as p53, KRas, PIK3CA, APC and Smad4 (Castro et al., 2015; C. Chen et 
al., 2014; S. Chen et al., 2015; Heckl et al., 2014; Shalem et al., 2014). Here, we show for 
the first time that knocking out NOTCH1 and NOTCH2 relieves Jagged1 induced growth 
inhibition in vitro. When NOTCH1 is knocked out in PJA34 cells and cultured on 
Jagged1, there is some signaling through NOTCH2 which partially relieves growth 
inhibition when compared to the parental cells cultured on Jagged1 (grey bar of parental 
versus grey bar of NOTCH1 KO in Figure 27). Similarly, when NOTCH2 is knocked out, 
signaling through NOTCH1 partially relieves growth suppression compared to parental 
controls (grey bar of parental versus grey bar of NOTCH2 KO in Figure 27). This shows 
that NOTCH1 or NOTCH2 is not sufficient to completely prevent the growth inhibitory 
phenotype. Interestingly, knocking out NOTCH2 and NOTCH2 completely relieves 
growth inhibition suggesting that both NOTCH1 and NOTCH2 are required for cell 
growth suppression. It is intriguing that knocking out either NOTCH1 or NOTCH2 
individually inhibits growth in the Fc controls compared to the parented cells cultured on 
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Fc (black bar of parental cells versus black bars of NOTCH1 KO or NOTCH2 KO cells 
in Figure 27). PJA34 cells express the ligand Jagged1. It might be possible that knocking 
out one of the NOTCH receptors increases ligand sensitivity to the other NOTCH 
receptor enhancing signaling activity. For example, NOTCH1 KO cells may have 
enhanced sensitivity of the NOTCH2 receptor to the ligand and vice versa. In skin 
keratinocytes, Demehri et al. have shown that conditional deletion of NOTCH2 in the 
epidermis does not exacerbate carcinogen induced tumor initiation in the presence of 
NOTCH1 as much as conditional deletion of NOTCH1 that generated spontaneous 
tumors (Demehri et al., 2009), but progressive deletion of  NOTCH1 and NOTCH2 
enhanced epidermal hyperplasia.  Our results are similar to this previously reported study 
in that knocking out NOTCH1 or NOTCH2 separately could not relieve growth 
suppression but knocking out both enhanced cell growth. In the previous study, 
conditional deletion of NOTCH1 or NOTCH2 resulted in late tumor onset but conditional 
deletion of both initiated early onset of tumors (Demehri et al., 2008). It might be 
possible that NOTCH1 and NOTCH2 play roles in different stages of tumor 
development. In cervical keratinocytes, loss of NOTCH1 with retention of NOTCH2 
occurs in cells that are more aggressive and invasive implying that different NOTCH 
receptors may participate in early and late stages of tumor progression (Talora, Sgroi, 
Crum, & Dotto, 2002). Restoration of NFL1 in the dKO PJA34 cells rescues abrogation 
of growth inhibition. This shows that NOTCH1 alone might be sufficient to mirror the 
parental phenotype in the double knockout cell line. NOTCH2 might also result in a 
similar phenotype, but at this point, we are unaware if NOTCH2 alone is sufficient to 
rescue the dKO mediated growth.  
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Identification of downstream effectors of the NOTCH signaling pathway 
 
After we established a growth inhibitory phenotype after NOTCH activation in 
wild type and mutant HNSCC cell lines, we evaluated the mechanism behind such an 
effect. In our study, 1808 genes were differentially modulated after NOTCH activation. 
We set a threshold of 1.4 fold, which filtered the 1808 genes to 120. Among these 120 
genes, 50 were up regulated and 70 were down regulated. We report here that NOTCH 
activation the significantly alters cell growth and proliferation pathways based on 
“Ingenuity Pathway Analysis” of the differentially expressed genes. This finding 
corroborates our earlier report of NOTCH activation inhibiting cell growth (Chapter 5).  
In a study performed in laryngeal squamous cell carcinoma, in which NOTCH is 
overexpressed, Dai et al. show that inhibiting NOTCH activity down regulates genes 
associated with cell growth, proliferation, apoptosis, invasion and migration (Dai et al., 
2015). In our system, since NOTCH1 acts as a tumor suppressor, we found that NOTCH 
activation down regulates genes associated with cell growth, proliferation and migration.  
The oncogenic protein α-catulin found to be down regulated by NOTCH in our 
experiments is overexpressed at the invasive front of human HNSCC tumors (Cao et al., 
2012). It is associated with poor clinical outcome in non-small cell lung cancer (NSCLC) 
(Liang et al., 2013). Silencing α-catulin induces senescence in HNSCC (Fan et al., 2011), 
and inhibits proliferation, migration, and invasion in both HNSCC and NSCLC cell lines. 
Αlpha-catulin interacts with molecules regulating cell adhesion and the cytoskeleton, 
functions as an activator of Rho GTPase and NF-κB signaling, and is a downstream 
target of integrin-linked kinase (Fan et al., 2011). AXL, also downregulated by JAG1 in 
our experiments, encodes a receptor tyrosine kinase frequently overexpressed in cancers, 
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where it has been associated with poorer survival and increased metastasis (Paccez, 
Vogelsang, Parker, & Zerbini, 2014), including in HNSCC (C. H. Lee et al., 2012). 
Oncogenic properties of AXL have been attributed to proliferative and pro-survival 
signaling, and inhibiting AXL reportedly blocks migration, invasion, and growth of 
certain HNSCC cell lines (C. H. Lee et al., 2012). Integrins mediate attachment to 
extracellular matrix proteins and are involved in proliferation, survival, migration and 
invasion of tumor cells. Integrin α3, also downregulated by NOTCH signaling in our 
experiments, is a major receptor for lamin-5; the principal component of the basement 
membrane extracellular matrix (ECM) found in squamous epithelial of the skin and upper 
aerodigestive tact. Loss of adhesion to ECM leads to apoptotic death known as anoikis, 
and integrin α3 is necessary for survival of keratinocytes in culture (Manohar et al., 
2004). Overexpression of integrin α3 has been associated with lymph node metastasis in 
HNSCC (Kurokawa et al., 2008; Nagata et al., 2013) while expression of integrin α5 has 
been linked to increased metastasis and proliferation in laryngeal cancers (Lu, Sun, 
Wang, Jin de, & Liu, 2009). We don’t know if NOTCH activation directly inhibits 
integrins or there is a mediator downstream of NOTCH singling that facilitates this 
modulation. P63 has previously been shown to inhibit integrins in the basal layer of 
keratinocytes (Okuyama et al., 2008). We show that in one of the mutant cell lines ICN1 
could significantly downregulate protein expression of ΔNP63 (Figure 56). However, in 
wild-type cell lines, activation of NOTCH signaling using Jagged1 only modestly 
suppressed ΔNp63 (Figure 57). Moreover, ΔNP63 was not significantly modulated after 
NOTCH activation in the gene expression analysis. Mutations in NOTCH1 and TP63 
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tend to be mutually exclusive (Figure 58). Thus, it is possible that in HNSCC, modulation 
of integrins may be p63 independent. 
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Figure 56:  ICN1 inhibits p63 expression 
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Figure 57:  Activation of NOTCH signaling by Jagged1 slightly inhibits protein 
expression of ΔNP63 
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Figure 58: NOTCH1 and TP63 mutations tend to be mutually exclusive 
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The gene expression analysis is based on mRNA levels of effectors altered after 
NOTCH activation. We observed increased gene expression of potential tumor 
suppressor genes and decreased levels of proto-oncogenes. Since we are interested in the 
subset of patients that have inactive NOTCH signaling, we focused on proto-oncogenes 
that had increased expression in the absence of NOTCH activation. We confirmed that 
NOTCH indeed inhibited protein expression levels of AXL and α-catulin by inhibiting 
NOTCH activity using the pan-NOTCH inhibitor dnMAML1. Blocking NOTCH activity 
completely relieved NOTCH mediated inhibition of α-catulin and partially relieved AXL 
inhibition. The dnMAML1 functions in the nucleus, suggesting that blocking of NOTCH 
activity in the nucleus prevents inhibition of these proto-oncogenes. There are two 
possible ways in which NOTCH activation could downregulate proto-oncogenes; by 
directly binding to the promoter of these genes and impinging transcription (non-
canonical NOTCH signaling) or by activating its canonical downstream targets (HES and 
HEY), which then repress proto-oncogenes (canonical NOTCH signaling). 
 Non-canonical NOTCH signaling 
 
Activated NOTCH by itself can regulate targets independent of HES and HEY. 
For example, Rangarajan et al. have shown that expression of the activated form of 
NOTCH1 caused a significant increase in p21 (Rangarajan et al., 2001) in keratinocytes. 
Furthermore, they also showed that at the transcriptional level, p21 has an RBP-Jκ 
binding site within close proximity to the TATA box to which ICN binds. In addition, 
involcurin, a differentiation marker was found to be under transcriptional control of 
NOTCH when keratinocytes differentiate at the basal layer. The promoter of involucrin 
has two critical regions that contribute to its activation; sp1 and AP1 binding sites at the 
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distal promoter region and a TATA box at the proximal region with a critical AP-1 
binding site that overlaps with a motif for ets transcription factor binding sites (Efimova, 
LaCelle, Welter, & Eckert, 1998). Rangarajan et al. have shown that intracellular 
NOTCH binds to this promoter region independent of RBP-Jκ and upregulates expression 
levels of involucrin. NF-κB is another target that is transcriptionally activated when ICN 
binds to its promoter (Vilimas et al., 2007). NOTCH1 also directly interacts with the 
transcription factor YY1 to drive c-myc transcription in human myelogenous leukemia 
(Liao et al., 2007). In breast cancer, Lin et al. have shown that NOTCH activity 
transcriptionally upregulates IL-6 that results in the activation of the JAK-STAT pathway 
(Jin et al., 2013).  We haven’t investigated if NOTCH activation transcriptionally 
regulates AXL and α-catulin. Both these proto-oncogenes have AP1 and sp1 binding 
sites. Chu et al. had demonstrated that ICN could inhibit the expression of AP-1 
dependent genes. Overexpression of ICN in cells transfected with AP-1 component gene 
strongly decreased AP1-mediate gene expression such as IL-8, MMP1 and IκBα (Chu et 
al., 2002). It might be possible that in our system, activation of NOTCH signaling by 
culturing cells on Jagged1 inhibits AP1 mediated transcriptional activation of AXL and 
CTNNAL1. Transcriptional regulation of α-catulin is not completely explored. Xiang et 
al. suggested that AP-2α and LEF-1 transcription factors regulate expression of 
CTNNAL1 (Xiang et al., 2012). However, their evidence was limited to ozone-induced 
stress activation of CTNNAL1.  
Canonical transcriptional modulation of NOTCH targets 
 
The canonical downstream targets of the NOTCH signaling pathway include 
members of the HES and HEY family genes. We show here that restoration of NFL1 in a 
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mutant cell line HN31 increased expression levels of HES2, HES5 and HEY2 by a least 
two fold. Previously, we found at least 500-fold increase in HES5 after activating wild-
type and mutant cell lines with ICN1. These levels however, are not physiological since 
cells were transduced with high amounts of ICN1. Zage et al. have shown that in 
neuroblastoma cell lines, ICN1 could induce more than 1000-fold increase in HES4 and 
more than a 100,000-fold increase in HES5. When these cells were cultured on Jagged1, 
they observed a 100-fold and 20-fold increase in HES4 and HES5 respectively (Zage et 
al., 2012). Since HES and HEY family are known canonical repressors, we hypothesized 
that HES2 and HES5 might transcriptionally suppress expression levels of AXL and 
CTNNAL1. Thus, we overexpressed HES2 and HES5 in the mutant cell lines HN31 and 
evaluated expression levels of AXL and CTNNAL1 by qRT-PCR. HES2 and HES5 
didn’t seem to modulate mRNA expression levels of either proto-oncogenes (Figure 60).  
HES and HEY transcriptionally modulate genes such as Achaete-scut-like 1 
(ASCL1/HASH1), atonal homolog-1 (ATOH) and neurogenin (NGN1) have been 
reported as targets of HES in neural tissues (Kageyama et al., 2005). Among the HES and 
HEY1 family, the downstream effectors of HES1 and HEY1 have been well 
characterized. Genes downregulated by HES1 included NEUROG3 (J. C. Lee et al., 
2001), GAA (Yan, Raben, & Plotz, 2002), CDKN1B (Murata et al., 2005), RCOR1, and 
CFD and genes downregulated by HEY1 include GATA4 and GATA6 (Fischer et al., 
2005). Hes factors play critical roles in the development of many organs and expand 
progenitor cell pools regulating cell fate decisions. HES1 and HES5 are regulated by 
auto-negative feedback loops and function as effectors of NOTCH signaling coordinating 
cell proliferation and differentiation via cell-cell interaction (Kobayashi & Kageyama, 
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2014). Hey proteins are also basic helix- loop-helix (bHLH) transcription factors related 
to the HES family. HEY proteins play critical roles in embryonic development, 
differentiation and tissue homeostasis (Weber, Wiese, & Gessler, 2014).  
 
 
Figure 59: Activated NOTCH1 increases gene expression of HES5 
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Both HES and HEY proteins have a conserved bHLH domain that is essential for 
DNA binding and homo and heterodimer formation. The N-terminal region defines the 
specificity of binding to target DNA sequences which are N-box (CACNAG), E-box 
(CANNTG) and class C site (CACG(C/A)G) (Sasai, Kageyama, Tagawa, Shigemoto, & 
Nakanishi, 1992). It has been suggested that certain proline residues, which is conserved 
in all HES factors, may be involved in target specificity, providing higher affinity for N-
box sites rather than E-box sites. On the contrary, the bHLH domain of HEY proteins 
preferentially to E-box sites (Heisig et al., 2012). HES itself is regulated canonically after 
ICN binds with RBP-Jκ upstream of the HES promoter (Katoh & Katoh, 2007). The 
promoter sequences of AXL and CTNNAL1 did not harbor the N-box or E-box binding 
motifs (Figure 61Figure 62) (Mudduluru & Allgayer, 2008; Xiang et al., 2012). At the 
same time, non-canonical NOTCH signaling also upregulates HES proteins. These 
pathways include bone morphogenetic protein (BMP), fibroblast growth factor (FGF), 
leukemia inhibitory factor (LIF), NF-κB, sonic hedgehog (Shh) and Wnt signaling 
pathways (Nakayama, Satoh, Igari, Kageyama, & Nishida, 2008).  
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Figure 60: HES2 and HES5 don’t seem to transcriptionally modulate levels of AXL or 
CTNNAL1.  
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Figure 61:  Promoter sequence of AXL lacks N-box or E-box motifs suggesting that HES 
and HEY might not directly transcriptionally regulate AXL gene expression.  
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Figure 62: Promoter sequence of CTNNAL1 lacking N-box and E-box binding sites.  
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Gene expression in TCGA HNSCC patient tumors 
 
TCGA analysis of patient tumors using the 120-gene signature confirmed our 
previous microarray analysis performed in cell lines. In addition, we also analyzed more 
than 20,000 genes from the TCGA RNA-Seq data for differentially expressed genes at 
two anatomical sites: Oral Cavity and Larynx/Hypopharynx. We found a few stem cell 
markers among the top upregulated genes in patients harboring an active NOTCH 
signature. These markers included Aldehyde Dehydrogenase ALDH1A1 and ALDH1A3, 
which were not among the top modulated genes in cell lines. This finding is interesting 
because it suggests that NOTCH activation might promote maintenance of stem cells, 
which is contradictory to our hypothesis that NOTCH activation inhibits tumor growth. 
Biologically, this is not surprising, since NOTCH signaling can promote stem cell 
maintenance and suppress differentiation in certain lineages while promoting 
differentiation in other lineages (Artavanis-Tsakonas, Rand, & Lake, 1999). NOTCH 
activation is known to suppress growth of AML, however, there are reports that 
activating mutations in β-catenin in osteoblasts stimulated Jagged1, which subsequently 
activates NOTCH signaling in hematopoietic stem cells causing AML (Kode et al., 
2014). The hallmarks distinguishing normal stem cells from cancer stem cells is self-
sufficiency in growth signals and insensitivity to anti-growth signals (L. Li & Neaves, 
2006). The molecular pathways used by normal stem cells for homing to their niche may 
be hijacked by cancer stem cells that promote invasion and metastasis. These results 
suggest that activation of NOTCH signaling by ligands expressed by the supporting ECM 
may contribute to a stem cell phenotype. We haven’t confirmed a cancer stem cell 
phenotype in our panel of cell lines after NOTCH activation since we observed only two 
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of the stem cell markers in patient samples. The most commonly used cancer stem cell 
markers to date have been CD34, CD133, CD24, CD44, CD29 and CD31. Aldehyde 
Dehydrogenase has only recently been propounded as a marker for HNSCC (Hoffmann, 
Matthes, Stucker, Segerling, & Altmeyer, 1990). ALDH positive cells exhibit high self-
renewal capacity and radioresistance (Fabian, Barok, Vereb, & Szollosi, 2009). In 
HNSCC cancer cell lines that have been evaluated previously, specifically- oral cavity, 
pharynx, larynx, nasopharynx and hypopharynx, the most common cancer stem cell 
markers include CD34 (Barth, Schenck zu Schweinsberg, Ramaswamy, & Moll, 2004), 
CD117 (Tan, Selvaratnam, Kananathan, & Sam, 2006), CD44 (Kojc, Zidar, Vodopivec, 
& Gale, 2005) and SCF (Pries, Witrkopf, Trenkle, Nitsch, & Wollenberg, 2008) .We did 
not observe these markers in our cell lines and patient tumors. Stem cell proliferation is 
regulated by nice signaling. Maintaing the balance between proliferation and anti-
proliferation is an important contributor or stem cell regulation. Any genetic mutation 
that leads normal stem cells to become independent of growth control will cause them to 
become cancer stem cells. Although the molecular markers of CSC’s may provide useful 
information about the tumor pathogenicity, it is unclear whether every stem cell possess 
some or all of these markers that enable a cancer cell to be stem cell like. Thus, the 
stability of these CSC’s need to evaluate by sphere forming assays. It might be worth 
considering an activated NOTCH1 inducible system in mutant cell lines and evaluating 
sphere formations in 3-D cultures. Physiological and artefactual differences between cell 
lines and patient tumors may also contribute to the differences in gene signatures we 
observe in the two systems. The intensity of NOTCH activation varies from cell lines to 
tumors. We are unaware of the physiological levels of NOTCH signaling needed to 
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modulate these stem cell markers and this might confound our understanding of stem cell 
regulation by NOTCH activation.  Also, other genetic alterations in patient tumors such 
as NUMB overexpression of p63 activation may also contribute to such a difference. The 
microenvironment also plays an important role in stem cell regulation which we cannot 
elucidate in a 2-D in vitro culture system. Alternatively, the modulation of stem cell 
markers may not be specific to the tumor site due to infiltration of muscle or immune 
cells in the tumor creating an artifact in our data. Lastly, two different techniques were 
used to analyze differentially expressed genes in cell lines and TCGA patient tumors. 
While we used the Affymetrix 2.0 microarray technique, TCGA analysis was performed 
by RNA-Seq. Such differences in analysis may have confounded our results. 
Inhibition of AXL and α-catulin modulates cell growth 
 
In the last chapter, we show evidence that inhibition of AXL and α-catulin 
modulates cell and tumor growth in mutant HNSCC cell lines. AXL is an attractive target 
since it is overexpressed in several cancers including HNSCC where it is activated and 
tightly correlated with cetuximab resistance (Brand et al., 2015). Here we show that 
inhibition of AXL significantly inhibits cell and tumor growth. Brand et al. have recently 
demonstrated that knocking down AXL using siRNA’s and a pharmacological inhibitor 
R428 significantly inhibits growth. Our results corroborate with published data and 
suggest that the AXL inhibitor can be effective in patients with inactivated NOTCH 
signaling. We also observed that knocking down AXL in vivo is more effective than α-
catulin. Clonogenic assays showed that knocking down α-catulin had the most significant 
reduction in cell growth. It will be interesting to investigate the combined effect of 
inhibiting both AXL and α-catulin in vivo. Since we observed significant suppression of 
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growth when individually knocking down AXL or α-catulin, we assumed that combined 
inhibition would produce a more aggressive suppressive effect. A limitation to our study 
is that we haven’t proved NOTCH dependent modulation of AXL and α-catulin in vivo. 
To show an in vivo effect, we will use the wild-type cell line PJA34 in which NOTCH1 
and NOTCH2 have been knocked out using CRISPR-Cas9 and examine if they accelerate 
tumor growth. Further, we will stain these tumors for AXL and α-catulin. It is possible 
that the absence of NOTCH activation increases expression levels of these proto-
oncogenes. This would give us a definitive correlation between NOTCH, AXL and α-
catulin in a more physiological system. We will also evaluate the AXL inhibitor R428 on 
tumorigenesis in comparison with mutant cells after NFL1 is restored. The restoration of 
the NOTCH pathway could possibly provide a similar protective effect to the tumors as 
those treated with R428. Although there is an inhibitor of AXL, currently there is no 
pharmacological inhibitor of α-catulin. Recently Zheng et al. showed that overexpression 
of α-catulin possibly plays an important role in malignant transformation of HNSCC by 
inducing apoptotic resistance, promoting proliferation, cell cycle progression, migration, 
and invasion. They also suggested that knockdown or silencing α-catulin might reverse 
the aggressive phenotypes and EMT process (Z. Zhang et al., 2015). They demonstrate 
that overexpression of α-catulin in a cell line that had low α-catulin mRNA expression 
accelerated cell growth. Here, we show that knocking down α-catulin in a NOTCH1 
mutant HNSCC cell line reverses cell growth and aggressive tumor formation and 
prolongs overall survival. Besides cell growth, AXL and α-catulin are also involved with 
cell migration and invasion. We haven’t demonstrated the effects of modulating AXL and 
α-catulin on invasion since our primary focus was on NOTCH mediated growth 
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suppression. Cell migration and invasion was the second most modulated pathway based 
on IPA of our unbiased microarray. Thus, the role of NOTCH signaling in regulation cell 
migration/invasion mediated by AXL and α-catulin can potentially be explored in the 
future. 
HES2 and HES5 inhibtis cell growth 
 
After restoring NOTCH signaling in a mutant cell line HN31, we observed 
elevated levels of HES2, HES5 and HEY2 about 20h after culturing these cells on 
Jagged1. We did not observe a significant change in HES1, HES3, HES4 and HEY1. The 
experiments were performed at 4 different time points after culturing cells on Jagged1. 
While we did observe maximal upregulation of HES2, HES5 and HEY2 at 20h, other 
time points (12h, 16h and 24h) also had higher expression, which was not seen in HES1, 
HES3, HES4 and HEY1.  
A critical aspect of HES regulation is its oscillatory nature on cell proliferation in 
cultured cells. HES1 expression oscillates in many cell types including fibroblasts, 
myoblasts and neuroblasts. The period of HES1 oscillation is about 2h in many murine 
cell lines. After HES1 activation, the translated HES1 protein represses its own activity 
by directly binding to the N-box sequence of its own promoter. HES1 gene products: 
mRNA and protein are very unstable and have a half-life of about 20 min. Thus, they 
disappear rapidly, indicating that auto repression is short and transient. HES1 
autonomously initiates oscillatory expression with short periodicity. Several studies have 
indicated HES1 oscillation and cell proliferation correlate with each other (Yoshiura et 
al., 2007). While we do not observe modulations in HES1 levels, it might be possible that 
in our system oscillations in HES2 and HES5 modulate cell growth and proliferation. 
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HES1 can also repress cell cycle related genes such as E2F1, p27 and p57 (Castella, 
Sawai, Nakao, Wagner, & Caudy, 2000; Georgia, Soliz, Li, Zhang, & Bhushan, 2006; 
Hartman et al., 2004). We show that overexpression of HES2 and HES5 can suppress 
AXL and α-catulin at the protein level. Whether HES2 and HES5 transcriptionally 
modulates AXL and α-catulin in yet to be explored. AXL and α-catulin both lack N-box 
or E-box motifs at their promoter sites. Thus, it might be possible that HES 2 or HES5 
may not transcriptionally regulate AXL and α-catulin. Takata and Ishikawa have shown 
that HES1 can repress target genes in a transcription- independent manner by recruiting 
Sirt1, a homologue of silent information regulator 1 and class 3 histone deacetylase 
through its bHLH domain, thereby suppressing target gene expression (Takata & 
Ishikawa, 2003).  HEY1 has been shown to directly interact with NcoR and Sin3a via its 
bHLH domain. This forms part of the Sin3 corepressor complex which recruits histone 
deacetylase-1 (HDAC1) (Gould, Harrison, Hewitt, & Whitehouse, 2009). Hey proteins 
were also shown to bind to the androgen receptors and its co-activator Src1 to repress 
transcription from promoters that depend on androgen (Belandia et al., 2005). In order to 
address such non-transcriptional inhibition of AXL and α-catulin by HES2 and HES5, we 
would have to perform a high-throughput screen to identify potential binding partners. 
Techniques such as yeast 2-hybrid screens could be employed that would screen for a 
library of potential interacting proteins. 
Lastly, we show that overexpression of HES2 and HES5 inhibits growth that is 
possibly mediated by AXL and α-catulin. First, we demonstrated that overexpression of 
NOTCH1 inhibits cell and tumor growth. Next, we showed that NOTCH1 inhibits AXL 
and α-catulin, which produces a similar growth inhibitory effect. Lastly, we prove that 
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HES2 and HES5 may be sufficient to inhibit AXL and α-catulin. Taken together, these 
results suggest that NOTCH mediated inhibition of cell growth might involve HES2, 
HES5, AXL and α-catulin (Figure 54). Following NOTCH activation, the NOTCH-CBF1 
complex binds to the HES promoter and activates transcription. In neural development, 
Ohtsuka et al. have shown that HES1 and HES5 are required for mammalian neuronal 
differentiation (Ohtsuka et al., 1999). In their model, overexpression of NOTCH1 in 
HES1 or HES5 null mice inhibited cell differentiation and increased cell proliferation 
suggesting that HES1 and HES5 may be required for NOTCH mediated inhibition of cell 
proliferation and induction of differentiation. We haven’t completely evaluated the roles 
of HES2 and HES5 in modulating AXL, α-catulin and cell growth. We have shown that 
HES2 and HES5 may be sufficient to inhibit AXL and α-catulin in a cell line that has 
inactivated NOTCH signaling. To prove that these canonical downstream targets are 
necessary, we might have to overexpress NFL1 in cell lines that have HES2 and HES5 
knocked out (by CRISPR-Cas9 system) and evaluate tumor formation, further staining 
the tumors for AXL and α-catulin. This would indicate if HES2 and HES5 are necessary 
for tumor growth and inhibition of AXL and α-catulin.  
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Figure 63: Mechanistic model of NOTCH mediated growth suppression 
 
 
 
 
 
 
 
 201 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 9: CONCLUSIONS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 202 
 
 
 
Conclusions 
 
We were among the first group to identify frequent inactivating somatic mutations 
in HNSCC (Agrawal et al., 2011). Recent TCGA data has shown that NOTCH is mutated 
at a frequency of 15-19% in primary tumors ("TCGA Releases Head and Neck Cancer 
Data," 2015), however the functionality of NOTCH in this cancer type was unknown. In 
this thesis, we have shown evidence that NOTCH1 acts as a tumor suppressor in HNSCC. 
For the first time, we cloned the full length NOTCH1 receptor and restored NOTCH 
signaling in mutant cell lines and showed a growth inhibitor effect in vitro and in vivo. 
Furthermore, we also evaluated the downstream effectors of the NOTCH signaling 
pathway that mediate growth inhibition. We identified a novel link of two proto-
oncogenes AXL and α-catulin in relation to the NOTCH signaling pathway. We propose 
that NOTCH regulates these molecules at the protein expression level that might be 
mediated by HES2 and HES; canonical downstream effectors of NOTCH signaling.  
 
There are limitations to this study that need to be addressed. Firstly, how NOTCH 
inhibits growth is not completely elucidated. We have shown partial evidence of 
senescence and G1 growth arrest. However, the appearance of spherical ball like 
structures after NOTCH is activated in a few cell lines like UM22A and HN31 are 
reminiscent of stem cell morphology. In addition, stem cell markers ALDH3A1 and 
ALDH1A1 were significantly upregulated in patients with an active NOTCH gene 
signature. This necessitates the need to understand the balance between stem cell 
maintenance and differentiation after NOTCH activation in our system. Secondly, we 
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selected two proto-oncogenes AXL and α-catulin based on significance of modulation, 
intensity of change and novelty to literature. There are several other molecules like 
KRT13, KRT15, INTGA5 and INTGA3 that are involved with differentiation and 
adhesion that were also upregulated after NOTCH activation. We couldn’t address 
adhesion and cell migration/invasion in this study. Since cell migration/invasion was the 
also one of significantly modulated pathways, it will be worth understand this aspect of 
NOTCH signaling. Lastly, how NOTCH activation regulates AXL and α-catulin is 
unknown. From our data, NOTCH might transcriptionally regulate AXL and α-catulin 
but this might happened independent of HES2 and HES5. ChIP assays to evaluate 
binding sites along the promoter regions of AXL and α-catulin will help address 
transactional regulation of AXL and α-catulin by NOTCH signaling.  
 
Besides these limitations, the identification of AXL being downstream of 
NOTCH signaling has clinical relevance. Patients that are mutant for NOTCH1 have high 
expression levels of AXL. Using the AXL inhibitor, it might be plausible to identify this 
subset of patients for treatment with this inhibitor. Taken together, NOTCH1 acts as a 
tumor suppressor in HNSCC, activates HES2 and HES5 and suppresses proto oncogenes 
AXL and α-catulin which can potentially be exploited to treat patients harboring 
inactivating NOTCH1 mutations.  
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Appendix 1: Differentially expressed genes after activation of NOTCH signaling in 
PJA34 and 183 cells. Green highlighted “Significance” cells show genes modulated 
based on treatment, independent of cell lines. Orange highlighted “Significance” cells 
show genes modulated based on treatment and cell lines 
 
  Test statistics Significance Fold changes 
GENE P-VALUE SIGNIFICANCE PJA34 on Fc 183 on Fc 
NETO2 1.31E-06 TRUE -1.786766469 -1.591373679 
ORC1 2.03E-06 TRUE -1.293608993 -1.259996923 
SVIL 2.19E-06 TRUE 1.223653112 1.250670199 
HYOU1 9.68E-06 TRUE -1.495332483 -1.292542472 
SNX9 1.06E-05 TRUE -1.262373825 -1.334064475 
SDC4 1.09E-05 TRUE -1.368789079 -1.283115657 
LOC100131564 1.48E-05 TRUE 1.875013231 1.623158874 
BUB1 1.58E-05 TRUE -1.226914977 -1.200692744 
PLEK2 1.86E-05 TRUE -1.786902142 -1.605018829 
LOXL2 2.16E-05 TRUE -2.494472424 -1.62763903 
TMEM55A 2.32E-05 TRUE -1.478416916 -1.322108616 
GLTP 2.64E-05 TRUE 1.376199925 1.313716811 
EPHX1 3.02E-05 TRUE 1.35263688 1.449610284 
TRAF6 3.86E-05 TRUE -1.152709899 -1.267995575 
MTA2 4.28E-05 TRUE -1.12559422 -1.152395292 
RBBP8 5.12E-05 TRUE -1.258116005 -1.308456843 
PFDN1 5.39E-05 TRUE -1.219056404 -1.345029118 
CCNE1 5.45E-05 TRUE -1.474795156 -1.335716497 
CHKA 5.90E-05 TRUE -1.234297491 -1.456601315 
EHD4 5.99E-05 TRUE -1.487946593 -1.295572884 
TMEM45B 6.02E-05 TRUE 1.429789064 2.055369763 
PIGK 6.27E-05 TRUE -1.175155846 -1.172503044 
ACD 7.57E-05 TRUE -1.157926571 -1.213096054 
VPS13D 7.72E-05 TRUE 1.268872579 1.132285777 
CAP1 8.26E-05 TRUE -1.229542907 -1.138716253 
KRT13 9.57E-05 TRUE 1.77026689 3.60191253 
TRIM21 9.63E-05 TRUE -1.179553244 -1.193941252 
LAMC1 9.95E-05 TRUE -1.319869362 -2.021028169 
LOC100505648 0.000103862 TRUE 1.813266152 1.463558142 
NEK4 0.000104204 TRUE -1.130451774 -1.209764606 
FKSG49 0.000114433 TRUE 1.574041091 1.549512174 
CDCA2 0.000115175 TRUE -1.219181131 -1.265979904 
SPATA5 0.000115519 TRUE -1.19604649 -1.252998702 
E2F7 0.000158426 TRUE -1.289616457 -1.302467882 
LINC00305 0.000163931 TRUE 1.120782192 1.117798109 
PRODH 0.00016933 TRUE 1.82869686 1.593180575 
ALDH1B1 0.000194034 TRUE -1.414398822 -1.209027432 
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C22orf32 0.000197178 TRUE 1.160389924 1.199436895 
VPRBP 0.000201273 TRUE -1.293232462 -1.169661492 
BIN1 0.000202017 TRUE -1.322500096 -1.514343369 
GRWD1 0.000207466 TRUE -1.36700702 -1.141186622 
TOE1 0.000214969 TRUE -1.336199744 -1.326452408 
GALT 0.00021556 TRUE 1.297673436 1.185341207 
FADS3 0.000216641 TRUE -1.223837056 -1.341600513 
C16orf57 0.000223521 TRUE -1.346730387 -1.32449736 
SQRDL 0.000224705 TRUE -1.516282869 -1.33368959 
TWF2 0.000225339 TRUE -1.37447999 -1.176127818 
SLAMF7 0.000234851 TRUE -1.283074106 -1.167099379 
TP53BP2 0.000241564 TRUE -1.179167952 -1.316301924 
CDCA8 0.000249332 TRUE -1.273954509 -1.171928341 
H3F3B 0.00026069 TRUE 1.329345141 1.364899342 
MALAT1 0.000264194 TRUE 2.066669804 1.355450487 
HSPH1 0.000270567 TRUE -1.160921812 -1.224394234 
CBL 0.000314101 TRUE -1.194529075 -1.273433504 
CTNNBIP1 0.000315766 TRUE -1.393831987 -1.347872954 
ABHD3 0.000343651 TRUE -1.346209522 -1.202183782 
ZBTB25 0.000355473 TRUE 1.228214388 1.240702106 
ADAM15 0.000358385 TRUE -1.224466846 -1.235001168 
FAM219A 0.000379691 TRUE -1.290578907 -1.348998551 
TOMM40 0.000383483 TRUE -1.29218039 -1.135574829 
NBR1 0.000386537 TRUE 1.260411621 1.175231438 
PCMTD1 0.000392268 TRUE 1.231978882 1.345370524 
NOL11 0.000392324 TRUE -1.199564185 -1.165537578 
LSM2 0.000397076 TRUE -1.11575537 -1.257140018 
WDR44 0.000400631 TRUE -1.167975473 -1.15586707 
IGHG3 0.000405287 TRUE 1.450297705 1.52644626 
DPP7 0.000407105 TRUE 1.267265071 1.145468908 
CPD 0.000414971 TRUE 1.203387714 1.557163358 
SMURF2 0.000431243 TRUE -1.239318784 -2.068924561 
LINC00511 0.000455291 TRUE 1.202667989 1.443979779 
LOC647012 0.000458961 TRUE -1.202200671 -1.09464217 
SOX13 0.000468285 TRUE -1.166520205 -1.364274341 
IL1R1 0.0004875 TRUE 1.289275026 1.938324922 
EIF2S2 0.00050376 TRUE -1.073577415 -1.128741207 
UHRF1 0.000507888 TRUE -1.30266581 -1.202528743 
FEN1 0.000510527 TRUE -1.380328609 -1.141452263 
SPRED1 0.00052766 TRUE -1.339721849 -1.392720777 
ZNF594 0.000556438 TRUE 1.410535469 1.276505876 
VKORC1L1 0.000564705 TRUE -1.170939583 -1.094360572 
HSPA5 0.000572539 TRUE -1.147947658 -1.203772664 
LOC100272216 0.000585628 TRUE 1.738720093 1.514815069 
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HSPA13 0.000590424 TRUE -1.054196479 -1.150919628 
FAM157B 0.000594079 TRUE 1.909602286 1.387007581 
GPD2 0.000635699 TRUE -1.12685908 -1.428244225 
FAM57A 0.000648745 TRUE -1.328236535 -1.251381626 
OR8B3 0.000678339 TRUE -1.206940332 -1.165626136 
FRK 0.000694778 TRUE 1.388054496 1.167870118 
PRORSD1P 0.000703802 TRUE 1.394405033 1.244419143 
MAP2K1 0.000716848 TRUE -1.394362066 -1.110948043 
SLC9A1 0.000718803 TRUE -1.273198995 -1.304208168 
VARS 0.000806383 TRUE -1.314578851 -1.141278214 
ZBTB8A 0.000812592 TRUE -1.480987827 -1.352056694 
GJC1 0.000821452 TRUE -1.156469072 -1.447435154 
LOC100131434 0.000822597 TRUE 1.683313028 1.482152043 
MCM6 0.000825588 TRUE -1.208127076 -1.115939086 
CD97 0.000832563 TRUE -1.287670548 -1.363728948 
TTI1 0.000854126 TRUE -1.279442153 -1.176280036 
CRYZL1 0.000883016 TRUE 1.207725873 1.204011237 
ESYT1 0.00088412 TRUE -1.595067548 -1.149591818 
UAP1 0.000892989 TRUE -1.466897988 -1.144797967 
PCYT2 0.000919649 TRUE -1.207264975 -1.363135773 
EIF3F 0.00097262 TRUE 1.159942667 1.086747285 
THRAP3 0.000974314 TRUE -1.098936044 -1.088246955 
FLJ45340 0.000987726 TRUE 1.782429293 1.304067101 
UFD1L 0.000989381 TRUE -1.166051339 -1.097111777 
SMCR9 0.001008265 TRUE -1.298573703 -1.26293699 
SLC16A1 0.00101877 TRUE -1.154026654 -1.451774579 
NT5C2 0.001030223 TRUE 1.119115853 1.337324108 
RABGEF1 0.001037365 TRUE -1.178031674 -1.102004091 
AMPD3 0.001042321 TRUE -1.265653826 -1.422929114 
RAB26 0.001050574 TRUE 1.222881856 1.216314483 
IL20RA 0.001086824 TRUE 1.318803561 2.148012943 
PSMC3 0.001092144 TRUE -1.322784003 -1.129624084 
TRBV5-1 0.00110443 TRUE -1.327061294 -1.21561504 
TUBGCP4 0.001113621 TRUE -1.145609803 -1.1032789 
MYSM1 0.001129062 TRUE 1.269770512 1.129472381 
CSE1L 0.001141472 TRUE -1.152464387 -1.083511616 
LOC100288069 0.001141889 TRUE 1.765061556 1.328881943 
GSG2 0.001163901 TRUE -1.262337699 -1.334676676 
PSMD12 0.001170838 TRUE -1.285504432 -1.122910038 
NDST1 0.001181211 TRUE -1.380693357 -1.169410689 
OCIAD2 0.001182903 TRUE -1.556949385 -1.122781668 
KCTD9 0.001210061 TRUE -1.20445099 -1.128654543 
CLK4 0.001212289 TRUE 1.398852928 1.263704401 
HNRNPU-AS1 0.00122636 TRUE 2.157469333 1.453534529 
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PSMA1 0.001259243 TRUE -1.196766829 -1.095626295 
SLC35E2 0.001264955 TRUE 1.200316252 1.126374789 
CLEC17A 0.001276609 TRUE -1.283001599 -1.340105009 
TCTN1 0.0012788 TRUE 1.177566714 1.250927959 
EPHB4 0.001313916 TRUE -1.117776332 -1.296898448 
TTK 0.001350236 TRUE -1.172201035 -1.088664024 
CLK1 0.001398848 TRUE 1.3904032 1.194132732 
COX10 0.001410188 TRUE -1.104828409 -1.173120573 
LOC100506479 0.001452983 TRUE 1.918322565 1.306739336 
LOC100132062 0.001482583 TRUE 1.810779445 1.300552223 
LOC100653348 0.001493134 TRUE 1.871788981 1.32519271 
CDH3 0.001518356 TRUE -1.205714629 -2.323396352 
SNORD84 0.001529692 TRUE -1.108867356 -1.133102691 
STK4 0.001544275 TRUE -1.098528954 -1.133062626 
SFR1 0.001550509 TRUE -1.326122306 -1.274766477 
FOXN2 0.001585853 TRUE -1.123577645 -1.273755938 
CDC27 0.001614763 TRUE -1.182725124 -1.085424244 
SNORD91B 0.001617171 TRUE 1.130501138 1.257632747 
ZNF35 0.001691019 TRUE -1.394711983 -1.221597473 
FAM118B 0.001699061 TRUE -1.21144686 -1.143650655 
LAMA3 0.001738458 TRUE -1.205982894 -2.62113096 
ATL2 0.001763792 TRUE 1.189065324 1.451325041 
ODF3B 0.001778024 TRUE 1.246758179 1.290313533 
TPD52 0.001778274 TRUE 1.124090552 1.105773284 
CCNF 0.001821216 TRUE -1.266024078 -1.182778925 
EIF3I 0.001836842 TRUE -1.204890771 -1.122326063 
NCAPH 0.001849109 TRUE -1.183510252 -1.105393594 
C1orf146 0.001852168 TRUE -1.105574468 -1.141910078 
OCA2 0.001862792 TRUE 1.372399845 1.21903518 
IGFL4 0.001863598 TRUE 1.248627502 1.354082104 
DCAF8 0.001887869 TRUE 1.290723733 1.119782767 
PAN2 0.001906978 TRUE 1.250390504 1.202139158 
MRPS11 0.001919266 TRUE -1.310008296 -1.10850888 
SH3BGRL3 0.001926675 TRUE -1.351744876 -1.168113905 
TAF5 0.001948789 TRUE -1.141204504 -1.243739076 
FAM122C 0.001985931 TRUE 1.151456395 1.282829205 
OR6B3 0.002004681 TRUE -1.679502672 -1.257620124 
FAM46A 0.002008932 TRUE -1.479562317 -1.216231584 
PSMA7 0.002063621 TRUE -1.304162877 -1.115425852 
CTSA 0.002072446 TRUE 1.181721107 1.104804888 
GOLGA8C 0.002143645 TRUE 1.258968127 1.247813024 
POGK 0.002145979 TRUE -1.195107669 -1.210291568 
GLT25D1 0.002159086 TRUE -1.374305197 -1.162192046 
RASA4 0.002168785 TRUE 1.130235813 1.174806859 
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LOC100506636 0.002182729 TRUE 1.965580857 1.298851484 
AP3B2 0.002185912 TRUE -1.139617117 -1.209679085 
TOMM34 0.00222442 TRUE -1.155041684 -1.413960853 
RAD54B 0.002234403 TRUE -1.198440837 -1.234573886 
ELOF1 0.002236058 TRUE -1.190819571 -1.071162823 
TAF13 0.002248343 TRUE -1.301445786 -1.09392258 
ARMC9 0.002268096 TRUE -1.348939983 -1.220935505 
ZNF593 0.002272196 TRUE -1.221642777 -1.252188572 
ABCA5 0.002275699 TRUE 1.446113105 1.199999554 
ADAT1 0.002293045 TRUE -1.159905253 -1.266511687 
ABCA2 0.002317235 TRUE 1.277503114 1.143709909 
PCDHB18 0.002327844 TRUE 1.376796784 1.114361557 
SLC4A1AP 0.002372555 TRUE -1.15309246 -1.164520462 
HSPA14 0.002380471 TRUE -1.259227341 -1.245634752 
C9orf78 0.002406737 TRUE -1.151618977 -1.168343497 
ASNA1 0.002442203 TRUE -1.279293663 -1.101563842 
WDR36 0.002462321 TRUE -1.140522857 -1.046372381 
OXNAD1 0.002467984 TRUE -1.224988221 -1.156874243 
SPATA5L1 0.002489387 TRUE -1.40801875 -1.181282725 
ROR1 0.002546865 TRUE -2.771381193 -1.334780243 
MLLT11 0.002551575 TRUE -1.551308408 -1.118740801 
LOC100653350 0.002557473 TRUE -1.604746916 -1.380776818 
C3orf38 0.002584638 TRUE -1.180209063 -1.16586902 
RDH11 0.002611957 TRUE -1.240587233 -1.082844886 
DUX4L9 0.002635471 TRUE 1.088351303 1.426573737 
MCM3 0.002635823 TRUE -1.123201497 -1.105011312 
LOC100133032 0.00263938 TRUE 1.133191665 1.254169884 
LYST-IT2 0.002648508 TRUE 1.409364984 1.167814212 
SNORA16B 0.002660148 TRUE 1.432638092 1.714984897 
PDCD1LG2 0.002668483 TRUE -1.251598029 -3.302925645 
PBXIP1 0.00269523 TRUE 1.248909473 1.191319012 
ARHGDIA 0.002736477 TRUE -1.388162796 -1.173613809 
CTCF 0.002762059 TRUE -1.062049945 -1.114575891 
RNF207 0.002783972 TRUE 1.332365881 1.278784301 
PTPLAD1 0.002844242 TRUE -1.175048628 -1.090491122 
DOLK 0.002894157 TRUE -1.134445711 -1.243752331 
MLKL 0.002901199 TRUE -1.204360821 -1.212046639 
BORA 0.002920487 TRUE -1.237885463 -1.177660205 
MIR3689D1 0.002946025 TRUE 1.131992593 1.476894034 
SLC25A34 0.002980464 TRUE 1.369878113 1.141297974 
HHAT 0.003022559 TRUE 1.229899811 1.208087909 
USP48 0.003022715 TRUE 1.170695227 1.094216952 
LOC100506926 0.003039253 TRUE -1.157971455 -1.129393974 
LDLRAD1 0.003041538 TRUE 1.211917067 1.531508357 
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ZCCHC17 0.003051979 TRUE -1.302214406 -1.118168788 
NOLC1 0.003058899 TRUE -1.150051442 -1.087622331 
ANO1 0.003072006 TRUE 1.139045653 2.076667977 
APCDD1L 0.00311888 TRUE -2.026960024 -1.143485905 
GPM6A 0.003191475 TRUE -1.219558763 -1.199435033 
C17orf96 0.003209697 TRUE -1.099247753 -1.41801 
BOLA3 0.003217741 TRUE -1.232781555 -1.159255018 
LOC654342 0.003246446 TRUE -1.523898262 -1.309840007 
VASP 0.003281192 TRUE -1.234048503 -1.334912987 
PLAC8L1 0.003283025 TRUE 1.206297563 1.236947949 
MIR4668 0.003283186 TRUE 1.398813602 1.572780922 
GOLGA8F 0.003304404 TRUE 1.181782911 1.126158306 
ANXA2P3 0.003324505 TRUE -1.523805742 -1.334015604 
LRWD1 0.003335295 TRUE -1.355611739 -1.190733455 
SCARNA21 0.003342125 TRUE 1.410408644 1.137917443 
LINC00514 0.003363033 TRUE 1.156422128 1.168801951 
THOP1 0.003389264 TRUE -1.304545151 -1.151971597 
GRIK1-AS1 0.003407719 TRUE 1.301317831 1.161168282 
LOC729737 0.003409182 TRUE 2.103759441 1.294475749 
AMMECR1-IT1 0.003442353 TRUE 1.139656571 1.139566251 
ADPGK 0.003465772 TRUE -1.203901795 -1.156404935 
TBC1D8 0.003468426 TRUE 1.185818317 2.313449352 
ADIPOR2 0.003482462 TRUE 1.144721272 1.081682242 
EPHA2 0.003589923 TRUE -1.485376135 -1.616781185 
DBP 0.003608038 TRUE 1.175918938 1.339803253 
DNER 0.003626329 TRUE -1.614963336 -1.235236778 
LOC554249 0.003690705 TRUE 1.311408353 1.31568982 
GPR65 0.003692228 TRUE -1.256768361 -1.122144414 
IRF6 0.00372726 TRUE 1.063972323 1.264426131 
C9orf118 0.003737204 TRUE -1.043415261 -1.181264887 
DNLZ 0.003740105 TRUE -1.388288522 -1.255445771 
FAF1 0.003743002 TRUE 1.094334874 1.149666445 
LOC100287314 0.003817511 TRUE -2.081614963 -1.211822115 
GBA 0.003826381 TRUE 1.327467973 1.281804471 
TRDJ2 0.003858077 TRUE 1.278546253 1.168678249 
NFYA 0.003865274 TRUE -1.148997031 -1.143601777 
ZFAND2A 0.003878197 TRUE -1.107301118 -1.249088208 
BMS1P5 0.003882601 TRUE 1.15825541 1.154195964 
ATP5S 0.003915878 TRUE 1.288044456 1.11439769 
MIR146B 0.003934832 TRUE -1.712102686 -1.141662684 
SRD5A1P1 0.003985077 TRUE 1.216775526 1.359809448 
SNORD41 0.003990502 TRUE 1.314774035 1.238238355 
SELK 0.00400774 TRUE -1.209650652 -1.258921629 
ITPA 0.004018787 TRUE 1.07017234 1.114499093 
 211 
PRMT7 0.00404008 TRUE -1.272695461 -1.077379596 
BLM 0.004068344 TRUE -1.136694174 -1.199473082 
CRISP1 0.004206731 TRUE -1.221353692 -1.105957874 
PAFAH1B2 0.004213345 TRUE -1.231352047 -1.083086604 
PIWIL4 0.004224568 TRUE -1.336913491 -1.311766301 
UBE3A 0.004312855 TRUE -1.089941778 -1.087460488 
RNU105C 0.004339569 TRUE -1.158404128 -1.120062761 
FOSL1 0.004399443 TRUE -2.537182189 -1.816340812 
MIR4742 0.004420224 TRUE 1.448336912 1.886408558 
AHNAK 0.004497224 TRUE 1.188870686 1.266188378 
TBC1D22A 0.004514445 TRUE 1.056050372 1.298516422 
SRA1 0.004609955 TRUE -1.231012615 -1.117901999 
IARS 0.004613694 TRUE -1.067750282 -1.071573565 
SNRPB 0.004633707 TRUE -1.181061134 -1.103884557 
FUBP3 0.004675741 TRUE -1.100113723 -1.042948477 
ND3 0.00478452 TRUE 1.149465184 1.077011755 
ARHGEF10 0.004812048 TRUE -1.283419759 -1.244259404 
PSMD8 0.00484086 TRUE -1.198190776 -1.063805748 
TMPRSS11BNL 0.004849467 TRUE -1.075984204 -1.159451655 
GCFC1 0.004863511 TRUE 1.248138338 1.114546701 
CAV1 3.59E-09 TRUE -1.879864475 -2.213279734 
AXL 6.41E-09 TRUE -2.740535194 -3.550417429 
RAB40B 1.78E-08 TRUE 1.700767531 1.981179136 
KRT15 2.22E-08 TRUE 1.901707382 1.686342124 
VTCN1 2.24E-08 TRUE 3.084901816 2.960660781 
C11orf54 3.57E-08 TRUE 1.430378176 1.436548543 
EPHA4 8.73E-08 TRUE 1.651338226 1.937497399 
FHL2 1.15E-07 TRUE -1.793647944 -2.050525456 
TP53INP1 1.21E-07 TRUE 2.990640742 2.270578316 
SLPI 1.58E-07 TRUE 1.435747632 1.556415025 
CMTM8 1.64E-07 TRUE -1.467111422 -1.621031591 
LOC645553 1.78E-07 TRUE 1.953409711 1.785603835 
SERPINE1 2.07E-07 TRUE -2.737937127 -2.216887593 
ACSS1 2.27E-07 TRUE 1.330140299 1.292522869 
PTRF 3.53E-07 TRUE -2.018511855 -2.160152521 
NAV3 4.33E-07 TRUE -2.015300831 -1.840096007 
LAMC2 5.09E-07 TRUE -2.601950467 -4.660258605 
MIR622 5.60E-07 TRUE -1.713406578 -1.927822216 
DRAM1 5.62E-07 TRUE -1.88475279 -2.08255253 
AFAP1L2 6.00E-07 TRUE -1.48813128 -1.599475888 
ANK3 6.37E-07 TRUE 1.38241757 1.536904057 
LURAP1L 7.13E-07 TRUE 1.743066142 2.034945317 
SUV39H1 8.88E-07 TRUE -1.236273258 -1.256763713 
PLD1 8.95E-07 TRUE 1.65776883 2.024055226 
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SKA1 1.29E-06 TRUE -1.430599512 -1.283475658 
TJP1 1.32E-06 TRUE -1.403405606 -1.258711109 
ELK3 1.50E-06 TRUE -1.25967842 -1.326464126 
CXorf49 1.70E-06 TRUE -2.373220082 -1.770249814 
MICB 1.78E-06 TRUE -1.386492784 -1.609662747 
PDCD4 2.01E-06 TRUE 1.722340546 2.077520061 
FUCA2 2.13E-06 TRUE -1.460606691 -1.34140004 
ME2 2.21E-06 TRUE -1.21872262 -1.256448596 
TMCC3 2.29E-06 TRUE -1.718795461 -1.879758243 
SEMA7A 2.29E-06 TRUE -1.57210976 -1.593661908 
ITGA5 2.34E-06 TRUE -1.548089254 -1.66591199 
HOMER3 2.38E-06 TRUE -1.605475502 -1.464097707 
ZBED2 2.55E-06 TRUE -1.892263387 -1.69646004 
TUBB 2.59E-06 TRUE -1.130891546 -1.119801012 
SYT16 2.68E-06 TRUE -1.762607899 -1.621434495 
SLC44A2 2.69E-06 TRUE -1.285656293 -1.210443909 
TINAGL1 2.94E-06 TRUE -1.409760798 -1.386166566 
MCM5 3.03E-06 TRUE -1.26952641 -1.204929668 
KIAA1147 3.24E-06 TRUE 1.467491511 1.705353015 
PANX1 3.28E-06 TRUE -1.363988338 -1.260007079 
USP10 3.30E-06 TRUE -1.115595875 -1.180940474 
SLC16A2 3.34E-06 TRUE -1.802144115 -2.572954157 
TNFSF10 3.47E-06 TRUE 1.409020665 1.626315216 
FGFBP1 3.66E-06 TRUE -1.843775565 -2.194481884 
FHOD1 3.75E-06 TRUE -1.44140405 -1.467252458 
GALNT2 3.92E-06 TRUE -1.352325102 -1.585801864 
TC2N 4.16E-06 TRUE 1.424823062 1.265983844 
UTP20 4.29E-06 TRUE -1.386989262 -1.250498328 
PPAP2A 4.43E-06 TRUE 1.832492561 3.047363185 
SKP2 4.46E-06 TRUE -1.26281721 -1.455441508 
ITCH 4.79E-06 TRUE -1.175851935 -1.137027189 
CTSC 4.94E-06 TRUE 1.587310285 1.366280459 
P4HA1 4.95E-06 TRUE -1.419798997 -1.303381516 
ITGA3 5.03E-06 TRUE -1.561938907 -1.882561378 
PYGL 5.22E-06 TRUE -1.275687899 -1.22819576 
PXN 5.48E-06 TRUE -1.509970786 -1.831901732 
KRT18P10 5.51E-06 TRUE -1.655976362 -1.665664242 
MAP4K4 5.53E-06 TRUE -1.383645241 -1.265791535 
MBTD1 5.65E-06 TRUE 1.247070835 1.220390928 
PKP2 5.73E-06 TRUE -1.509984202 -1.542301169 
GLTSCR2 6.21E-06 TRUE 1.334066127 1.226318855 
CYP1A1 6.40E-06 TRUE 1.652873806 2.249775191 
THSD4 6.42E-06 TRUE -1.49717886 -1.54261147 
NEDD4 6.86E-06 TRUE -1.139600153 -1.183365917 
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PBX1 7.54E-06 TRUE 1.636231577 1.820221527 
NOP2 7.91E-06 TRUE -1.272774869 -1.198788856 
PNRC1 8.05E-06 TRUE 1.337523493 1.422605915 
DFNA5 8.18E-06 TRUE -1.337065625 -1.760828617 
SLC12A2 8.22E-06 TRUE 1.574053144 2.286239693 
WDHD1 8.32E-06 TRUE -1.205294668 -1.217696276 
ANLN 8.40E-06 TRUE -1.161794953 -1.173841188 
GCNT1 8.44E-06 TRUE -1.317217456 -1.333733481 
RCN3 8.87E-06 TRUE 1.165354094 1.272609596 
SHMT1 9.17E-06 TRUE -1.24460801 -1.182589194 
RIPK4 9.50E-06 TRUE 1.32600794 1.375810181 
E2F4 9.52E-06 TRUE -1.318311614 -1.361232757 
KIF14 9.64E-06 TRUE -1.185854918 -1.194170515 
ACPP 9.76E-06 TRUE 1.618462626 1.441360018 
PLXDC2 1.03E-05 TRUE 1.589624055 1.339970703 
HBP1 1.07E-05 TRUE 1.352290858 1.228506724 
SPAG5 1.08E-05 TRUE -1.207325799 -1.193867684 
KLK6 1.11E-05 TRUE -1.833552194 -1.761434628 
FAM83D 1.11E-05 TRUE -1.221983101 -1.136892115 
HES5 1.15E-05 TRUE 1.455861404 1.640565012 
ST6GALNAC2 1.15E-05 TRUE 1.456881687 1.566976092 
LCN2 1.19E-05 TRUE 1.507570226 1.373787535 
MCM8 1.22E-05 TRUE -1.277139977 -1.26620438 
SF3A3 1.26E-05 TRUE -1.152827264 -1.179602843 
FAM214A 1.28E-05 TRUE 1.40523228 1.46286467 
SGSM2 1.28E-05 TRUE 1.376786204 1.333257908 
CDCP1 1.30E-05 TRUE -1.360600651 -1.463711133 
DNAJC10 1.33E-05 TRUE -1.215384665 -1.279713107 
SOX15 1.34E-05 TRUE -1.761679288 -1.402531829 
ZWILCH 1.36E-05 TRUE -1.198039909 -1.267075109 
TUBB6 1.42E-05 TRUE -1.469844481 -1.250822924 
RNF138P1 1.42E-05 TRUE 2.983802218 2.426622264 
INADL 1.45E-05 TRUE 1.327631165 1.242823532 
ABCC3 1.46E-05 TRUE -1.397553493 -1.761489599 
LRFN4 1.47E-05 TRUE -1.405695071 -1.357507549 
RN5S496 1.52E-05 TRUE -3.410915511 -1.917774556 
GCLC 1.57E-05 TRUE 1.774180387 1.412309223 
NMT1 1.59E-05 TRUE -1.106073586 -1.123937492 
CNKSR3 1.67E-05 TRUE 1.405179404 1.917444165 
NF2 1.91E-05 TRUE -1.247962622 -1.216113273 
GATA6 1.93E-05 TRUE -1.478216462 -1.31407147 
YIPF1 1.94E-05 TRUE -1.272397024 -1.329164765 
CALB1 1.94E-05 TRUE 1.427729205 1.339999325 
MOB3B 1.94E-05 TRUE -1.584894299 -1.51973541 
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WNT7A 1.97E-05 TRUE -1.332383813 -1.683790922 
PCMTD2 2.07E-05 TRUE 1.409059196 1.481326956 
CAP2 2.08E-05 TRUE -1.50968777 -1.313624236 
DNAJC2 2.17E-05 TRUE -1.29249164 -1.24023538 
CLSPN 2.22E-05 TRUE -1.306358909 -1.286925784 
KPNA2 2.31E-05 TRUE -1.136255138 -1.080337381 
PLAUR 2.35E-05 TRUE -1.910431499 -1.743558843 
MMP9 2.35E-05 TRUE -1.598714895 -2.528770321 
PRKX 2.37E-05 TRUE 1.562484797 1.660797133 
MPV17L2 2.42E-05 TRUE -1.400850335 -1.300737366 
NPLOC4 2.46E-05 TRUE -1.18580229 -1.157307387 
DSP 2.46E-05 TRUE 1.467566441 1.651192413 
FLII 2.47E-05 TRUE -1.340949221 -1.278247522 
RHOD 2.57E-05 TRUE -1.412526842 -1.297628171 
C20orf20 2.57E-05 TRUE -1.339681283 -1.31992651 
GPX8 2.75E-05 TRUE -1.204988833 -1.370357629 
TCF19 2.78E-05 TRUE -1.215235775 -1.155721191 
MFN2 2.80E-05 TRUE -1.181066435 -1.12823715 
NFE2L3 2.80E-05 TRUE -1.389423572 -1.46206054 
UPP1 2.80E-05 TRUE -1.432519049 -1.548333718 
FAM102B 2.85E-05 TRUE 1.660198946 1.408780083 
CFLAR 2.86E-05 TRUE 1.220136259 1.283926877 
UBE2T 2.91E-05 TRUE -1.224744388 -1.20240708 
LOXL4 2.94E-05 TRUE -3.122215928 -1.797933225 
SLC7A2 3.00E-05 TRUE -1.504287819 -2.240838573 
CYB5A 3.02E-05 TRUE 1.329640469 1.394810557 
BRCA1 3.03E-05 TRUE -1.135070532 -1.116543091 
MCM7 3.09E-05 TRUE -1.191800102 -1.208786606 
TMEM27 3.16E-05 TRUE -1.63390962 -1.484812487 
GTF2IP1 3.23E-05 TRUE 1.260071836 1.195103599 
DOCK5 3.38E-05 TRUE -1.146817587 -1.109710407 
CDS1 3.47E-05 TRUE -1.471580804 -1.365683477 
RAP2B 3.50E-05 TRUE -1.261172536 -1.246133097 
ANKRD2 3.72E-05 TRUE -1.665783348 -1.563020181 
BAG2 3.76E-05 TRUE -1.474943714 -1.29861083 
ISYNA1 3.88E-05 TRUE 1.349583497 1.344983351 
MPPE1 3.90E-05 TRUE 1.252157724 1.146987714 
P4HTM 3.91E-05 TRUE 1.225615466 1.169545978 
WNK2 3.92E-05 TRUE 1.485789317 1.350053332 
FANCD2 3.95E-05 TRUE -1.116855619 -1.120172785 
1-Mar 4.02E-05 TRUE -1.379733209 -1.209994276 
CCDC85C 4.03E-05 TRUE -1.333526241 -1.213183336 
ADD3 4.08E-05 TRUE 1.358820282 1.410445919 
KRT18P54 4.08E-05 TRUE -1.371958391 -1.604895302 
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FAM116A 4.14E-05 TRUE 1.205069728 1.195905164 
CIRH1A 4.17E-05 TRUE -1.397767207 -1.232822721 
ARHGDIB 4.24E-05 TRUE -1.96602048 -1.391176075 
DARS2 4.26E-05 TRUE -1.199047349 -1.131005693 
AP2B1 4.28E-05 TRUE -1.431655239 -2.222986212 
PEA15 4.30E-05 TRUE -1.509446711 -1.253661547 
TPMT 4.37E-05 TRUE -1.601193275 -1.303637071 
PLOD3 4.40E-05 TRUE -1.36954968 -1.976501665 
FAM21A 4.44E-05 TRUE 1.163310643 1.141073698 
LOC439990 4.50E-05 TRUE -1.97086006 -1.581887867 
SH3TC2 4.54E-05 TRUE 1.288006009 1.280236117 
MANSC1 4.58E-05 TRUE 1.562403784 1.730101187 
H3F3A 4.58E-05 TRUE 1.185208302 1.149451876 
SMS 4.58E-05 TRUE -1.215885914 -1.182905969 
INTS7 4.62E-05 TRUE -1.182604393 -1.26712887 
SOX2 4.62E-05 TRUE 1.439008166 1.375236492 
SLC25A13 4.62E-05 TRUE -1.168402185 -1.210186803 
LY6K 4.62E-05 TRUE -1.510338848 -1.267068197 
CD3EAP 4.64E-05 TRUE -1.533856284 -1.314359608 
CDC25A 4.70E-05 TRUE -1.453085166 -1.316096195 
GOLGA8B 4.87E-05 TRUE 1.755164941 1.430585282 
FERMT2 4.92E-05 TRUE -1.525847841 -1.310791219 
SDF2L1 4.92E-05 TRUE -1.377527908 -1.269674802 
SFSWAP 5.00E-05 TRUE -1.126488176 -1.116264512 
ANKRA2 5.03E-05 TRUE 1.342585244 1.275819028 
ZC3H14 5.04E-05 TRUE -1.100060431 -1.071990957 
MCM10 5.06E-05 TRUE -1.335189746 -1.163231602 
PRIM2 5.45E-05 TRUE -1.231896516 -1.221243314 
JAG2 5.48E-05 TRUE -1.213845854 -1.392949812 
GEMIN5 5.48E-05 TRUE -1.271575948 -1.188542557 
PSMB1 5.52E-05 TRUE -1.283745597 -1.121026262 
CASD1 5.69E-05 TRUE 1.198303744 1.138690168 
LSR 5.82E-05 TRUE -1.160269975 -1.216788602 
SRP68 5.86E-05 TRUE -1.125162221 -1.112908479 
CACNG4 5.87E-05 TRUE -1.267468044 -1.32472122 
ORC6 5.91E-05 TRUE -1.467914621 -1.222637654 
DLL1 5.92E-05 TRUE -1.338208803 -1.646450978 
FXYD5 5.93E-05 TRUE -1.175943928 -1.384971547 
BFAR 6.02E-05 TRUE -1.207693857 -1.132621484 
TBC1D3G 6.07E-05 TRUE 1.196220852 1.274581238 
CRIM1 6.27E-05 TRUE -1.198495189 -1.397970117 
LEPREL1 6.37E-05 TRUE -1.629279347 -1.505439876 
SERINC2 6.53E-05 TRUE -1.618478241 -1.376283612 
DDX56 6.53E-05 TRUE -1.239628019 -1.140127332 
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SLC39A14 6.56E-05 TRUE -1.460453143 -2.261275184 
GOLGB1 6.57E-05 TRUE 1.324327257 1.267323124 
GLUL 6.63E-05 TRUE 1.671557955 1.434873429 
PPAP2C 6.79E-05 TRUE 1.16900111 1.385468694 
WDR19 6.82E-05 TRUE 1.308874626 1.250091094 
PDIA4 6.94E-05 TRUE -1.249534891 -1.217454913 
MELK 7.00E-05 TRUE -1.296728801 -1.19070894 
LETMD1 7.01E-05 TRUE 1.289321084 1.296732181 
FAF2 7.04E-05 TRUE -1.167500406 -1.195980278 
DNMT1 7.09E-05 TRUE -1.15081456 -1.211846273 
SLC3A2 7.27E-05 TRUE -1.229056493 -1.193028566 
CANT1 7.28E-05 TRUE -1.263101153 -1.325381965 
TPR 7.30E-05 TRUE 1.155543982 1.165324222 
PKD1P1 7.33E-05 TRUE 1.381327638 1.22173835 
YARS2 7.38E-05 TRUE -1.335294464 -1.21395653 
STAC 7.54E-05 TRUE -1.724328789 -1.368932259 
RHOV 7.68E-05 TRUE 1.309605705 1.615115896 
EIF2C4 7.76E-05 TRUE 1.316108752 1.282118598 
GOLGA8A 7.85E-05 TRUE 1.696759181 1.403030571 
B4GALNT1 7.86E-05 TRUE -1.313654459 -1.657225633 
CUL1 7.92E-05 TRUE -1.22546041 -1.15876126 
TMEM59 8.35E-05 TRUE 1.37694188 1.228639864 
CD55 8.36E-05 TRUE -1.42095849 -1.72847595 
THSD1 8.37E-05 TRUE -1.701477442 -1.310144595 
KHNYN 8.44E-05 TRUE 1.194914334 1.148038266 
NUP88 8.56E-05 TRUE -1.132512485 -1.137218206 
C1QBP 8.56E-05 TRUE -1.169364152 -1.135026527 
GCH1 8.60E-05 TRUE -1.364705711 -1.666349608 
KPNA3 8.62E-05 TRUE -1.157837018 -1.139180939 
CHRNA5 8.64E-05 TRUE -1.253404087 -1.222216732 
MTM1 8.69E-05 TRUE -1.11230361 -1.228309266 
HEG1 8.76E-05 TRUE -1.489284699 -1.867101731 
SCRN1 8.84E-05 TRUE -1.156697525 -1.313001516 
SERPINE2 8.89E-05 TRUE -1.369715324 -1.598968503 
ZAK 9.32E-05 TRUE -1.240993049 -1.397499274 
OLFML3 9.39E-05 TRUE -1.376356582 -1.285810891 
HLTF 9.39E-05 TRUE 1.222382931 1.487774907 
WDR60 9.44E-05 TRUE 1.243347578 1.262711226 
SLC11A2 9.48E-05 TRUE 1.168255724 1.282132254 
CENPN 9.55E-05 TRUE -1.274710571 -1.240757009 
SLC25A6 9.55E-05 TRUE 1.126789546 1.119678886 
TIMP1 9.57E-05 TRUE -1.18153691 -1.356171271 
TYMS 9.60E-05 TRUE -1.241345088 -1.153860772 
PI4K2A 9.68E-05 TRUE -1.4942046 -1.400038662 
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STAM 9.74E-05 TRUE -1.387963716 -1.312774585 
EXO1 9.78E-05 TRUE -1.23873618 -1.247638667 
NOMO3 9.80E-05 TRUE -1.195281414 -1.101620962 
PKP1 9.86E-05 TRUE 1.232903721 1.360957134 
IPO9 0.000100404 TRUE -1.188523973 -1.172573525 
FST 0.00010061 TRUE -1.985150282 -5.3153921 
CLOCK 0.0001013 TRUE -1.24239604 -1.147297409 
NPIP 0.000103775 TRUE 1.351216977 1.23180045 
KLHL24 0.00010392 TRUE 1.741500364 1.545723369 
DLAT 0.000104889 TRUE -1.180222797 -1.150167221 
DIAPH3 0.000105834 TRUE -1.304281888 -1.252877818 
PELI2 0.000106871 TRUE 1.486457442 1.258656044 
LPAR1 0.000107489 TRUE -1.336840129 -1.407432313 
ACO1 0.000107568 TRUE -1.77471041 -1.293598741 
MAL2 0.000107997 TRUE -1.219185367 -1.175573379 
CDC6 0.000109142 TRUE -1.239669677 -1.287635628 
ZNF658B 0.000109385 TRUE 1.390951125 1.209824992 
NXPE3 0.000109425 TRUE -1.520349076 -1.690504953 
VEGFC 0.000109475 TRUE -2.014026443 -1.497205405 
CXCL16 0.000110021 TRUE -1.422118031 -1.395273239 
ETV4 0.000110256 TRUE -1.260040685 -1.33407348 
NEK3 0.000110287 TRUE -1.393380197 -1.536496255 
ETHE1 0.000110842 TRUE -1.454724904 -1.25989776 
CPPED1 0.000113126 TRUE -1.307208579 -1.397153705 
MICAL3 0.00011452 TRUE -1.324226219 -1.243332578 
CLIC1 0.000115447 TRUE -1.225052491 -1.15332439 
PLXNA2 0.000116539 TRUE -1.298680192 -1.372448664 
HSP90B1 0.000117002 TRUE -1.131376806 -1.178549854 
RAB3D 0.000118126 TRUE 1.311233188 1.294328322 
GBP2 0.000119409 TRUE 1.360413598 1.640683921 
TJP2 0.000119862 TRUE -1.194202233 -1.14433086 
EMC1 0.000120037 TRUE -1.174426978 -1.167427417 
ZDHHC16 0.000120428 TRUE -1.264630158 -1.104047711 
PVR 0.000120639 TRUE -1.468257426 -1.186739576 
SIRPA 0.000121239 TRUE -1.798870851 -1.416787658 
TXNIP 0.000124053 TRUE 2.626598723 1.665566548 
STXBP1 0.000124291 TRUE -1.316633091 -1.298607274 
TTC13 0.000125826 TRUE -1.283584096 -1.197292853 
RFWD3 0.000125975 TRUE -1.161337313 -1.237966391 
KIRREL 0.000126131 TRUE -1.770394052 -1.455777418 
MAML2 0.000126779 TRUE 1.200555625 1.26831129 
CERS6 0.000126906 TRUE 1.253810849 1.273062251 
NOMO2 0.000127704 TRUE -1.197527939 -1.095538934 
VGLL3 0.000128607 TRUE -1.151060371 -1.295448274 
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RBL2 0.000128657 TRUE 1.148332559 1.18979772 
PIM1 0.000130393 TRUE -1.338092789 -1.287994761 
OLR1 0.00013061 TRUE -6.593014033 -2.079015688 
PSMD2 0.000131133 TRUE -1.241205525 -1.162526183 
VPS36 0.00013134 TRUE 1.291499687 1.129650201 
TXNDC12 0.000131498 TRUE -1.085144955 -1.083696684 
MPHOSPH6 0.00013259 TRUE -1.292402445 -1.214202508 
NEBL 0.000134046 TRUE 1.286885398 1.643426513 
SEH1L 0.000135952 TRUE -1.125631789 -1.130986249 
CYB5B 0.000136916 TRUE -1.129290092 -1.228622902 
ZCCHC2 0.000136977 TRUE -1.173435814 -1.298030922 
ACOT9 0.000137038 TRUE -1.351231814 -1.2684911 
HSF4 0.000137223 TRUE 1.148093441 1.175934745 
FKBP14 0.000137232 TRUE -1.436561452 -1.173360801 
STAMBPL1 0.000138956 TRUE -1.306682129 -1.43335589 
ANXA3 0.000139997 TRUE -1.583029242 -1.349604018 
DBNL 0.000140159 TRUE 1.146970395 1.191510937 
MYH14 0.000141238 TRUE 1.572475683 1.730454879 
RPS27 0.00014398 TRUE 1.055957332 1.086223937 
CTSB 0.000145272 TRUE 1.185355928 1.231324654 
BMP2K 0.000145427 TRUE -1.330493071 -1.552107745 
TCOF1 0.000145856 TRUE -1.41542631 -1.266377001 
FAM21C 0.000146041 TRUE 1.270631874 1.199604992 
LOC401561 0.000148086 TRUE 1.649211391 1.470136681 
TK1 0.000149338 TRUE -1.331678598 -1.321397108 
NLRP2 0.000149947 TRUE -1.232331092 -1.32647322 
KIAA0040 0.000150652 TRUE -1.55138277 -1.461947231 
DPP4 0.000152024 TRUE -1.303076488 -1.183726898 
AKAP9 0.000153399 TRUE 1.209742836 1.24546084 
GABARAP 0.000154087 TRUE 1.160762625 1.162612807 
CYR61 0.000154488 TRUE -1.917068636 -1.697498787 
MGEA5 0.000154813 TRUE 1.260700811 1.229362711 
MIR4640 0.000155638 TRUE 1.177069801 1.215226637 
MRPL39 0.000156396 TRUE -1.21625183 -1.126594416 
C8orf46 0.000157188 TRUE -1.248317153 -1.251454368 
RRAS 0.00015826 TRUE -1.28076513 -1.183682416 
PTAFR 0.000158438 TRUE -1.353423693 -1.804724925 
MCMBP 0.000158533 TRUE -1.170769472 -1.159160244 
OAT 0.000160086 TRUE -1.285508001 -1.607076323 
JMJD6 0.000162102 TRUE -1.324361315 -1.151635456 
DIAPH1 0.000163211 TRUE -1.215219668 -1.250376819 
DCLRE1B 0.000166884 TRUE -1.36373508 -1.192861699 
CHML 0.000167976 TRUE -1.597081385 -1.279224973 
FAM21B 0.000168372 TRUE 1.146016411 1.155356286 
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CCNA2 0.000174051 TRUE -1.174797098 -1.091181929 
NKX1-2 0.000177005 TRUE -1.492677011 -1.335451615 
ZC3HAV1 0.000177802 TRUE -1.192226982 -1.286243346 
PRKCDBP 0.000179403 TRUE -1.664242664 -1.218909765 
LASP1 0.000181513 TRUE -1.252079602 -1.29549853 
KARS 0.00018201 TRUE -1.179188418 -1.088139507 
VLDLR 0.00018433 TRUE -1.582824968 -2.03474913 
SORL1 0.000184793 TRUE 1.229216004 1.45642516 
HEATR1 0.000185163 TRUE -1.17483543 -1.098202489 
TEAD4 0.000185529 TRUE -1.205489319 -1.200823774 
RALGAPA2 0.000186118 TRUE 1.244111383 1.37276222 
ABCC5 0.000186165 TRUE 1.633557517 1.347721622 
PRPF4 0.000186629 TRUE -1.260510032 -1.177526575 
ADAM9 0.000187849 TRUE -1.183954662 -1.092258817 
ATP11C 0.000188532 TRUE -1.343794796 -1.299415373 
FAM53A 0.000188586 TRUE -1.211837916 -1.331239224 
SLC30A6 0.000189679 TRUE -1.222344786 -1.119678722 
FOXN3 0.000189923 TRUE 1.281457321 1.303567232 
FZD6 0.000190746 TRUE 1.229515086 1.148164809 
ITGB6 0.000193008 TRUE -1.334627181 -1.340142473 
ARID3B 0.000194849 TRUE -1.376856696 -1.823429638 
ATP2C1 0.000197257 TRUE 1.272914338 1.193186263 
SYF2 0.000198774 TRUE 1.186657176 1.159074472 
LAMB1 0.000201107 TRUE -1.208656242 -1.520539289 
SKA3 0.000201989 TRUE -1.256462495 -1.269966115 
FAM84A 0.000207119 TRUE 1.320521161 1.22475819 
KLF5 0.000208562 TRUE 1.1617269 1.213677895 
RAB32 0.000209603 TRUE -1.479021293 -1.801964392 
TMEM30A 0.000210213 TRUE 1.263619983 1.113659747 
SAMD4A 0.000217179 TRUE -1.377379174 -1.128595584 
SPR 0.000217473 TRUE -1.184735714 -1.246897802 
PTBP1 0.000218831 TRUE -1.173585682 -1.137846803 
ERV3-1 0.000219413 TRUE 1.375311101 2.052480665 
C6orf165 0.000223184 TRUE 1.381043681 1.170540974 
MOCOS 0.000226977 TRUE -1.423209418 -1.21834116 
PALLD 0.000228332 TRUE -1.414526972 -1.222083655 
FAM63B 0.000230183 TRUE -1.284453124 -1.190846517 
SLC7A5 0.000230817 TRUE -1.248829373 -1.149629545 
TMEM179B 0.0002314 TRUE 1.260924525 1.172412358 
HAS3 0.000231477 TRUE -1.578672124 -1.302197181 
TCHH 0.00023262 TRUE 1.579845583 1.348696719 
RUSC2 0.000233435 TRUE -1.306457967 -1.437612054 
LHFP 0.00023378 TRUE -1.723069618 -1.220986856 
DOCK10 0.000234026 TRUE -1.296767806 -1.929596045 
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NAT10 0.000234149 TRUE -1.168857975 -1.103733029 
IMPDH1 0.000234618 TRUE -1.235753742 -1.368780499 
TBC1D3B 0.000237602 TRUE 1.264148035 1.212473727 
ATIC 0.00023766 TRUE -1.20604795 -1.13518368 
ACTN1 0.000238037 TRUE -1.210219655 -1.2533989 
UBLCP1 0.000239024 TRUE -1.253229939 -1.231617332 
NUDC 0.000239859 TRUE -1.276227195 -1.130574209 
EHD1 0.000241775 TRUE -1.236428606 -1.130977491 
UGGT1 0.000242424 TRUE -1.156504447 -1.122268492 
LOC100506642 0.000242446 TRUE 1.283913602 1.283086491 
GALNT5 0.000246347 TRUE -1.217249433 -1.163914074 
CENPO 0.000247984 TRUE -1.211149201 -1.186898785 
CUL7 0.000248577 TRUE 1.400573398 1.215672681 
RAD51 0.000251478 TRUE -1.43068189 -1.243320085 
MIR525 0.000252032 TRUE -1.266632404 -1.264326579 
FOXD1 0.000252063 TRUE -1.222640877 -1.332116549 
ESCO2 0.000253454 TRUE -1.269443153 -1.216026834 
TIPARP 0.000254503 TRUE -1.449674808 -1.27682851 
TCF25 0.000254555 TRUE 1.15803223 1.131243501 
WDR27 0.000254571 TRUE 1.250768761 1.283727916 
LRBA 0.000255492 TRUE 1.228653437 1.090909674 
TMEM205 0.000258499 TRUE 1.252828633 1.359534642 
QSOX1 0.000260581 TRUE -1.805719258 -1.307023989 
TIMP4 0.000261133 TRUE -1.404216098 -1.460939361 
PLAU 0.000263114 TRUE -1.647117974 -1.319414987 
KRT4 0.000263173 TRUE 2.00019907 7.953067935 
LIMK1 0.000264328 TRUE -1.428165077 -1.210252291 
SNORD59B 0.000265121 TRUE 1.510727321 1.232666676 
PPP1R3E 0.000265159 TRUE 1.152240112 1.134403823 
CDV3 0.00026529 TRUE -1.122606238 -1.115015548 
PTPN1 0.000265926 TRUE -1.158598226 -1.144637111 
PLEKHG1 0.000269287 TRUE 1.315911808 1.363640669 
TARS 0.000273428 TRUE -1.11458299 -1.098573674 
GALNTL4 0.000275503 TRUE -1.525054857 -1.207628203 
BCAT1 0.000276784 TRUE -1.283464515 -1.871113366 
TGFBRAP1 0.000277133 TRUE -1.237017388 -1.315893799 
RRP12 0.000277682 TRUE -1.438354478 -1.230514184 
FAM49B 0.000279676 TRUE -1.187853366 -1.397427958 
METTL7A 0.00027996 TRUE 2.169741035 1.335303208 
ZNF84 0.000280049 TRUE 1.344416222 1.364854842 
UBE2Q2P3 0.000281714 TRUE 1.315607567 1.185772599 
STIL 0.000283325 TRUE -1.209125943 -1.174571755 
OGT 0.000283938 TRUE 1.239065213 1.180666549 
PCDH1 0.000286697 TRUE -1.960020009 -1.355610088 
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FAM98A 0.000287065 TRUE -1.442439238 -1.156892608 
RNASEH2A 0.000290059 TRUE -1.207746271 -1.117177962 
ORC3 0.000291348 TRUE -1.194760527 -1.140101193 
RPL31 0.000293117 TRUE 1.25640145 1.145365005 
FOXO4 0.000293421 TRUE 1.557674534 1.250727071 
CTSS 0.000295009 TRUE 1.129789489 1.217655031 
PLXDC1 0.000298272 TRUE 1.141517911 1.139270165 
FLOT1 0.000300376 TRUE 1.100666417 1.088624747 
LOC100506935 0.000302553 TRUE 1.430678231 1.424488892 
ABCG2 0.000307053 TRUE -1.840993127 -6.595932251 
PLEKHM3 0.000310256 TRUE 1.283268195 1.227954822 
TRIP13 0.000310665 TRUE -1.353190978 -1.145040559 
CDC7 0.000310739 TRUE -1.10572237 -1.241761546 
SRI 0.000312296 TRUE 1.175916012 1.217541175 
ASNS 0.000312816 TRUE -1.149648453 -1.226739845 
ALS2CR8 0.00031319 TRUE 1.631122823 1.319786257 
JMY 0.000315048 TRUE 1.456572275 1.272182613 
ACER3 0.000316994 TRUE -1.551363012 -1.243252732 
DONSON 0.00031732 TRUE -1.22742729 -1.128293933 
PLCE1 0.000318331 TRUE 1.540953497 1.199927888 
MRP63 0.000320155 TRUE -1.174698757 -1.100974838 
HSPA4 0.00032145 TRUE -1.130127173 -1.146876655 
RAB7L1 0.0003233 TRUE -1.329652548 -1.192857565 
RPN1 0.000324194 TRUE -1.117483298 -1.085571681 
GLA 0.000324335 TRUE -1.549920116 -1.221684458 
ADAM8 0.000325857 TRUE -1.24321647 -1.227970694 
TXNL1 0.000325906 TRUE -1.14475063 -1.110377152 
DPYD 0.000328209 TRUE 1.975114736 1.29580529 
OAZ1 0.000328364 TRUE -1.121996324 -1.12764447 
SERPINH1 0.000329939 TRUE -1.2716395 -1.964693633 
ECH1 0.00033046 TRUE 1.199772041 1.140797118 
MRM1 0.000331348 TRUE -1.368464778 -1.160283049 
ZNF250 0.000331756 TRUE 1.165688967 1.094164499 
DLX5 0.000332635 TRUE 1.773681707 1.643323949 
IKZF2 0.00033363 TRUE 1.409508975 1.446120059 
ZNF22 0.000335975 TRUE -1.326502968 -1.298118361 
VPS13C 0.000339616 TRUE 1.335101102 1.187367721 
TMEM184C 0.000342295 TRUE -1.168528379 -1.137299011 
C2orf18 0.000345685 TRUE -1.279155646 -1.222216226 
RN5S402 0.00034665 TRUE -2.094243389 -1.82277049 
LOC100130476 0.00034892 TRUE -1.502695813 -1.503344309 
ARHGEF12 0.000349716 TRUE 1.147202384 1.076751774 
U2AF2 0.000350018 TRUE -1.184107597 -1.125368369 
DNM1P41 0.000352588 TRUE 1.483164879 1.275378048 
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DGKE 0.000353441 TRUE -1.260957911 -1.337517938 
GPRC5A 0.00035589 TRUE -1.311761982 -1.327476756 
NUP93 0.000356243 TRUE -1.271206327 -1.107937094 
PRMT5 0.00035667 TRUE -1.165549375 -1.168698641 
KRT18P49 0.000357895 TRUE -1.292834105 -1.605403809 
TES 0.000357904 TRUE -1.160941069 -1.110593195 
PMS2L2 0.000359986 TRUE 1.439119651 1.212335364 
PMS2P5 0.000359986 TRUE 1.439119651 1.212335364 
GSTA4 0.000361327 TRUE 1.590912499 1.274311438 
C6orf211 0.000364231 TRUE -1.17348653 -1.225366797 
AKT1S1 0.000364962 TRUE -1.1100692 -1.13104742 
CDK8 0.000365801 TRUE -1.228256127 -1.276149129 
DBT 0.000367342 TRUE 1.086812505 1.180747621 
CASK 0.000370181 TRUE 1.138163985 1.46202143 
NLN 0.000370875 TRUE -1.177901578 -1.146674214 
STK10 0.000371016 TRUE -1.189543578 -1.618581834 
PGLYRP4 0.000373443 TRUE 1.435101296 2.226299786 
FAM101B 0.000374899 TRUE -2.277261896 -1.450537858 
RNF219 0.000378321 TRUE -1.147913364 -1.192659235 
MYBL2 0.000379107 TRUE -1.314265138 -1.173781215 
USP39 0.000379132 TRUE -1.080629468 -1.182676322 
SLC41A1 0.000380477 TRUE -1.199676563 -1.452884206 
PPT1 0.000380835 TRUE -1.093386609 -1.097100531 
GUSBP9 0.000383478 TRUE 1.521824158 1.326504944 
RNF19B 0.000384782 TRUE -1.371650258 -1.183815139 
MYO1B 0.000385759 TRUE -1.248379215 -1.648823193 
MIR3118-4 0.000386184 TRUE 1.498860631 1.256512862 
ARNTL2 0.00038825 TRUE -1.193232673 -1.522893129 
EBP 0.000391217 TRUE -1.263148341 -1.132080357 
NDST2 0.000392231 TRUE 1.254525871 1.201595683 
RPN2 0.000392231 TRUE -1.13038129 -1.05901345 
ERLIN1 0.000394002 TRUE -1.148578165 -1.164722288 
XPO5 0.000394361 TRUE -1.210434815 -1.117951235 
ISG15 0.000394798 TRUE -1.182644619 -1.264439744 
GINS2 0.000396571 TRUE -1.376554814 -1.141047609 
SH3BP4 0.000397478 TRUE -1.193214817 -1.579219229 
ABLIM1 0.000398989 TRUE 1.298356204 1.238585109 
RAD51C 0.000399977 TRUE -1.252490529 -1.288075293 
GLIPR1 0.000400231 TRUE -1.905034225 -1.248103139 
ARFGEF1 0.000400335 TRUE 1.252426728 1.106949583 
PERP 0.000410611 TRUE 1.214338733 1.167502082 
SLC25A44 0.000410707 TRUE -1.362905828 -1.25459698 
PIR-FIGF 0.000411148 TRUE 1.239320758 1.25333293 
SH2B2 0.000412761 TRUE 1.267326869 1.371170765 
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TMEM222 0.000418161 TRUE -1.132163406 -1.181137478 
MEA1 0.000420433 TRUE -1.19018474 -1.187661609 
QARS 0.000426096 TRUE 1.129330411 1.144844025 
RFC2 0.000426119 TRUE -1.21783339 -1.10985627 
HAUS2 0.000426211 TRUE -1.318649401 -1.170033909 
LOC647979 0.000427466 TRUE 1.240307358 1.247846774 
TIPIN 0.00042835 TRUE -1.219811799 -1.302642991 
HPRT1 0.000428437 TRUE -1.17903191 -1.196121536 
UTP15 0.000430994 TRUE -1.37843241 -1.245847317 
MUC16 0.000431455 TRUE 2.026128216 1.468663634 
LOC100506290 0.000432292 TRUE 1.670214782 1.554751672 
PSMD1 0.000434354 TRUE -1.394527668 -1.126170689 
TRIM2 0.000436444 TRUE 1.375156749 1.394340441 
SBF1P1 0.000437353 TRUE -1.214372994 -1.159817018 
ALOX12 0.000442432 TRUE -1.162794445 -1.240116603 
HK2 0.000450298 TRUE -1.550770824 -1.241913665 
MPP5 0.000451158 TRUE -1.116850495 -1.162400946 
RPAP3 0.000451444 TRUE -1.146979965 -1.216548346 
ZDHHC7 0.000453953 TRUE -1.106400032 -1.092583846 
ABCD3 0.000454202 TRUE -1.219134 -1.174268814 
PDLIM1 0.000454591 TRUE -1.095258272 -1.337934288 
MFAP5 0.000455964 TRUE -1.478819118 -3.139033811 
STS 0.000460998 TRUE -1.340771707 -1.265197302 
RARRES1 0.000461643 TRUE 1.226912609 1.465701522 
NOL10 0.000461765 TRUE -1.251842777 -1.101358409 
CDK4 0.000463178 TRUE -1.194554413 -1.087780014 
NT5E 0.000464717 TRUE -1.480174664 -2.337974947 
TGFA 0.000468305 TRUE -1.418222296 -1.313560883 
TMC7 0.00047177 TRUE -1.284458373 -1.907917739 
NCS1 0.000478377 TRUE -1.533531795 -1.251854445 
COL17A1 0.000479488 TRUE -1.430252434 -3.369209972 
SAT1 0.000480785 TRUE 1.398732593 1.21063313 
RANBP3 0.000482191 TRUE -1.198483587 -1.23327753 
MICA 0.000483363 TRUE -1.198544144 -1.651612814 
LENG8 0.000483747 TRUE 1.368191747 1.263895588 
MIR3676 0.000487013 TRUE -1.843221848 -1.323379118 
GOLGA8G 0.000490984 TRUE 1.202486305 1.178326662 
FAM129A 0.000492087 TRUE -1.303456156 -2.062373963 
STARD13 0.000492427 TRUE -1.221427498 -1.265248543 
GOT2 0.000493577 TRUE -1.187586043 -1.094510737 
SNAI2 0.000495325 TRUE -1.232970827 -1.452932665 
RHOF 0.000504387 TRUE -1.132011235 -1.406164656 
LMBRD1 0.000505787 TRUE 1.272861006 1.143712271 
ZNF117 0.000509494 TRUE 1.626818393 2.632758366 
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MIR604 0.00051253 TRUE 1.373334152 1.548266438 
ATP6V1B1 0.000513896 TRUE 1.345765004 1.678777376 
DSG3 0.000515293 TRUE 1.152599008 1.563168816 
DUSP11 0.00051542 TRUE -1.142985362 -1.161218734 
COTL1 0.000518556 TRUE -2.038697352 -1.250166583 
GLT8D2 0.000519097 TRUE -1.637172733 -1.333282501 
PXDC1 0.000521503 TRUE -1.544102236 -1.215308425 
R3HDM2 0.000522297 TRUE 1.448574992 1.20282285 
RNF115 0.000523985 TRUE -1.130255846 -1.201886197 
COL16A1 0.000526458 TRUE -1.13954184 -1.149237932 
C11orf92 0.000526987 TRUE 1.766385454 1.255404344 
LOC100507246 0.000527199 TRUE 1.081239626 1.114368834 
TPBG 0.000529801 TRUE -1.134853603 -1.128199138 
GJB3 0.000531072 TRUE -1.645448784 -1.300553429 
WDR54 0.000531552 TRUE -1.155332006 -1.173694769 
PDLIM7 0.000538951 TRUE -1.324166234 -1.327565362 
PSMB4 0.000541015 TRUE -1.20102979 -1.199348861 
AKR1C3 0.00054151 TRUE 1.52382786 1.760795703 
C3 0.00054209 TRUE 1.403875859 1.171946658 
CAV2 0.000544092 TRUE -1.196683459 -1.168171517 
RAPGEF1 0.000544619 TRUE -1.203831512 -1.383980847 
ECI2 0.000546006 TRUE -1.243921845 -1.197036583 
APEX2 0.000546729 TRUE -1.402186037 -1.203790916 
DDX27 0.000547319 TRUE -1.157790264 -1.133284579 
HAUS8 0.00054765 TRUE -1.32905615 -1.277787951 
POP1 0.000553031 TRUE -1.312847662 -1.132281077 
MRPL3 0.000556298 TRUE -1.204463552 -1.157523394 
GUSBP3 0.000559537 TRUE 1.499782294 1.459929138 
POC5 0.000564986 TRUE -1.358779735 -1.205240311 
GTF2I 0.000567686 TRUE 1.191963145 1.276633066 
MLL3 0.000570346 TRUE 1.276481595 1.224283141 
ADHFE1 0.000570583 TRUE 1.18943858 1.30070258 
CX3CL1 0.000573927 TRUE 1.392881848 2.146916292 
SRPK2 0.000574199 TRUE -1.104144483 -1.152969708 
GRAMD2 0.000574281 TRUE -1.298022503 -1.487095197 
ELF4 0.00058007 TRUE -1.417224458 -1.332432954 
CPA4 0.000582963 TRUE -1.452735428 -1.555289209 
SLFN11 0.000584503 TRUE -1.208243553 -1.675638131 
USP9X 0.000585833 TRUE 1.290694487 1.172403498 
TMOD3 0.000589855 TRUE -1.133693413 -1.210097482 
FHL3 0.000590076 TRUE -1.497665466 -1.291103098 
PFN1 0.000596219 TRUE -1.188416809 -1.178498982 
SEMA3C 0.00059906 TRUE -1.217572308 -1.841082541 
OXSR1 0.000599963 TRUE -1.081237746 -1.1748069 
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KIAA1524 0.000600491 TRUE -1.161790468 -1.211277624 
PMS1 0.000601916 TRUE -1.196767418 -1.161239175 
MATN2 0.000607162 TRUE -1.131501159 -1.314854132 
MFSD6 0.000612958 TRUE 1.154980046 1.123077081 
CENPI 0.000614203 TRUE -1.19362436 -1.341475072 
EPPK1 0.000614982 TRUE 1.357365752 1.550650431 
TACO1 0.000619082 TRUE -1.235714167 -1.126352335 
EFEMP1 0.000625158 TRUE -1.068481485 -1.242841909 
RBM28 0.000627341 TRUE -1.245365292 -1.176991541 
NUP205 0.000630118 TRUE -1.159102832 -1.085691289 
ADRM1 0.000631168 TRUE -1.254267956 -1.212769425 
VAV2 0.000635237 TRUE -1.247269079 -2.150572863 
NEIL3 0.000638708 TRUE -1.190166654 -1.132852287 
KIF3C 0.000641728 TRUE -1.270073417 -1.501714934 
GPR126 0.00064457 TRUE 1.172385976 1.538376925 
SMCR8 0.000646064 TRUE -1.194083482 -1.155493075 
DDAH1 0.00064659 TRUE -1.612827728 -1.290432962 
IFNAR2 0.000646843 TRUE -1.176321531 -1.176280562 
TTL 0.000647001 TRUE -1.390035739 -1.292778826 
FAM96B 0.000647143 TRUE -1.315690673 -1.164691432 
HIST1H1B 0.000649139 TRUE -1.238476216 -1.101216363 
TMPRSS11E 0.000652038 TRUE -1.575440077 -1.150112353 
PSMC4 0.000654542 TRUE -1.245044655 -1.13838766 
GSN 0.000662043 TRUE 1.43268062 1.300659931 
TRIM6-TRIM34 0.000667451 TRUE -1.302742315 -1.295112938 
TMEM168 0.00066816 TRUE 1.203686861 1.115470967 
SGCB 0.00066888 TRUE -1.299292514 -1.236033406 
GNPTAB 0.000670713 TRUE -1.262080244 -1.118202952 
CRIPAK 0.000674297 TRUE 1.147877381 1.419845249 
PTP4A1 0.000674702 TRUE -1.172085151 -1.271938886 
TSPAN6 0.000675882 TRUE 1.267655651 1.113359649 
PRIM1 0.000676564 TRUE -1.169707264 -1.185184813 
PZP 0.00067711 TRUE 1.135515437 1.144630519 
DEPDC1B 0.000677189 TRUE -1.220824114 -1.205779355 
PON2 0.000677898 TRUE 1.140415914 1.460477642 
SERPINB8 0.000683735 TRUE -1.572617062 -1.169322031 
SIDT1 0.00068595 TRUE 1.249483044 1.326082932 
FOXM1 0.000687367 TRUE -1.143699705 -1.186810517 
EMP3 0.000688038 TRUE -2.13164752 -1.533763012 
ACTN4 0.000690755 TRUE -1.108242299 -1.083746207 
RAMP1 0.000696378 TRUE -1.232846735 -1.636862421 
PARS2 0.000699299 TRUE -1.187451354 -1.281943012 
RPP30 0.000699974 TRUE -1.198628194 -1.13928284 
HDAC5 0.000703172 TRUE 1.265584926 1.686525798 
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SYMPK 0.000705142 TRUE -1.194820892 -1.105386936 
IPMK 0.000706133 TRUE 1.139967642 1.372578269 
IL27RA 0.000707473 TRUE -1.762852686 -1.364678351 
CYP2E1 0.000710732 TRUE -1.184018094 -1.254291737 
PCM1 0.000710742 TRUE 1.129808309 1.071666752 
IGFBP7 0.00071841 TRUE -1.201820747 -1.889165242 
RAD18 0.000718892 TRUE -1.202941018 -1.264784061 
OGFOD1 0.0007229 TRUE -1.399891803 -1.167897024 
ING4 0.00072356 TRUE 1.373876609 1.256140318 
BRCA2 0.00072591 TRUE -1.206593226 -1.288603607 
SDR42E1 0.000727985 TRUE -1.266016649 -1.276865668 
BNC1 0.000730132 TRUE -1.391265953 -1.804120297 
MRPS12 0.000734108 TRUE -1.282189999 -1.164266633 
TNFRSF4 0.000742016 TRUE 1.272879369 1.147809916 
UTP11L 0.000745753 TRUE -1.244012792 -1.158951889 
SBF2 0.000748578 TRUE 1.239079636 1.125902342 
DDX21 0.000754224 TRUE -1.187994768 -1.099063769 
LY6G6C 0.000757731 TRUE -1.14179877 -1.50388925 
CKS2 0.000758207 TRUE -1.206545999 -1.167190834 
SDAD1 0.000760505 TRUE -1.181120772 -1.120854822 
AGR2 0.000760828 TRUE 1.570548479 1.184839389 
SMYD2 0.000760963 TRUE -1.233490616 -1.322790227 
KCTD12 0.00076218 TRUE -1.305265428 -1.543834715 
ZNF12 0.000775308 TRUE 1.164404702 1.121825476 
MFAP2 0.000779268 TRUE 1.308821679 1.377890923 
NUAK2 0.000780394 TRUE -1.279698412 -2.015706524 
NUP107 0.000782383 TRUE -1.230140632 -1.14539431 
CMTM4 0.000784435 TRUE 1.190056553 1.124137908 
ABCG1 0.00078468 TRUE 1.319185818 1.319885066 
GPR39 0.000790115 TRUE -1.299924627 -1.776531126 
RALGPS1 0.000790922 TRUE 1.431086128 1.213487846 
INF2 0.00080018 TRUE -1.205505186 -1.294277323 
XPO6 0.000803822 TRUE -1.27585122 -1.204310554 
DDX47 0.000808368 TRUE -1.100556232 -1.16212792 
CDK19 0.000809867 TRUE 1.337778649 1.103699299 
PTGS2 0.000810904 TRUE 1.313527574 1.664072431 
SLC5A6 0.000823949 TRUE -1.350732224 -1.198367857 
CENPP 0.000825169 TRUE -1.16026611 -1.113769723 
WDR75 0.000829648 TRUE -1.138632674 -1.211119358 
COL4A2 0.000830712 TRUE -1.335384404 -1.134269488 
DTL 0.000831615 TRUE -1.175425313 -1.241206589 
OSBPL11 0.000834721 TRUE -1.091437979 -1.194842683 
MRPL11 0.000836706 TRUE -1.15753979 -1.17193492 
IL4R 0.000844586 TRUE -1.265541503 -1.358132448 
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ILF3 0.000844973 TRUE -1.121739257 -1.09659805 
TUBG1 0.000850654 TRUE -1.233498731 -1.176974014 
ABCC2 0.000851326 TRUE -1.190850677 -1.48445276 
HAT1 0.000853277 TRUE -1.116941957 -1.14741 
CKAP2L 0.000859114 TRUE -1.386751006 -1.110742856 
C10orf57 0.000874993 TRUE 1.183573898 1.321097418 
BDNF-AS 0.000879984 TRUE 1.243420102 1.121108378 
ARG2 0.000880077 TRUE -1.222868307 -1.258138711 
TTC27 0.000880758 TRUE -1.145647674 -1.231327079 
KLHL5 0.000881204 TRUE 1.106142661 1.38037741 
IL13RA1 0.000881814 TRUE -1.103225969 -1.152708679 
NSFL1C 0.000882103 TRUE -1.23124561 -1.126874773 
RQCD1 0.000884378 TRUE -1.153499595 -1.142083281 
RRM2 0.000888959 TRUE -1.200327209 -1.066997389 
EEF2 0.000891413 TRUE 1.056604702 1.061013909 
DUSP14 0.000895603 TRUE -1.210354566 -1.287170303 
ASAP2 0.000896129 TRUE -1.132627535 -1.397973834 
CD24 0.000904049 TRUE -1.218456986 -1.171777607 
GMPS 0.000904791 TRUE -1.120059474 -1.171919008 
SCARNA17 0.00090611 TRUE 1.469796093 1.67313633 
CXorf26 0.000910121 TRUE -1.364148411 -1.24963176 
EMC8 0.000910899 TRUE -1.275316153 -1.126519202 
PPP1R18 0.00091436 TRUE -1.211788233 -1.151363923 
NTN4 0.000914917 TRUE 1.473587882 1.122463003 
RN5S141 0.000915637 TRUE -1.621217205 -2.128259883 
FLJ38717 0.00091743 TRUE 1.575567637 1.298999224 
VPS13B 0.000921359 TRUE 1.24827577 1.144901959 
ARGLU1 0.000923889 TRUE 1.23818442 1.176963458 
CDH1 0.00092567 TRUE -1.091796841 -1.178500458 
PHTF1 0.000929853 TRUE -1.293587747 -1.191933219 
PTGS1 0.000932815 TRUE -2.352679179 -1.292299307 
C1orf116 0.000932931 TRUE -1.445451554 -1.167236979 
PARP4 0.000933158 TRUE 1.091828536 1.153117476 
CYLD 0.000935093 TRUE 1.130257723 1.384883899 
AAED1 0.00093778 TRUE -1.48094638 -1.255276215 
PLEKHA7 0.000938517 TRUE 1.096132261 1.255650101 
ZCCHC10 0.000938548 TRUE -1.205033556 -1.244907763 
ZNF608 0.000939121 TRUE 1.234019542 1.770837086 
SFN 0.000939983 TRUE -1.609135183 -1.163326399 
GUSBP2 0.000941458 TRUE 1.398116632 1.681486061 
POLA1 0.000947849 TRUE -1.13507446 -1.228171987 
CACYBP 0.000948221 TRUE -1.18556201 -1.157731116 
EPHA1 0.000950274 TRUE -1.19533359 -1.166914062 
ACAD10 0.000950563 TRUE 1.386545331 1.225719954 
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ICMT 0.000952607 TRUE -1.162943999 -1.077875997 
ABLIM3 0.00095293 TRUE -1.234230909 -1.956271505 
RMND5A 0.000957436 TRUE 1.110575416 1.244916254 
FLJ42969 0.000959406 TRUE -1.260569561 -1.137984484 
SYNE2 0.000959855 TRUE 1.78113032 1.210340979 
SYK 0.000964668 TRUE -1.177421271 -1.471814497 
RRM1 0.000972796 TRUE -1.076512083 -1.112546198 
POMGNT1 0.000973227 TRUE -1.140911679 -1.42278981 
SLC25A30 0.000974159 TRUE -1.447048358 -1.250804223 
SEMA3A 0.000975056 TRUE -1.882510187 -1.199523659 
POLR2J4 0.000980301 TRUE 1.479629678 1.358347929 
SNORD89 0.00098063 TRUE 1.318861215 1.140530145 
PHF10 0.000981202 TRUE 1.167819638 1.37985371 
EMP1 0.00098153 TRUE -1.171674389 -1.113216819 
GPNMB 0.000981954 TRUE 1.48014167 1.309320424 
CTNNAL1 0.0009852 TRUE -2.1214858 -24.8561035 
MTHFD1 0.000987164 TRUE -1.076583605 -1.138626508 
NYNRIN 0.000994242 TRUE 1.536353114 1.236500873 
LOC100506394 0.000994914 TRUE -1.329984927 -1.288546039 
UBE2I 0.000994964 TRUE -1.130555975 -1.097049356 
ZNF142 0.000996292 TRUE -1.113324395 -1.15118056 
TNFAIP1 0.00100187 TRUE -1.248208544 -1.201887735 
PLEKHJ1 0.001002547 TRUE -1.283739269 -1.092581987 
OGFRL1 0.001008465 TRUE 1.199222376 1.105500785 
MEIS1 0.001020179 TRUE 1.368418649 1.179074824 
APBB2 0.001027845 TRUE -1.293902126 -1.578561538 
ALDH3B2 0.001033554 TRUE 1.704218782 1.271750792 
CALCOCO1 0.001034386 TRUE 1.260380629 1.437899244 
SERINC5 0.001035734 TRUE 1.178625735 1.468007583 
XRN1 0.001038287 TRUE 1.116664415 1.08812908 
MCOLN2 0.001040274 TRUE -1.173969397 -1.146565398 
ZNHIT6 0.001040426 TRUE -1.198937576 -1.285648331 
KIF20B 0.001042811 TRUE -1.133560114 -1.109959442 
10-Sep 0.001047817 TRUE 1.196196205 1.11100309 
PDPN 0.001053677 TRUE -1.265802281 -1.494904294 
DEGS1 0.001065155 TRUE -1.286993708 -1.205410308 
NOTCH3 0.001065657 TRUE 1.370106227 1.710864492 
KRT80 0.001067682 TRUE -2.492491213 -1.287124069 
COBL 0.001070467 TRUE -1.264742265 -1.156731987 
PSME3 0.001071623 TRUE -1.152352813 -1.180757177 
C12orf52 0.0010766 TRUE -1.216881728 -1.207517135 
NBPF9 0.001079741 TRUE 1.403796627 1.202039762 
MIR554 0.001080725 TRUE 1.362702231 1.597081576 
CLMP 0.001080808 TRUE -2.253807061 -1.321050289 
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GRB2 0.001103725 TRUE -1.146271929 -1.167525031 
LONP2 0.001107504 TRUE 1.450078588 1.41392497 
LRP12 0.001111252 TRUE -1.477680992 -1.228810374 
UBE2Q2 0.001114725 TRUE -1.180200009 -1.185070249 
NUP153 0.001114848 TRUE -1.277902877 -1.18501199 
HCCS 0.001115016 TRUE -1.205638121 -1.172626097 
RRP36 0.001118257 TRUE -1.224368754 -1.101229487 
TCP11L2 0.001120543 TRUE 1.276431961 2.70759893 
RMI1 0.001121308 TRUE -1.138795518 -1.245052125 
PRNP 0.001123621 TRUE -1.169093629 -1.247101301 
ESRP1 0.001128 TRUE 1.087027442 1.10706682 
EIF3L 0.001129478 TRUE 1.167946855 1.068528314 
NUDCD1 0.00113594 TRUE -1.337414797 -1.194440988 
HNRNPF 0.001137028 TRUE -1.109532511 -1.127922669 
CCDC41 0.001145757 TRUE -1.19969162 -1.160625013 
LYAR 0.001148631 TRUE -1.655435064 -1.222563388 
ANXA7 0.001151527 TRUE -1.101708845 -1.101959531 
ISG20L2 0.00115211 TRUE -1.371536389 -1.123069287 
HIF1A 0.001153776 TRUE 1.155249778 1.086477386 
FSCN1 0.001162646 TRUE -1.453754223 -1.191782033 
TBC1D3H 0.001163475 TRUE 1.14149564 1.316820649 
DUOX1 0.001166187 TRUE 1.230226047 1.271301736 
CXorf1 0.001166442 TRUE -1.222916324 -1.222808101 
DCTPP1 0.001169036 TRUE -1.314334006 -1.122237651 
TMEM123 0.001169914 TRUE 1.198501196 1.218780078 
RNF41 0.00117257 TRUE -1.189564188 -1.12559562 
TOR1A 0.001178727 TRUE -1.173399842 -1.125277622 
ITPRIPL2 0.001181298 TRUE 1.160803361 1.196214415 
EDEM2 0.001184432 TRUE 1.305955459 1.27038979 
MYO5A 0.001185833 TRUE -1.1382975 -1.390018502 
XGPY2 0.001186003 TRUE -1.253044767 -1.444222901 
SLC39A11 0.001187415 TRUE 1.326893172 1.178954266 
GSTA1 0.001190598 TRUE 2.046465982 1.328055528 
MIR21 0.001191982 TRUE 1.402867727 1.71199778 
CCT4 0.001201646 TRUE -1.223712629 -1.078968048 
AUP1 0.001204002 TRUE -1.159905891 -1.05730467 
TIMP3 0.001204042 TRUE -1.535393281 -1.407362715 
SPDYE1 0.001205404 TRUE 1.37727744 1.151626391 
CD276 0.001209768 TRUE -1.133457612 -1.389832655 
PXMP4 0.001211502 TRUE 1.184284753 1.502300451 
ZW10 0.001213644 TRUE -1.330751406 -1.118262471 
GTF2F1 0.001215589 TRUE -1.128889767 -1.085278368 
F2RL1 0.001218105 TRUE 1.14258099 1.232083625 
PCGF3 0.001222003 TRUE -1.07418608 -1.144362927 
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PLCD3 0.00122295 TRUE -1.223228996 -1.542141136 
SPATS2 0.00122521 TRUE -1.269512824 -1.210292566 
IL36RN 0.001227352 TRUE -1.519358394 -1.32328596 
FAM65A 0.001227516 TRUE -1.180200472 -1.48176942 
RAPGEF5 0.001229062 TRUE 1.593934756 1.187385291 
LOC100130171 0.001245601 TRUE -1.579934549 -1.276187074 
GAD1 0.001246999 TRUE 1.226049648 1.219059775 
NFKBIZ 0.001254104 TRUE 1.340959627 1.124132784 
PSMB2 0.001257414 TRUE -1.235256785 -1.069332385 
IKBKAP 0.001262905 TRUE -1.111470244 -1.148359671 
RNU12 0.001269223 TRUE -1.255494977 -1.375663431 
VANGL1 0.001269286 TRUE -1.204117527 -1.073931496 
ITGA1 0.001269749 TRUE -1.251228127 -1.333835705 
PDSS1 0.001270522 TRUE -1.261479372 -1.303877898 
ST6GALNAC1 0.00127404 TRUE 1.293984271 2.574589481 
CDH13 0.001276195 TRUE -1.614135001 -1.446680393 
NOC4L 0.001277621 TRUE -1.306206527 -1.1995611 
NSDHL 0.001281565 TRUE -1.187281305 -1.234055201 
SH3D19 0.001286112 TRUE -1.117426667 -1.295806422 
BCL11A 0.00129014 TRUE 1.477987883 1.174073775 
CCL22 0.001290235 TRUE 1.133301254 1.339513612 
CWC22 0.001296268 TRUE -1.169882832 -1.108304725 
NUP188 0.001302387 TRUE -1.174814169 -1.097677622 
CNTNAP3B 0.001303376 TRUE 1.314725495 1.327010122 
CDK2 0.001308565 TRUE -1.178840228 -1.093650308 
FJX1 0.001309318 TRUE -1.699628722 -1.240860842 
TP53 0.001329223 TRUE 1.161568959 1.38633366 
ERBB3 0.001333768 TRUE 1.203510441 1.109930721 
PTPLA 0.00133508 TRUE -1.183297545 -1.506405162 
CHAF1B 0.001335356 TRUE -1.434941192 -1.151303398 
DHRS3 0.001337919 TRUE 1.190412238 1.98806535 
SLC46A3 0.0013397 TRUE 1.319384912 1.710798254 
NAA15 0.001340886 TRUE -1.228657283 -1.094936649 
SSBP2 0.001345234 TRUE 1.789325193 1.186165227 
PHF19 0.001347785 TRUE -1.254595002 -1.185347131 
AVPI1 0.00134918 TRUE -1.266114165 -1.064712166 
TM7SF2 0.001350825 TRUE 1.365953495 1.141461865 
ABCF2 0.001351503 TRUE -1.206556532 -1.08445368 
RERE 0.001354473 TRUE 1.156347965 1.130032467 
BUB1B 0.001355748 TRUE -1.093631037 -1.089008767 
GRB14 0.001359199 TRUE -1.232016477 -1.317410636 
FADS2 0.00135952 TRUE -1.197218216 -1.286840355 
ABCB7 0.001361836 TRUE 1.137172633 1.171729623 
ITGB8 0.001381044 TRUE 1.218925139 1.114313148 
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CEL 0.001388198 TRUE 1.340804126 1.372356893 
GJB2 0.001392775 TRUE -1.550273551 -1.186006894 
TNFRSF12A 0.001396515 TRUE -2.341633739 -1.233750779 
HSPA8 0.001404473 TRUE -1.166754211 -1.11439866 
DBF4B 0.001404895 TRUE -1.232766185 -1.101196728 
FPGS 0.001405808 TRUE -1.208388841 -1.142723125 
TAF3 0.001407922 TRUE -1.202313036 -1.135742577 
DPP3 0.00141076 TRUE -1.092294726 -1.216525353 
SENP5 0.001414698 TRUE -1.096285358 -1.1546162 
TGFBR2 0.001417222 TRUE -1.183852733 -1.123351494 
ZNFX1 0.001418503 TRUE -1.112638278 -1.150952746 
TIMM50 0.001421477 TRUE -1.31894106 -1.091943231 
C19orf33 0.00143348 TRUE -1.342742384 -1.143809224 
IFNGR1 0.001436703 TRUE 1.226814535 1.498257433 
TMPRSS11A 0.001444316 TRUE 1.466246047 1.273259802 
CCDC86 0.001446269 TRUE -1.311432264 -1.122974073 
RPF1 0.001450566 TRUE -1.133087226 -1.161898333 
MB21D1 0.001451706 TRUE -1.339010707 -1.241961728 
MBOAT7 0.001452158 TRUE -1.269807925 -1.277562324 
NAB1 0.001460516 TRUE 1.185582643 1.28151164 
FAM46B 0.001472671 TRUE -1.414795759 -1.649355142 
AMD1 0.001476467 TRUE -1.251899882 -1.214332406 
TUFT1 0.001477703 TRUE 1.140963355 1.137466277 
KIAA1109 0.001481974 TRUE 1.245692252 1.092931675 
GLTPD1 0.001486466 TRUE -1.177801124 -1.21321892 
GABPB1 0.001487898 TRUE -1.216401676 -1.140353284 
DUOXA1 0.001489659 TRUE 1.151324789 1.156810917 
LYRM1 0.001497446 TRUE -1.269402804 -1.418898328 
FTSJ3 0.001498784 TRUE -1.20521071 -1.169594844 
IL20RB 0.001503662 TRUE -1.184112697 -1.762295872 
RAPGEFL1 0.001508814 TRUE 1.237370564 1.586575314 
MSN 0.001522687 TRUE -1.23313557 -1.419859376 
TUBA1B 0.001527054 TRUE -1.505878133 -1.309378629 
ILK 0.001527135 TRUE -1.336420855 -1.091769677 
MFSD4 0.001534739 TRUE 1.643016039 1.231230696 
SSX2IP 0.001534995 TRUE -1.207673933 -1.346228866 
E2F8 0.00154308 TRUE -1.262078211 -1.161808004 
PHLDA1 0.001544646 TRUE -1.2224323 -1.138535969 
RAB38 0.001547491 TRUE -1.280250989 -1.140434634 
FTSJ1 0.001548145 TRUE -1.317200679 -1.097254255 
CHMP1B 0.001551715 TRUE 1.111469325 1.240296725 
SCARNA9 0.001560804 TRUE 2.159395854 1.530425976 
ATG16L1 0.001561655 TRUE -1.103690792 -1.23444781 
AIM2 0.001562325 TRUE -1.176411052 -1.633801341 
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UBL4B 0.001564197 TRUE 1.100648817 1.159740464 
DHX37 0.001564566 TRUE -1.34013498 -1.179388567 
FLJ14186 0.001564729 TRUE 1.80047719 1.317123866 
C1RL 0.001566619 TRUE 1.381145527 1.147127438 
GPX2 0.001572546 TRUE 1.287491544 1.146209418 
TM4SF1 0.001579043 TRUE 1.327555262 1.469193589 
ZC3H6 0.001586275 TRUE 1.323810527 1.369627583 
NKX3-1 0.001594272 TRUE -1.421848291 -1.099355435 
TRAM2 0.001595858 TRUE -1.235538085 -2.701319124 
ZBTB2 0.001600866 TRUE -1.274403875 -1.280707866 
POMP 0.001601396 TRUE -1.292431582 -1.115094405 
GSPT1 0.001606404 TRUE -1.223006456 -1.077711489 
HIST1H2BC 0.001608078 TRUE -1.255272041 -1.287529045 
ECD 0.001608965 TRUE -1.172017589 -1.127102234 
PHF15 0.001610779 TRUE -1.288074551 -1.195964193 
PCNT 0.001611838 TRUE 1.115459949 1.1496592 
NUFIP1 0.001619404 TRUE -1.220619176 -1.265636262 
PSMA2 0.00162153 TRUE -1.28741315 -1.116562835 
SNRPD2 0.001623559 TRUE -1.189800056 -1.07051603 
MTUS1 0.001634375 TRUE 1.249070825 1.219192877 
ECHDC2 0.001635451 TRUE 1.179462392 1.359621033 
CHD3 0.001638785 TRUE 1.458033792 1.102622393 
PPP3CA 0.001639156 TRUE -1.10324315 -1.101903138 
SEPW1 0.001640865 TRUE -1.519620583 -1.1050454 
SMG1P1 0.001642851 TRUE 1.378948163 1.284892531 
CAMLG 0.001643155 TRUE 1.162277848 1.186139956 
ABCE1 0.001645522 TRUE -1.276707136 -1.170774229 
TRIM24 0.0016482 TRUE 1.184551446 1.287662421 
MXRA5 0.001651249 TRUE -2.155046346 -1.212587055 
LYRM4 0.0016521 TRUE -1.191505186 -1.255715303 
THRA 0.001656766 TRUE 1.179557849 1.38595627 
TMEM141 0.001659966 TRUE 1.226407223 1.129469963 
PSMB9 0.001660134 TRUE -1.104367265 -1.362472407 
CASP2 0.001663229 TRUE -1.199424619 -1.189035551 
GTF3C1 0.001664223 TRUE -1.166259268 -1.074307839 
NRG1 0.001664435 TRUE -1.746382495 -1.203422955 
ACAA2 0.001679736 TRUE 1.122078567 1.511711127 
HEXB 0.001680107 TRUE -1.127682645 -1.229744367 
CBFA2T2 0.00168061 TRUE 1.475096054 1.115874886 
HIST1H3J 0.001682296 TRUE -1.333463136 -1.177663691 
SF3B4 0.001685292 TRUE -1.207630189 -1.329891045 
MRTO4 0.00169116 TRUE -1.363927364 -1.185285641 
TRIM32 0.001691549 TRUE -1.196023348 -1.257436376 
TMED4 0.001694386 TRUE 1.102334908 1.158585429 
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GOLGA6L9 0.001694958 TRUE 1.475971347 1.179278772 
CSTF2 0.001696428 TRUE -1.451104436 -1.162140154 
MCM2 0.001697398 TRUE -1.171806758 -1.187694795 
RFC1 0.001699054 TRUE -1.143029942 -1.105130838 
TANC2 0.001703977 TRUE -1.307225034 -1.197072427 
TBC1D3F 0.001704152 TRUE 1.17226144 1.243354088 
SS18 0.001705882 TRUE -1.072729504 -1.076871499 
BACE1-AS 0.001711884 TRUE 1.381616901 1.245603539 
LOC100506178 0.001714927 TRUE -1.165856211 -1.367922067 
KLF11 0.001726258 TRUE -1.454282236 -1.17097328 
DDR1 0.001727243 TRUE 1.10983549 1.244166998 
SEZ6L2 0.00173243 TRUE 1.137640807 1.131144143 
CAMK1D 0.001733158 TRUE 1.490012241 1.198314832 
VPS13A 0.001737815 TRUE 1.280915662 1.199477 
LPIN2 0.001740617 TRUE -1.194713542 -1.592150915 
RICTOR 0.001742831 TRUE 1.126294017 1.084626589 
ASUN 0.001743114 TRUE -1.210143274 -1.095927995 
POLR2J2 0.001744418 TRUE 1.168729181 1.51187421 
DDX18 0.00174642 TRUE -1.180665036 -1.083950627 
NAIP 0.001754661 TRUE 1.519860443 1.263967574 
MAK16 0.001780911 TRUE -1.332179163 -1.145527748 
RBM22 0.001782112 TRUE -1.114030193 -1.177584253 
BCAR1 0.001785618 TRUE -1.252161402 -1.494904572 
ARSI 0.001787443 TRUE -1.971970524 -1.26329965 
YDJC 0.001791405 TRUE -1.233558229 -1.126383896 
HERC6 0.001794875 TRUE -1.214584305 -1.293875966 
RPF2 0.001803664 TRUE -1.229345839 -1.105119582 
FAM19A3 0.001806276 TRUE -1.507746138 -1.230062895 
ECM2 0.001808656 TRUE -1.317618682 -1.207004547 
CENPL 0.001816082 TRUE -1.283186906 -1.281818182 
NGF 0.001819218 TRUE -1.857263836 -1.189445563 
FAM168A 0.001832311 TRUE 1.409268783 1.142975315 
PIGW 0.00183746 TRUE -1.23160181 -1.285592524 
ENTPD6 0.001838015 TRUE -1.095562629 -1.139383141 
DEFB109P1 0.001842684 TRUE -1.166430883 -1.101038234 
CD59 0.001855089 TRUE 1.206591282 1.160892118 
SELT 0.001860183 TRUE -1.183195816 -1.073168366 
SRD5A3 0.001861031 TRUE 1.087791906 1.349127008 
CDY2A 0.001863158 TRUE -1.509110178 -1.386819522 
HLA-DRA 0.001875278 TRUE 3.392956715 1.502073608 
RAB31 0.00187611 TRUE -1.123412358 -1.117950864 
MGAT2 0.001877608 TRUE -1.163717111 -1.138087572 
NR2C2AP 0.001878535 TRUE -1.273546491 -1.288206742 
REL 0.001879293 TRUE 1.122486639 1.247730276 
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FTH1 0.001887898 TRUE 1.515797787 1.183563924 
AMIGO2 0.0018889 TRUE -1.370059748 -2.654541156 
PDGFB 0.001895263 TRUE -1.30514377 -1.145577838 
PCYT1B 0.001895392 TRUE -1.687008186 -1.319150183 
KIF13B 0.001904202 TRUE 1.154246125 1.275083274 
IL6ST 0.001909535 TRUE -1.097519898 -1.49688535 
PHLDB2 0.001912044 TRUE -1.52103877 -1.187214728 
TTI2 0.001915738 TRUE -1.192488871 -1.150062302 
LOC100505769 0.001920731 TRUE 1.216849037 1.793648665 
LOC554223 0.001928648 TRUE -1.244880047 -1.104705254 
ACSL4 0.001932316 TRUE -1.196418266 -1.566722851 
DENND4A 0.001937241 TRUE 1.22788202 1.074825569 
MED12 0.001940255 TRUE 1.175610128 1.189952731 
LOC440434 0.001944679 TRUE 1.417685291 1.538107228 
CHTF8 0.001944822 TRUE -1.159554928 -1.10619544 
ITPR2 0.001947595 TRUE -1.267331222 -1.201172766 
NXT1 0.001948121 TRUE -1.3153281 -1.268249653 
EIF4E3 0.001950195 TRUE 1.24483531 1.354018173 
SLC44A1 0.001953701 TRUE 1.091772711 1.40607191 
LANCL1 0.00196403 TRUE 1.126603435 1.24952106 
GTF2H1 0.001967902 TRUE -1.077663498 -1.165380412 
C12orf59 0.001973807 TRUE -4.462578882 -1.351332975 
CREB3L2 0.00199343 TRUE 1.177117834 1.340860052 
ZWINT 0.001995665 TRUE -1.079439671 -1.158654893 
AP2S1 0.001996914 TRUE -1.215380118 -1.105028331 
SPIRE2 0.001998905 TRUE 1.179102772 1.342107252 
RBBP9 0.002000119 TRUE -1.146073802 -1.196902189 
FARSB 0.002003137 TRUE -1.205994364 -1.100465177 
GOT1 0.002005937 TRUE -1.128530028 -1.198985205 
RPUSD1 0.00201212 TRUE -1.333890094 -1.23427085 
BCAS1 0.002016284 TRUE 1.21686995 2.281925522 
THRB 0.002017064 TRUE 1.28056743 1.137884719 
STRN3 0.002021722 TRUE -1.086980717 -1.264304572 
SAMD7 0.002024152 TRUE -1.146964707 -1.194701411 
NRAS 0.002025715 TRUE -1.155318164 -1.066594519 
C10orf47 0.002026082 TRUE -1.183113047 -1.277951478 
WDR12 0.002029242 TRUE -1.166794406 -1.093704268 
BOK 0.002033838 TRUE -1.245632077 -1.183243098 
CEP76 0.002038679 TRUE -1.176622723 -1.173187332 
MARVELD2 0.002038922 TRUE -1.310658671 -1.147250866 
LOC344887 0.002041176 TRUE 1.496098538 1.173339399 
FAM222A 0.002044775 TRUE -1.167014202 -1.207788541 
SCARNA9L 0.00205073 TRUE 1.217027797 1.320618211 
ZNF750 0.002051615 TRUE 1.254607421 1.563344097 
 235 
DNAJC11 0.002052131 TRUE -1.142415932 -1.138009672 
DHX9 0.00205335 TRUE -1.067735008 -1.155838053 
PGAM1 0.00205944 TRUE -1.402702428 -1.145015809 
RAD23B 0.00206069 TRUE -1.052766468 -1.144559637 
CDK5RAP3 0.002062668 TRUE 1.158793292 1.127149198 
C6orf48 0.002064983 TRUE 1.349574988 1.115607203 
BDKRB2 0.002070944 TRUE -1.839552791 -1.168585584 
IL6R 0.002073781 TRUE -1.613502897 -1.631757591 
SPAG16 0.00207774 TRUE 1.15167729 1.49652797 
HIST1H3I 0.002085524 TRUE -1.101093387 -1.040258483 
ANKHD1-
EIF4EBP3 
0.002086012 TRUE 1.169884293 1.058190366 
MUT 0.002094237 TRUE 1.117245853 1.178885859 
GCNT4 0.002100862 TRUE -1.361015306 -1.463133484 
PHF5A 0.002101862 TRUE -1.329219151 -1.128645948 
ZNF846 0.002101903 TRUE 1.302815936 1.09906791 
DNA2 0.002110724 TRUE -1.10717826 -1.243066418 
NOC3L 0.002122419 TRUE -1.344916592 -1.255595288 
SGK196 0.002124806 TRUE -1.143762307 -1.055077789 
KCNN4 0.00212935 TRUE -1.165088533 -1.470899749 
MBOAT2 0.002130308 TRUE -1.527001782 -1.099922551 
CCDC127 0.002130445 TRUE 1.102536654 1.265324461 
GIPC1 0.002132464 TRUE -1.265939656 -1.100917231 
NRG4 0.002144277 TRUE -1.806812138 -1.229129855 
SLC46A1 0.002145612 TRUE -1.234678001 -2.055444891 
HMOX2 0.002149694 TRUE -1.209511061 -1.245151881 
TNFRSF9 0.002151461 TRUE -3.696606898 -1.348722585 
FAM203A 0.002158012 TRUE -1.134403819 -1.076893547 
BCL7B 0.002184737 TRUE -1.313308379 -1.087795697 
MRPL18 0.002191749 TRUE -1.198455694 -1.15546227 
DICER1 0.002194187 TRUE 1.087241442 1.056457945 
DDX60 0.002199101 TRUE -1.249212937 -1.121971114 
LOC100499467 0.002201694 TRUE 1.19716327 2.258450783 
CYP4F3 0.002215465 TRUE 1.377293367 2.068479422 
DCDC1 0.002218499 TRUE 1.552188768 1.239102932 
CDR2 0.002221049 TRUE -1.624659354 -1.122050251 
AGFG1 0.002221564 TRUE -1.185567425 -1.090608332 
CAMSAP2 0.002223147 TRUE -1.063866289 -1.110574929 
DDX52 0.00222489 TRUE -1.197720554 -1.087266256 
MAMLD1 0.002232412 TRUE -1.118988164 -1.311351969 
PDIA5 0.00224384 TRUE -1.226478628 -1.195226001 
PFKP 0.002244232 TRUE -1.134523211 -1.209129111 
KIF18A 0.002245181 TRUE -1.085760013 -1.17937557 
IFT57 0.002245986 TRUE -1.192021015 -1.170468386 
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SART1 0.002249354 TRUE -1.078145098 -1.103160366 
RN5S104 0.002254274 TRUE -1.118190375 -1.124513105 
IGFBP6 0.002255934 TRUE -2.151902836 -1.14926457 
NBPF24 0.002257625 TRUE 1.40727203 1.181699558 
ITGA11 0.002263489 TRUE 1.129921048 1.191949199 
ZFP42 0.002265391 TRUE -1.144515741 -1.401934812 
PRKAR1B 0.002265725 TRUE -1.297097788 -1.251690115 
LMNB2 0.002266644 TRUE -1.145498067 -1.122192012 
SOX21-AS1 0.002272671 TRUE 1.516658148 1.161536697 
GMNN 0.002277658 TRUE -1.394830351 -1.2178873 
LOC100506258 0.002281291 TRUE 1.124551789 1.217540745 
GPRC5B 0.002291121 TRUE -1.48442547 -1.15520556 
FZD2 0.002291203 TRUE -1.173954957 -1.983459379 
AMOTL2 0.002291759 TRUE -1.31322146 -1.129505047 
CDCA5 0.002292976 TRUE -1.139114704 -1.27207661 
HK1 0.002308038 TRUE 1.104431342 1.112554287 
KLK5 0.002310367 TRUE -3.44621433 -1.269083517 
PPAT 0.002310672 TRUE -1.210088781 -1.179118187 
CRNDE 0.002312384 TRUE 1.339592474 1.436760647 
ZNF238 0.002312966 TRUE 1.126829959 1.363241735 
CELA1 0.0023271 TRUE 1.241493414 1.099401734 
ARHGEF3 0.002338956 TRUE -1.405865502 -1.109517764 
UTRN 0.00234781 TRUE 1.143030417 1.192591832 
PSMB7 0.002356647 TRUE -1.215839245 -1.180231502 
CLCF1 0.002366559 TRUE -1.387492113 -1.211882572 
MAP3K14 0.002369572 TRUE -1.20011968 -1.252290466 
GYS1 0.002373173 TRUE -1.407726583 -1.201935672 
SCARA3 0.002380121 TRUE -1.161514245 -1.490131153 
GET4 0.002382259 TRUE -1.089864812 -1.119664475 
GIT1 0.002383078 TRUE -1.147907731 -1.16428397 
ZMYM2-IT1 0.002383632 TRUE 1.382656396 1.516026909 
ARMCX5-
GPRASP2 
0.002389738 TRUE -1.170102188 -1.221563328 
ERP27 0.002390417 TRUE -1.340553883 -1.619644007 
ATAD2 0.002390747 TRUE -1.100247633 -1.116193715 
DDX24 0.002390752 TRUE -1.13489437 -1.122124321 
GCNT2 0.002392403 TRUE 1.203843067 1.186978527 
PPIP5K1 0.002412119 TRUE 1.201660985 1.100468453 
CHMP7 0.00242197 TRUE -1.108268488 -1.17284439 
TPD52L2 0.002430858 TRUE -1.362425014 -1.079315593 
SLC25A19 0.002431575 TRUE -1.642664601 -1.162905665 
TSTD1 0.002431678 TRUE 1.177143875 1.188517442 
DBN1 0.002433027 TRUE -1.1149707 -1.402299193 
FAM111B 0.002433605 TRUE -1.170432276 -1.203789251 
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PAICS 0.002437675 TRUE -1.267139331 -1.069742931 
CDIPT 0.002437713 TRUE 1.199036694 1.125028368 
NRARP 0.00245383 TRUE 1.176614385 2.57566935 
PLS3 0.002463006 TRUE -1.10673588 -1.102785943 
CIRBP 0.002465042 TRUE 1.345853159 1.148189191 
DDX60L 0.002466361 TRUE -1.116488356 -1.649649911 
ARPP19 0.00246997 TRUE -1.082051199 -1.092981974 
FBN2 0.002475414 TRUE -1.920316276 -1.193015985 
TNKS 0.002485846 TRUE 1.765935041 1.413357389 
LRRC37A2 0.002487235 TRUE 1.370565188 1.169556702 
ALDH1L1 0.002496596 TRUE 1.138416575 1.201907399 
FAR2 0.002498042 TRUE -1.419959775 -1.152290665 
FZD10 0.002504277 TRUE 1.206910044 1.349591423 
LOC728606 0.002517025 TRUE -1.22416332 -1.175778607 
NABP2 0.002517175 TRUE -1.383018175 -1.131442787 
NPIPL3 0.00252144 TRUE 1.395706503 1.270364901 
RNF168 0.002523641 TRUE 1.114028918 1.070066232 
KISS1 0.00252521 TRUE -1.170128188 -2.49035286 
MON2 0.002526281 TRUE 1.148741317 1.181160259 
SPHK1 0.00252676 TRUE -1.206943679 -1.145342787 
SCAPER 0.002538495 TRUE 1.246713199 1.209605425 
VGLL1 0.002539538 TRUE -1.855396271 -1.15455075 
TSPAN31 0.002547524 TRUE 1.399464065 1.139060721 
LOC257396 0.002549042 TRUE -1.233191072 -1.164321232 
CELSR2 0.002564932 TRUE 1.098233224 1.510270021 
CD27-AS1 0.002569054 TRUE 1.192694228 1.22525111 
MYO5B 0.002570386 TRUE 1.217441455 1.302003298 
TAP2 0.002572939 TRUE -1.230357542 -1.161281066 
DLGAP5 0.002573185 TRUE -1.107102838 -1.103633439 
ZFC3H1 0.002585062 TRUE 1.143696459 1.147895022 
GPT2 0.002588037 TRUE -1.144757003 -1.214038067 
GARS 0.002593585 TRUE -1.070619878 -1.090106976 
PAK1 0.00259737 TRUE 1.174139241 1.282416819 
ULBP3 0.002613593 TRUE -1.351813499 -1.278702364 
FLJ35390 0.002614073 TRUE 1.241784326 1.1604831 
SERPINF1 0.002616824 TRUE 1.728826262 1.198599959 
PSMD11 0.002619152 TRUE -1.343163299 -1.102540213 
HBEGF 0.002619748 TRUE -1.441997294 -1.722791715 
ABCA4 0.002642477 TRUE 1.095567231 1.270634246 
UBR7 0.002643359 TRUE -1.238384454 -1.148189901 
SUPT5H 0.002647834 TRUE -1.185310729 -1.092536255 
ICAM1 0.002648618 TRUE -1.851094079 -1.180240815 
SARNP 0.002654577 TRUE -1.12116317 -1.127744752 
BSG 0.002665114 TRUE -1.076064213 -1.122722406 
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PI15 0.002695354 TRUE 1.342300272 1.12681082 
SLC9A2 0.002696376 TRUE -1.262401045 -1.294304766 
BCL6 0.002698801 TRUE 1.612769819 1.492786603 
PCNA-AS1 0.00269972 TRUE -1.310258938 -1.101888765 
GSN-AS1 0.002706553 TRUE 1.190654083 1.296110839 
PTGFRN 0.002708448 TRUE -1.099257007 -1.304834208 
EIF1AD 0.002714002 TRUE -1.424563852 -1.15988229 
IL15RA 0.002723342 TRUE -1.246606873 -1.207906555 
POLA2 0.0027234 TRUE -1.120640471 -1.130819211 
PKM 0.002729077 TRUE -1.242955761 -1.095233742 
ANKRD18A 0.002730139 TRUE 1.447504023 1.205503467 
DHCR7 0.002732832 TRUE -1.352562039 -1.099655764 
CARD6 0.002735661 TRUE -1.405273853 -1.106023004 
PFN2 0.002735971 TRUE -1.108852942 -1.324108867 
CDC123 0.00273916 TRUE -1.112343497 -1.091116752 
GTF2E1 0.002741587 TRUE -1.249261636 -1.10088464 
LOC100289019 0.002746406 TRUE 1.687012677 1.126432613 
BIVM-ERCC5 0.002748825 TRUE 1.086643622 1.193060427 
ATP8B2 0.002760932 TRUE -1.429907169 -1.160025975 
CCNB1 0.002765899 TRUE -1.122703287 -1.13803194 
ACOT2 0.002768714 TRUE -1.189366492 -1.629533525 
CCT3 0.002772158 TRUE -1.157293809 -1.071512655 
CXCL1 0.002784748 TRUE 1.193737939 2.078109947 
RN7SK 0.002785229 TRUE 1.275156378 1.126100474 
SGTA 0.00279075 TRUE -1.244558614 -1.069019178 
NACC1 0.002794968 TRUE -1.386096742 -1.224529986 
LOC100652992 0.002797113 TRUE 1.421005768 1.212574119 
SUDS3 0.002799459 TRUE 1.227098702 1.118632693 
SCARNA27 0.002805637 TRUE 1.239233805 1.319997957 
GCFC2 0.00280636 TRUE -1.155049168 -1.146660982 
SNRNP40 0.002817561 TRUE -1.115553739 -1.151854133 
GLS2 0.002820875 TRUE 1.243205439 1.222093362 
FRY-AS1 0.00282321 TRUE 1.43902438 1.089422301 
SNX7 0.002831562 TRUE -1.312775495 -1.362793439 
EIF2AK4 0.002832392 TRUE -1.162871454 -1.234870388 
MYT1L 0.002835832 TRUE 1.165928009 1.1098912 
DNAJC4 0.002847734 TRUE 1.383735782 1.19224049 
NAGS 0.002855775 TRUE -1.116907005 -1.202224476 
VAMP2 0.002856759 TRUE 1.183496157 1.096094383 
APPL2 0.002860204 TRUE 1.112933131 1.146374826 
LAMB2 0.002871771 TRUE 1.472150566 1.173650715 
SRPX 0.002876775 TRUE -1.578515077 -1.149005227 
ANKRD10-IT1 0.002882154 TRUE 2.190458821 1.346461716 
CTNNBL1 0.002889617 TRUE -1.1930241 -1.105663299 
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LOC643837 0.002890426 TRUE -1.225685934 -1.140920259 
LIMCH1 0.002909008 TRUE 1.114587654 1.735944258 
CXorf23 0.002910325 TRUE 1.216649276 1.110283963 
SLC27A2 0.002928456 TRUE 1.382945581 1.107595642 
FASN 0.002929361 TRUE -1.323272797 -1.149428352 
C17orf28 0.002935067 TRUE 1.387421459 1.13643974 
MAP2K6 0.002937166 TRUE 1.484045831 1.218326397 
GALNT3 0.002939096 TRUE -1.154176915 -1.222822213 
DSCC1 0.00294281 TRUE -1.39931163 -1.173490177 
RNPEP 0.002956789 TRUE -1.073997946 -1.066248838 
WDFY1 0.00296533 TRUE 1.05833967 1.119753887 
EZH1 0.002967625 TRUE 1.458264596 1.158284663 
PSMC2 0.002971222 TRUE -1.254788 -1.093191446 
TPX2 0.002973191 TRUE -1.209193054 -1.06619505 
GOLM1 0.002978609 TRUE -1.257087057 -1.149576236 
SLC35B4 0.002994509 TRUE -1.287738815 -1.175406287 
UNC5B 0.002999856 TRUE 1.402450814 1.186394749 
STAG2 0.003009528 TRUE 1.068595927 1.082226979 
IFT81 0.003015101 TRUE 1.108790228 1.311488189 
C12orf57 0.00303509 TRUE 1.170580763 1.162838655 
MBNL2 0.003036181 TRUE -1.238289448 -1.063536153 
SAP30BP 0.003042976 TRUE -1.17661259 -1.092405533 
PINX1 0.003048383 TRUE -1.421303662 -1.172331129 
POP4 0.003049721 TRUE -1.191528888 -1.097556366 
BARD1 0.003049879 TRUE -1.154652812 -1.112292012 
AP3D1 0.0030509 TRUE -1.162894145 -1.074088895 
FAM203B 0.003052782 TRUE -1.110156315 -1.087277278 
CCP110 0.003066282 TRUE -1.120106405 -1.095360432 
BTG1 0.00307616 TRUE 1.084299393 1.298566002 
OPN3 0.003091637 TRUE -1.378527457 -1.187582613 
MRPS23 0.003092511 TRUE -1.300815737 -1.10542628 
SPRR2E 0.003107085 TRUE 1.098568851 1.143803489 
LOC100288160 0.003138126 TRUE -1.14559791 -1.12753567 
SPPL2B 0.003141676 TRUE 1.325435916 1.281562095 
UXS1 0.003144896 TRUE -1.068649301 -1.170440854 
KIAA0226 0.003144912 TRUE -1.158831682 -1.120836558 
ANKRD5 0.003145151 TRUE -1.200251027 -1.16101368 
RIT1 0.003147678 TRUE 1.208134711 1.14476044 
TNFRSF10D 0.003151111 TRUE -1.539228053 -1.275111909 
LOC100190986 0.003169444 TRUE 1.660177527 1.724934623 
MAP3K7 0.003171607 TRUE -1.082181618 -1.045339693 
ZNF619 0.003173685 TRUE -1.180786096 -1.168204128 
EREG 0.003182918 TRUE -1.931121423 -1.461798475 
DDB2 0.003185302 TRUE -1.12304318 -1.325501907 
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FAM169A 0.003195057 TRUE -1.17217684 -2.995086784 
NRF1 0.003201971 TRUE -1.098196536 -1.154305657 
EIF4G3 0.003202984 TRUE 1.106385013 1.065194481 
GNG12 0.003203886 TRUE -1.106649321 -1.24716913 
CYB5R4 0.003210069 TRUE -1.212716969 -1.104555573 
HMGA1P4 0.003215476 TRUE 1.406157001 1.272746004 
ACLY 0.003221855 TRUE -1.287566089 -1.041224964 
ZNF689 0.003222958 TRUE -1.265275331 -1.479481504 
NBPF11 0.003223878 TRUE 1.336698773 1.171242874 
CEBPA 0.003243341 TRUE 1.310685413 1.218178143 
ATP6V1B2 0.003243559 TRUE -1.161813572 -1.044054719 
XRCC6BP1 0.003244666 TRUE -1.074312058 -1.105370208 
PLS1 0.003253141 TRUE -1.241215571 -1.210463275 
FER 0.003261466 TRUE -1.071336909 -1.337982093 
RPL13AP20 0.003272268 TRUE 1.192903444 1.125402977 
SNAPIN 0.003274536 TRUE -1.159368136 -1.140680064 
MRPL15 0.003279463 TRUE -1.086250246 -1.232302451 
CNDP2 0.003289038 TRUE -1.365562389 -1.132041221 
PROS1 0.003289229 TRUE -1.285737913 -1.30550612 
LOC415056 0.003306014 TRUE 1.159801921 1.122750371 
LOC100133669 0.003314445 TRUE -1.178793239 -2.018987125 
KPNB1 0.003331162 TRUE -1.071652363 -1.160201966 
PTHLH 0.003333005 TRUE -2.3633521 -1.184768222 
LOC100507199 0.003336311 TRUE 1.322883461 1.115190706 
PION 0.003336927 TRUE 1.333610517 1.266179329 
AURKA 0.003337368 TRUE -1.354457355 -1.110315613 
AKAP13 0.003370835 TRUE 1.087849728 1.506385185 
GSK3B 0.003379306 TRUE -1.106976598 -1.873139921 
CDKN2AIPNL 0.003380381 TRUE -1.248592737 -1.248643063 
TLR4 0.003386971 TRUE -1.106566678 -1.520068773 
ZNF740 0.003397391 TRUE 1.164516484 1.175504417 
DKC1 0.003406962 TRUE -1.202241275 -1.114876953 
GDF11 0.003425076 TRUE -1.134603411 -1.231346233 
ANKRD27 0.003442147 TRUE -1.276613363 -1.069970688 
PSMB3 0.003445408 TRUE -1.244923217 -1.062206844 
NIPSNAP1 0.00344725 TRUE 1.097781127 1.284449757 
PSMB5 0.003449801 TRUE -1.172084358 -1.075886941 
KPNA4 0.003458955 TRUE -1.170024011 -1.208324225 
BCAR3 0.003462363 TRUE -1.255888709 -1.297509566 
LOC100506804 0.003463584 TRUE 1.202009396 1.168048552 
APOD 0.003476295 TRUE 1.367718163 1.472172658 
CA11 0.003479881 TRUE 1.289543166 1.177581642 
CLDN7 0.003483401 TRUE -1.190980605 -1.054353195 
C20orf72 0.00348514 TRUE -1.116330284 -1.14895433 
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THUMPD3 0.003490639 TRUE -1.130637291 -1.120661977 
CLDN1 0.003503503 TRUE 1.106736677 1.79761982 
TMEM48 0.003504059 TRUE -1.213399131 -1.085692405 
S100A8 0.003513288 TRUE 1.292746638 1.751789617 
FKBP5 0.00351514 TRUE -1.378728917 -1.140475381 
C1orf21 0.003515416 TRUE -1.203666892 -1.470173521 
TTF2 0.003519936 TRUE -1.122876679 -1.218695481 
ZNF563 0.003522237 TRUE -1.303223629 -1.309231386 
RBBP7 0.003529097 TRUE 1.119974572 1.080114075 
SCN8A 0.003530101 TRUE 1.308399796 1.208781854 
PIP4K2C 0.003543426 TRUE -1.20226338 -1.152433726 
CYTH1 0.003551255 TRUE 1.283807985 1.090690449 
RAB8A 0.003555313 TRUE -1.133348787 -1.066929524 
MAPK6 0.003560525 TRUE -1.297845976 -1.077482136 
PACSIN3 0.003564382 TRUE -1.209624035 -1.260059526 
C17orf53 0.00357018 TRUE -1.254742787 -1.172815706 
FLG-AS1 0.00357038 TRUE 1.218543112 2.096552226 
CLINT1 0.003574341 TRUE 1.201878826 1.093476115 
CD9 0.003579104 TRUE 1.291114621 1.095622778 
RORB 0.003581996 TRUE 2.305520197 1.156790204 
CCL5 0.003586256 TRUE -1.138367565 -1.244396278 
TRIM4 0.00358752 TRUE 1.256453563 1.176156361 
UBR3 0.003600691 TRUE 1.074661666 1.088516128 
EFNB2 0.003609829 TRUE -1.887020609 -1.212295967 
MYCBP2 0.00361039 TRUE 1.10358465 1.17444841 
PDIA6 0.003611713 TRUE -1.077698433 -1.188663018 
VDR 0.003612768 TRUE -1.480292037 -1.197292697 
BOLA2 0.003616414 TRUE -1.359190005 -1.107851369 
BCL10 0.003617988 TRUE -1.097934199 -1.268327415 
LAPTM4A 0.003623557 TRUE 1.079062036 1.142991613 
VAMP5 0.003636687 TRUE -1.14357966 -1.170539614 
STIP1 0.00363671 TRUE -1.097230887 -1.114602272 
CBLB 0.003636926 TRUE 1.444981564 1.239025545 
C18orf25 0.003640532 TRUE -1.093637814 -1.225321085 
DOCK9 0.003656273 TRUE 1.286139874 1.091243829 
AIFM2 0.003657111 TRUE -1.236242592 -1.157700853 
MED8 0.003664012 TRUE -1.360762755 -1.120778643 
MIG7 0.00366875 TRUE -1.279347539 -4.405221919 
SIPA1L2 0.003689658 TRUE 1.88251308 1.133681836 
ITGB1 0.003690357 TRUE -1.172624678 -1.145337663 
CHAMP1 0.003701113 TRUE -1.134070527 -1.339542844 
MGC2752 0.003705642 TRUE -1.155335628 -1.05803155 
LOC100506136 0.003712409 TRUE -1.316972579 -1.213485438 
FAM63A 0.003715406 TRUE 1.202699844 1.197762985 
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MICAL2 0.003716035 TRUE -1.170288627 -1.283499311 
SNX29P2 0.003723391 TRUE 1.751767962 1.683325307 
ARAP3 0.003725809 TRUE -1.173884988 -1.094235587 
GBE1 0.00374762 TRUE -1.270623414 -1.25934132 
FGFR1OP 0.003771042 TRUE -1.228498117 -1.093366926 
TBP 0.003772004 TRUE -1.207969848 -1.151420835 
UBL4A 0.003788764 TRUE -1.373996656 -1.080844233 
HECW1 0.003788943 TRUE -1.185810207 -1.107417142 
AJUBA 0.003794642 TRUE -1.095946407 -1.97432583 
MAOB 0.003800504 TRUE -2.459902328 -1.177104216 
HIST1H1A 0.003803799 TRUE -1.39855425 -1.143097135 
LOC440944 0.003804632 TRUE 1.149577821 1.103192592 
FAM13B 0.003806342 TRUE 1.100594453 1.153880883 
MAP3K5 0.003809359 TRUE 1.544726089 1.11024421 
GUF1 0.003815355 TRUE -1.164865929 -1.126860662 
IGLJ5 0.003817595 TRUE 1.428029229 1.637252849 
TMEM209 0.003834483 TRUE -1.137301411 -1.12152051 
PNP 0.003852553 TRUE -1.347254186 -1.078097371 
RHOBTB3 0.003858956 TRUE 1.215926571 1.397818569 
QRSL1 0.003859864 TRUE -1.138259386 -1.132257384 
ZMPSTE24 0.00387697 TRUE -1.223495418 -1.07050938 
KRT18 0.003886966 TRUE -1.117948851 -1.292367582 
OSGIN1 0.003892182 TRUE 1.201611666 1.132394157 
ZBTB44 0.00389521 TRUE 1.135579315 1.204476297 
AOX1 0.003901165 TRUE -1.611822784 -1.10504109 
EHHADH 0.003902219 TRUE 1.140698062 1.229721705 
FAM171B 0.003902872 TRUE 1.143958219 1.560654613 
C11orf82 0.00390619 TRUE -1.370248264 -1.109295697 
C3orf26 0.003907069 TRUE -1.13438655 -1.114804842 
HIST1H2BB 0.003911526 TRUE -1.505613308 -1.329101468 
USP6NL 0.003919954 TRUE -1.084426821 -1.291945527 
HUS1 0.003926221 TRUE -1.151164774 -1.135031706 
ENTPD7 0.003932098 TRUE -1.428519867 -1.087591361 
PNPT1 0.003933864 TRUE -1.185267731 -1.174778542 
RNF26 0.003934775 TRUE -1.320173515 -1.203379748 
INPP5F 0.003935839 TRUE -1.134769168 -1.254914581 
3-Sep 0.003940891 TRUE -1.182771003 -1.200939826 
GPR132 0.003957742 TRUE 1.400114335 1.234411717 
C12orf75 0.003970048 TRUE -1.086323232 -1.190054464 
MRPL40 0.003979484 TRUE -1.255231168 -1.08716925 
NLRP6 0.003980402 TRUE -1.221828347 -1.304519361 
ZNF695 0.003981614 TRUE -1.293683596 -1.23745659 
LMAN2 0.003998222 TRUE -1.080632128 -1.087144156 
AP1M1 0.004029601 TRUE -1.363355121 -1.100194177 
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LOC100128281 0.00403143 TRUE 1.242251371 1.650789252 
NCOA5 0.004032154 TRUE -1.082084766 -1.124284531 
C1orf106 0.004038427 TRUE -1.08549052 -1.06583896 
DDX10 0.0040408 TRUE -1.113859545 -1.153509504 
EFNB1 0.004041008 TRUE -1.616562135 -1.19028385 
AFAP1-AS1 0.004041949 TRUE -1.286392993 -1.054473916 
SCYL3 0.004050677 TRUE 1.176236419 1.161588912 
TMEM170A 0.004053174 TRUE -1.160372899 -1.18251556 
RPS6KC1 0.00405863 TRUE -1.095497802 -1.195345157 
PDDC1 0.004061403 TRUE 1.143999932 1.125551116 
C19orf53 0.004081333 TRUE -1.25015655 -1.062390496 
PUS7 0.004081597 TRUE -1.259396921 -1.084624549 
LOC100131541 0.004083052 TRUE 1.147725622 1.854010116 
KITLG 0.004087722 TRUE 1.164992545 1.329053537 
MYCL1 0.004096679 TRUE 1.178075883 1.642415235 
MSX1 0.004108082 TRUE -1.208747162 -1.217716168 
MIR548AL 0.004110371 TRUE 1.339608071 1.92724487 
IL23A 0.004118789 TRUE -1.146075704 -1.465917073 
B4GALT1 0.004119083 TRUE -1.107250234 -1.839768256 
ZNF101 0.004119494 TRUE -1.17114352 -1.271362587 
FAM43A 0.004119688 TRUE 1.264085829 1.50038922 
METTL5 0.004123839 TRUE -1.159113814 -1.14879745 
SAMM50 0.004126289 TRUE -1.158837606 -1.075291039 
TRIM52 0.004128557 TRUE 1.490052902 1.199511002 
CAMK2N1 0.004152479 TRUE -1.293968882 -1.087356902 
TMEM194A 0.004154253 TRUE -1.298127409 -1.133182897 
PCDH20 0.004173266 TRUE 1.159817835 1.098041328 
PPFIBP2 0.004177304 TRUE 1.237825081 1.116166451 
NDRG2 0.004178598 TRUE 1.091359315 1.419668742 
EDC3 0.00419786 TRUE 1.086870931 1.22488415 
GABRP 0.004203632 TRUE 2.02207947 1.111175515 
AKIRIN2 0.004204103 TRUE -1.260933636 -1.086567092 
HAGH 0.004208016 TRUE 1.148645506 1.292064291 
NBPF10 0.004211205 TRUE 1.404516994 1.179842423 
MRPS34 0.004224818 TRUE -1.322273042 -1.050062031 
SEC23B 0.004233923 TRUE -1.100206141 -1.060205693 
IL1RAP 0.004236118 TRUE 1.193526574 1.502868998 
BZW1 0.00424065 TRUE -1.25824909 -1.191338958 
KIAA1217 0.00424126 TRUE 1.154905573 1.180003245 
ARRDC4 0.004248674 TRUE 1.311793217 1.434698824 
LOC440149 0.004249805 TRUE -1.2207115 -1.166280647 
PLEKHA5 0.004255251 TRUE 1.379652685 1.070696468 
VTRNA1-3 0.004264186 TRUE -2.691442655 -1.404992161 
FEZ2 0.004269765 TRUE 1.2090904 1.090259907 
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CALR 0.004274298 TRUE -1.036209647 -1.173903819 
SLC20A1 0.004285127 TRUE -1.658305212 -1.17930484 
NRP2 0.004288149 TRUE -1.078444916 -1.365922441 
C9orf64 0.004290423 TRUE -1.195049481 -1.164332532 
TCEANC 0.00429656 TRUE 1.243734509 1.217387746 
KIF5B 0.004300333 TRUE -1.036819922 -1.065551353 
OMA1 0.004308375 TRUE 1.176422581 1.137270104 
SLC45A3 0.004310858 TRUE -1.213001219 -1.643509122 
IQSEC2 0.004313657 TRUE 1.157784395 1.173756915 
ATG4A 0.00431996 TRUE -1.402823052 -1.047225577 
LOH12CR1 0.004324276 TRUE 1.300008831 1.159797241 
YPEL3 0.004326632 TRUE 1.189489686 1.350877956 
DKFZP434I0714 0.004330564 TRUE 1.14384037 1.169318974 
SHCBP1 0.004332587 TRUE -1.275325063 -1.057083158 
GIGYF1 0.004342846 TRUE 1.376004176 1.088944141 
BCL2L1 0.004343814 TRUE -1.184137972 -1.32827688 
ACSL3 0.004353056 TRUE -1.165582627 -1.223124442 
NFKBIB 0.004355086 TRUE -1.269397039 -1.104230169 
ZHX2 0.004365018 TRUE -1.093884074 -1.210641632 
RBM27 0.004375577 TRUE -1.083589628 -1.136797624 
RAP1GDS1 0.004390651 TRUE -1.339744051 -1.119818895 
WISP2 0.00439078 TRUE 1.123830228 1.110013828 
RECQL4 0.004392177 TRUE -1.104963093 -1.223264795 
COL6A5 0.004399322 TRUE 1.119740619 1.124218203 
RNF185 0.004406729 TRUE -1.233341435 -1.141333983 
CHKB-CPT1B 0.004410121 TRUE 1.315946345 1.153855919 
LOC100130691 0.004410603 TRUE 1.229944632 1.152289363 
PLD6 0.004427323 TRUE -1.194057386 -1.477129885 
EZR 0.004431593 TRUE -1.155397527 -1.079645239 
DDAH2 0.004454441 TRUE -1.127709588 -1.135148666 
TTC3P1 0.004454853 TRUE 1.153668744 1.240291044 
JOSD1 0.004455513 TRUE -1.105060033 -1.174153892 
SLMAP 0.004473647 TRUE -1.083532819 -1.079570575 
XYLT2 0.004475296 TRUE -1.088270218 -1.226456577 
EBNA1BP2 0.004481313 TRUE -1.316743421 -1.062543118 
C1orf135 0.004481411 TRUE -1.177852784 -1.458163002 
FANCI 0.004490913 TRUE -1.172429925 -1.164778746 
CHD6 0.004495298 TRUE 1.42458742 1.088147242 
CMTM1 0.004502117 TRUE -1.076498425 -1.28792458 
MIR27B 0.004502838 TRUE 2.670782417 1.365566985 
ILF2 0.004504118 TRUE -1.140385878 -1.043763047 
TBC1D3 0.004505459 TRUE 1.113248061 1.248940488 
KLRAP1 0.004522846 TRUE 1.12535877 1.226925478 
HSD11B2 0.004523267 TRUE -1.261739246 -1.188009278 
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CXXC1 0.004531646 TRUE -1.287278235 -1.132789803 
MUC20 0.004537564 TRUE 1.231221954 1.184016722 
WNT2B 0.004538284 TRUE 1.251165848 1.099220242 
KBTBD8 0.004545545 TRUE -1.535118546 -1.14084761 
EXT2 0.004545622 TRUE -1.30540718 -1.082640676 
HNRNPAB 0.004550528 TRUE -1.115828718 -1.076557718 
ETS2 0.004552425 TRUE -1.059699545 -1.231031698 
SYNJ2 0.004552862 TRUE -1.291958383 -1.0921503 
SEC22C 0.004563696 TRUE -1.20404925 -1.140364763 
CWF19L1 0.004565285 TRUE -1.212187418 -1.07267011 
ANXA5 0.00457023 TRUE -1.091983605 -1.213170894 
TIMM10 0.004574681 TRUE -1.340203967 -1.11379973 
C18orf62 0.004586677 TRUE -1.271028807 -1.131889082 
LOC100289488 0.004590148 TRUE 1.126349835 1.355924183 
C21orf59 0.004596453 TRUE -1.16881241 -1.093295821 
ICK 0.004614763 TRUE 1.461220094 1.099171058 
ATP5D 0.004618436 TRUE 1.084637415 1.129080916 
PBK 0.004621447 TRUE -1.343428961 -1.126106391 
IL31RA 0.004632518 TRUE -1.334591948 -1.177130315 
C10orf55 0.004635059 TRUE -1.588741751 -1.263536559 
MEIS2 0.004636792 TRUE 1.303565578 1.155966099 
ELOVL5 0.004656555 TRUE -1.113404365 -1.146743145 
ORC2 0.004657139 TRUE -1.098404106 -1.124633289 
SERPINB4 0.004666116 TRUE -1.91972371 -1.188959179 
EFTUD2 0.004667626 TRUE -1.151727994 -1.054101369 
PDGFA 0.004670081 TRUE -1.126481472 -1.895154465 
CITED4 0.004670944 TRUE 1.167312628 1.175944667 
RALGDS 0.004676469 TRUE 1.081375279 1.178787196 
SCD 0.004678316 TRUE -1.940549062 -1.106325896 
BYSL 0.004682591 TRUE -1.304399026 -1.242852341 
CENPE 0.004691311 TRUE -1.232118565 -1.089289318 
ZNF652 0.00469199 TRUE 1.152234876 1.166833979 
FXR2 0.004708679 TRUE -1.357534561 -1.109798205 
FAM135A 0.004717198 TRUE 1.245677615 1.089870396 
PTPRG 0.004718958 TRUE -1.114649335 -1.566001932 
KREMEN2 0.004721884 TRUE -1.397514352 -1.134617164 
BRWD1 0.004728881 TRUE 1.12386667 1.124005633 
LOC100507431 0.004729159 TRUE -1.21609888 -1.214917183 
NCAPD3 0.004737876 TRUE -1.226685884 -1.076695166 
TNC 0.004741788 TRUE -6.6766172 -1.240216628 
TPM4 0.004743035 TRUE -1.306180835 -1.061591712 
DPAGT1 0.004747405 TRUE -1.241776712 -1.162593768 
B4GALT6 0.004750404 TRUE -1.461606731 -1.497859073 
MAPRE2 0.004759408 TRUE -1.407919846 -1.309954402 
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CD164 0.004764811 TRUE 1.216611369 1.073062693 
EXOC4 0.004769298 TRUE 1.139572044 1.055550076 
CST5 0.004772751 TRUE -1.217518515 -1.425639003 
SIAH2 0.004776657 TRUE -1.153068428 -1.144330104 
TRMT1 0.004780995 TRUE -1.245092095 -1.123824371 
TMED1 0.004784666 TRUE -1.171662031 -1.100043077 
PRKCH 0.004790524 TRUE 1.174798921 1.049270173 
BEND3 0.004793051 TRUE -1.261956531 -1.213828255 
PAIP2B 0.004793439 TRUE 1.384374543 1.261033303 
GCC2 0.004812118 TRUE 1.100738747 1.197230534 
LOC100170939 0.004834272 TRUE 1.81936338 1.344978625 
CLK2 0.004849416 TRUE 1.223342836 1.118383522 
POLR1A 0.004854934 TRUE -1.096706765 -1.069029034 
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Appendix 2: Correlation heat-map in the Oral Cavity group 
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Appendix 3:Histogram of p-values testing Cluster 1 versus Cluster 2 in the Oral Cavity 
group 
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Appendix 4: Ingenuity Pathway Analysis of significantly modulated pathways after 
NOTCH activation by Jagged1 in cell lines  
  Functions P-value # Molecules 
Cellular Movement     48 
  cell movement of tumor cell lines 4.79E-13 30 
  migration of tumor cell lines 9.92E-13 27 
  cell movement 2.72E-12 47 
  invasion of tumor cell lines 6.64E-11 24 
  migration of cells 6.65E-11 42 
  invasion of cells 1.63E-10 27 
  
cell movement of brain cancer cell 
lines 4.48E-10 11 
  migration of tumor cells 2.26E-09 13 
  migration of endothelial cells 6.04E-09 15 
  
cell movement of fibroblast cell 
lines 6.87E-09 11 
  migration of brain cancer cell lines 2.66E-08 9 
  migration of cancer cells 4.13E-08 11 
  migration of fibroblast cell lines 1.12E-07 9 
  homing 1.45E-07 18 
  homing of cells 4.80E-07 17 
  chemotaxis 1.71E-06 16 
  invasion of tumor cells 2.28E-06 9 
  cell movement of tumor cells 2.47E-06 9 
  migration of sarcoma cell lines 3.81E-06 6 
  invasion of carcinoma cell lines 4.70E-06 9 
  chemotaxis of cells 5.22E-06 15 
  leukocyte migration 6.30E-06 20 
  invasion of breast cancer cell lines 7.09E-06 10 
  cell movement of phagocytes 8.92E-06 15 
  
invasion of squamous cell 
carcinoma cell lines 1.24E-05 5 
  migration of endothelial cell lines 1.33E-05 6 
  dissemination of cells 2.26E-05 5 
  
invasion of prostate cancer cell 
lines 2.81E-05 6 
  cell movement of leukocytes 4.66E-05 17 
  cellular infiltration 5.76E-05 12 
  dissemination of tumor cells 7.25E-05 3 
  migration of skin cancer cell lines 8.89E-05 3 
  migration of keratinocytes 8.90E-05 5 
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invasion of ovarian cancer cell 
lines 1.13E-04 4 
  invasion of glioma cells 1.29E-04 3 
  cell movement of myeloid cells 1.30E-04 13 
  
migration of connective tissue 
cells 1.41E-04 7 
  recruitment of neutrophils 1.69E-04 7 
  invasion of brain cancer cell lines 1.80E-04 5 
  
movement of endometrial stromal 
cells 1.83E-04 2 
  
migration of breast cancer cell 
lines 2.09E-04 8 
  recruitment of phagocytes 2.14E-04 8 
  
cell movement of pancreatic 
cancer cell lines 2.15E-04 4 
  migration of kidney cell lines 2.19E-04 5 
  cell movement of neuroglia 2.64E-04 5 
  
migration of mesenchymal stem 
cells 2.73E-04 3 
  cell movement of cancer cells 2.83E-04 6 
  cell movement of epithelial cells 2.83E-04 6 
  migration of smooth muscle cells 2.93E-04 6 
  cellular infiltration by leukocytes 3.55E-04 10 
  transmigration of myeloid cells 3.94E-04 4 
  migration of phagocytes 4.89E-04 8 
  migration of myeloid cells 5.76E-04 6 
  
migration of cervical cancer cell 
lines 7.73E-04 4 
  migration of neuroglia 7.73E-04 4 
  migration of bone cancer cell lines 8.09E-04 3 
  cell movement of embryonic cells 9.18E-04 5 
  cell movement of granulocytes 1.03E-03 9 
  transmigration of phagocytes 1.04E-03 4 
  intravasation of cells 1.08E-03 2 
  migration of embryonic cell lines 1.19E-03 4 
  
cell movement of bladder cancer 
cell lines 1.23E-03 3 
  invasion of endothelial cells 1.23E-03 3 
Cellular Growth and 
Proliferation     64 
  proliferation of cells 3.95E-11 62 
  proliferation of tumor cells 1.02E-10 20 
  proliferation of tumor cell lines 5.32E-10 36 
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  proliferation of cancer cells 2.03E-07 14 
  proliferation of epithelial cells 3.96E-07 16 
  
proliferation of connective tissue 
cells 1.21E-06 17 
  
proliferation of ovarian cancer cell 
lines 1.51E-06 8 
  proliferation of muscle cells 1.62E-06 13 
  
proliferation of smooth muscle 
cells 3.21E-06 11 
  proliferation of blood cells 3.65E-06 20 
  proliferation of immune cells 5.35E-06 19 
  proliferation of endothelial cells 8.11E-06 11 
  
formation of connective tissue 
cells 8.46E-06 9 
  proliferation of lymphocytes 2.26E-05 17 
  colony formation 2.93E-05 14 
  inhibition of cells 3.70E-05 7 
  
proliferation of prostate cancer cell 
lines 3.90E-05 10 
  
proliferation of mammary tumor 
cells 6.16E-05 5 
  
proliferation of lung cancer cell 
lines 7.39E-05 9 
  expansion of neutrophils 9.16E-05 2 
  
proliferation of carcinoma cell 
lines 1.23E-04 11 
  formation of cells 1.26E-04 19 
  proliferation of fibroblasts 1.53E-04 10 
  
proliferation of brain cancer cell 
lines 2.45E-04 7 
  proliferation of neuronal cells 2.60E-04 13 
  proliferation of keratinocytes 3.56E-04 6 
  growth of neurites 4.20E-04 11 
  
formation of colony forming unit 
osteoblasts 4.53E-04 2 
  
colony formation of tumor cell 
lines 4.89E-04 8 
  
inhibition of mononuclear 
leukocytes 5.93E-04 4 
  colony formation of cells 7.46E-04 11 
  proliferation of fibroblast cell lines 7.64E-04 10 
  formation of osteoclasts 8.01E-04 5 
  outgrowth of cells 9.31E-04 10 
Cell Death and Survival     59 
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  cell viability 7.12E-11 34 
  cell survival 1.10E-10 35 
  necrosis 7.22E-10 48 
  cell viability of tumor cell lines 5.06E-08 22 
  cell death 7.44E-08 52 
  cell death of tumor cell lines 2.68E-07 31 
  apoptosis 5.44E-07 43 
  necrosis of epithelial tissue 1.09E-06 17 
  cell viability of endothelial cells 1.49E-06 6 
  apoptosis of pericytes 1.05E-05 4 
  apoptosis of tumor cell lines 1.07E-05 24 
  cell death of tumor 1.30E-05 12 
  cell death of muscle cells 1.78E-05 11 
  apoptosis of muscle cell lines 2.64E-05 5 
  apoptosis of heart cell lines 2.89E-05 4 
  repopulation of fibroblasts 3.06E-05 2 
  cell death of tumor cells 5.09E-05 11 
  anoikis 5.39E-05 6 
  apoptosis of tumor cells 1.23E-04 9 
  apoptosis of endothelial cells 1.59E-04 7 
  apoptosis of hepatic stellate cells 2.07E-04 3 
  cell death of epithelial cells 2.15E-04 12 
  anoikis of tumor cell lines 2.15E-04 4 
  
cell viability of carcinoma cell 
lines 2.39E-04 6 
  apoptosis of muscle cells 3.21E-04 8 
  
cell viability of prostate cancer 
cell lines 4.19E-04 4 
  
permeability of endothelial cell 
lines 4.44E-04 3 
  
cell death of lymphatic system 
cells 5.58E-04 5 
  cell viability of leukemia cell lines 5.93E-04 4 
  killing of lung cancer cell lines 6.32E-04 2 
  apoptosis of mammary tumor cells 7.38E-04 3 
  cell viability of kidney cell lines 8.13E-04 4 
  cell death of immune cells 1.04E-03 13 
Cellular Development     62 
  proliferation of tumor cells 1.02E-10 20 
  proliferation of tumor cell lines 5.32E-10 36 
  differentiation of cells 1.42E-08 42 
  endothelial cell development 1.34E-07 14 
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  proliferation of cancer cells 2.03E-07 14 
  
proliferation of ovarian cancer cell 
lines 1.51E-06 8 
  proliferation of muscle cells 1.62E-06 13 
  
proliferation of smooth muscle 
cells 3.21E-06 11 
  proliferation of blood cells 3.65E-06 20 
  proliferation of immune cells 5.35E-06 19 
  tubulation of endothelial cells 6.01E-06 7 
  proliferation of endothelial cells 8.11E-06 11 
  proliferation of lymphocytes 2.26E-05 17 
  
tubulation of endothelial 
progenitor cells 3.55E-05 3 
  differentiation of epithelial tissue 3.62E-05 11 
  
proliferation of prostate cancer cell 
lines 3.90E-05 10 
  differentiation of epithelial cells 5.11E-05 10 
  
proliferation of mammary tumor 
cells 6.16E-05 5 
  differentiation of tumor cell lines 6.17E-05 11 
  
proliferation of lung cancer cell 
lines 7.39E-05 9 
  expansion of neutrophils 9.16E-05 2 
  
development of connective tissue 
cells 9.57E-05 8 
  
proliferation of carcinoma cell 
lines 1.23E-04 11 
  proliferation of fibroblasts 1.53E-04 10 
  
differentiation of connective tissue 
cells 2.38E-04 14 
  
proliferation of brain cancer cell 
lines 2.45E-04 7 
  proliferation of neuronal cells 2.60E-04 13 
  differentiation of connective tissue 2.94E-04 15 
  proliferation of keratinocytes 3.56E-04 6 
  growth of neurites 4.20E-04 11 
  
hematopoiesis of bone marrow 
cells 4.44E-04 3 
  
formation of colony forming unit 
osteoblasts 4.53E-04 2 
  differentiation of osteoblasts 5.29E-04 8 
  differentiation of bone cells 5.43E-04 10 
  proliferation of fibroblast cell lines 7.64E-04 10 
  formation of osteoclasts 8.01E-04 5 
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  onset of differentiation of cells 8.39E-04 2 
  differentiation of skin 9.61E-04 6 
Cell-To-Cell Signaling and 
Interaction     41 
  adhesion of tumor cell lines 8.05E-10 15 
  cell-cell adhesion 1.01E-06 10 
  attachment of tumor cell lines 3.11E-06 5 
  activation of cells 3.11E-06 22 
  adhesion of epithelial cells 4.32E-06 7 
  binding of cells 7.29E-06 14 
  adhesion of kidney cell lines 7.63E-06 5 
  adhesion of embryonic cells 1.36E-05 5 
  adhesion of mesothelial cells 3.06E-05 2 
  activation of blood cells 3.29E-05 17 
  binding of endothelial cells 3.29E-05 6 
  adhesion of embryonic cell lines 3.69E-05 4 
  activation of leukocytes 5.00E-05 16 
  adhesion of melanoma cell lines 5.78E-05 4 
  adhesion of blood cells 5.83E-05 11 
  adhesion of epithelial cell lines 7.83E-05 4 
  
cell-cell adhesion of embryonic 
cell lines 9.16E-05 2 
  attachment of cells 1.67E-04 6 
  recruitment of neutrophils 1.69E-04 7 
  activation of T lymphocytes 1.78E-04 10 
  adhesion of muscle cells 1.78E-04 3 
  
cell-cell adhesion of epithelial cell 
lines 1.83E-04 2 
  recruitment of phagocytes 2.14E-04 8 
  aggregation of myoblasts 3.03E-04 2 
  activation of lymphocytes 4.08E-04 11 
  phagocytosis of cells 4.41E-04 8 
  
cell-cell adhesion of kidney cell 
lines 4.53E-04 2 
  cell-cell adhesion of leukocytes 5.50E-04 3 
  activation of endothelial cells 5.61E-04 4 
  adhesion of fibrosarcoma cell lines 6.32E-04 2 
  
adhesion of stomach cancer cell 
lines 6.32E-04 2 
  phagocytosis of leukemia cell lines 8.83E-04 3 
  adhesion of endothelial cell lines 9.62E-04 3 
  adhesion of carcinoma cell lines 1.13E-03 3 
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